Search Trials
For best results, use specific search terms. For example, instead of "brain tumor," try "glioblastoma." You can also contact the Clinical Trials Office at 312-695-1102 for assistance.
Trials |
---|
Clinical and Molecular Analysis Of Neoplasms STU00001127 |
NU 05H6: Acute Leukemias and Map KinaseNormally, white blood cells are produced in a controlled way by the bone marrow. In someone with AML or ALL, this production process is abnormal and immature cells are produced and sent into the blood stream. In this immature state, the cells affect the production of other normal cells and … Normally, white blood cells are produced in a controlled way by the bone marrow. In someone with AML or ALL, this production process is abnormal and immature cells are produced and sent into the blood stream. In this immature state, the cells affect the production of other normal cells and these cannot perform their usual functions. Therefore patients with AML or ALL are vulnerable to infection, anemia, and bleeding. The purpose of this study is to understand what causes the white blood cells to grow abnormally, and to determine if there are novel agents that can be used to stop this abnormal growth. In this research project, a sample of blood and bone marrow will be studied in the laboratory to learn more about the nature of the disease, and to understand what causes the defect in the growth of these cells. |
NCI 02X3: SPORE in Pancreatic Cancer Tissue CoreThe purpose of this research study is to examine many aspects of gastrointestinal disease including pancreatic and colon cancer, including its genetics, its early stages, and the effects of cancer on other tissues such as muscle and adipose (fat) tissue. Tissues from patients (with cancer as well as from those … The purpose of this research study is to examine many aspects of gastrointestinal disease including pancreatic and colon cancer, including its genetics, its early stages, and the effects of cancer on other tissues such as muscle and adipose (fat) tissue. Tissues from patients (with cancer as well as from those without), who are undergoing pancreatic surgery, will be used in this research. |
NUGene: Gene-Disease Associations and Treatment OutcomesShare your health data and a little blood to help with studies on all kinds of diseases— cancer, diabetes, heart disease. A ready pool of samples and treatment histories speeds up research. It’s simple to help. And your info is so important to the search for new ways to … Share your health data and a little blood to help with studies on all kinds of diseases— cancer, diabetes, heart disease. A ready pool of samples and treatment histories speeds up research. It’s simple to help. And your info is so important to the search for new ways to prevent and treat illnesses. Want to make an impact in just 20 minutes? Give some blood, answer some questions, and share your health records with your study team’s database. Researchers use it to find disease patterns and search for new ways to prevent and treat illnesses. |
Genetics of Prostate CancerRecruiting Research Participants for a New Study on the “Genetics of Prostate Cancer”At the time of conception, fertilization of the egg by the sperm brings together the genetic material (DNA) from both parents, half from the mother and half from the father, producing the embryo. In the very early … Recruiting Research Participants for a New Study on the “Genetics of Prostate Cancer” At the time of conception, fertilization of the egg by the sperm brings together the genetic material (DNA) from both parents, half from the mother and half from the father, producing the embryo. In the very early stages of embryonic development, the embryo is made up of cells that have the potential to develop into all types of cells, like skin, muscle, liver, brain, pancreas, breast, ovary, fallopian tube, or prostate cells. Because of this ability, these cells are called “pluripotent” embryonic stem cells (ESCs). However, about a week after fertilization, the embryonic cells lose their ability to develop into all of the different cells and tissues of the body and gradually “differentiate” into the various tissues and organs that have different specific functions. So, there is a relatively narrow window during which pluripotent ESCs exist in the embryo. At the end of the in vitro fertilization (IVF) process for couples undergoing subfertility treatment, the doctors are usually left with one-week-old embryos. In 1998, using such embryos for research, scientists figured out how to grow pluripotent ESCs in the lab that can stay in their pluripotent state if the right growth conditions are present. Changing the growth conditions in certain ways, scientists learned how to stimulate the ESCs to go through a process called “differentiation,” in which the stem cells can develop into any of the different cell types present in the body. ESCs were used in the early animal cloning experiments that produced the cloned ewe named “Dolly;” however, cloning human cells is illegal. While ESCs offer promising and exciting opportunities, like the possibility of growing organs in the lab, because their production involves technical and ethical problems, efforts were directed to produce pluripotent stem cells from mature cells to avoid the use of embryos. In 2007, Japanese researchers found an amazing way (for which they received a Nobel Prize) to transform mature cells, like regular skin or blood cells, directly into stem cells without using human eggs. They found a combination of proteins that, if injected into mature cells, gradually reprogrammed them into induced pluripotent stem cells, abbreviated iPSCs. Research Project Drs. Dan Theodorescu and Clive Svendsen, the Principal Investigators at the Cedars-Sinai Medical Center in Los Angeles, California in collaboration with Dr. William Catalona, the Principal Investigator at Northwestern University are engaged in research using iPSCs to develop a model of human prostate cancer using iPSCs from men who carry BRCA2 mutations that are related to a higher risk for developing aggressive prostate cancer (the Cedars-Sinai team has already accomplished this for ovarian cancer in women who carry BRCA1 mutations). As study controls, they will also enroll men with non-BRCA2-related prostate cancer and those without prostate cancer. They will not use embryos. In the laboratory, the researchers will take the white blood cells from a blood sample back in time to when they were capable of making any cell type in the body and differentiate them forward into prostate cells carrying (or for non-BRCA2-mutation carriers, not carrying) the BRCA2 mutation in a petri dish. Using these transformed prostate cells, they will use current genetic engineering and molecular biology research methods to study the mechanisms of the transformation of normal prostate cells into aggressive prostate cancer cells. This model also can be used in cell-signaling studies and drug screening studies for designing future therapies. The bank of prostate iPSCs that they will create may be shared with research institutions around the world. These researchers are now recruiting men and their male family members who carry a BRCA2 mutation and other prostate cancer patients and controls without prostate cancer to participate in this study. This research is being performed to discover the causes of prostate cancer and how it is passed down in families using the BRCA2 mutation as a model system and also can be applied to non-BRCA2-related cancers. This study is called “The genetics of prostate cancer” and is approved by the Institutional Review Boards at Northwestern University (STU00018651) and Cedars Sinai, whose function is to protect the rights of research subjects and to oversee ethical issues. Participation in this study will involve having up to 50 ml of your blood drawn (10 teaspoons), and completing family history questionnaires (baseline and follow-ups) and clinical follow-up questionnaires, if applicable. The time involved includes the time required to read the 10-page consent form, and the time required to travel to Northwestern Memorial Hospital, Galter Pavilion, 675 North St. Clair Street, Chicago, IL 60611 for the research blood draw.If it is not convenient for you to come to our clinic you may be able to get blood drawn at a clinic of your choice and we will arrange to have it shipped to Cedars-Sinai in Los Angeles, California. It will take about 20 to 40 minutes to complete the questionnaire. In the case that your family history suggests familial prostate cancer, Dr. Catalona may want your family members to participate in the study as well. You may be asked to contact your relative(s) about the study. We will follow up with a family history follow-up questionnaire annually, which takes 15 to 30 minutes to finish, to update the file. If you develop prostate cancer, we will want you to fill out a clinical follow-up questionnaire about prostate cancer and follow you up with the questionnaire annually as well, which takes 10 minutes to finish. In addition, we may request up one or more additional blood samples of 10 to 20 ml (2-4 teaspoons) from you at a later date, depending on the evolving needs of the study. You may refuse to provide these follow-up blood samples without affecting your participation in this study. The blood sample(s) will be saved for future analysis. Efforts will be made to limit the use and disclosure of your personal information, including research studies and medical records, to people who have a need to review this information. We cannot promise complete secrecy. Organizations that may inspect and copy your information include the IRB and other representatives of this institution. Research results will not be available to you or your physician except under extraordinary circumstances. These are situations in which a life-threatening medical disorder is discovered for which medical treatment is available to prevent or alleviate long-term medical complications. If such a situation should occur, we will contact you via phone, email or mail. Those interested in participating may contact Dr. Catalona at 312 695-4471 or william.catalona@nm.org. Further background information on stem cells is available from the author who created the background information for this article: Meshorer E (2020) What Are Embryonic Stem Cells and How Can They Help Us?. Front. Young Minds. 8:32. doi: 10.3389/frym.2020.00032. Copyright © 2020 Meshorer |
NU 00X3: Pathology Core FacilityThe main purpose of this project is to collect samples for research. The samples will be stored at the Pathology Core Facility (PCF) of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University Medical School (NUMS). PCF serves as the centralized resource that addresses the sample collection needs for … The main purpose of this project is to collect samples for research. The samples will be stored at the Pathology Core Facility (PCF) of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University Medical School (NUMS). PCF serves as the centralized resource that addresses the sample collection needs for the research community. The samples collected can be used by researchers at Northwestern University and third party commercial and non-profit institutions who have approval from their Institutional Review Board (a committee which is responsible for the ethical oversight of the study) for their projects. You will be asked to donate a sample of blood. In addition, any extra tissue or fluid from what has been collected from you for your routine care will be used. Examples of samples include but are not limited to tissue, blood, urine, and bone marrow. |
RTOG 0724 - A Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterecotmy…
RATIONALE: Drugs used in chemotherapy, such as cisplatin, paclitaxel, and carboplatin, work
in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells.
It is not yet known whether chemotherapy and radiation therapy are more effective when given
with or without additional chemotherapy in treating cervical cancer.
PURPOSE: This randomized phase III trial is studying chemotherapy and pelvic radiation
therapy to see how well they work when given with or without additional chemotherapy in
treating patients with high-risk early-stage cervical cancer after radical hysterectomy.
Some of the eligibility criteria include: - Participants must be 18 years old or older. - Participants must have undergone radical hysterectomy prior to entering the study. - Participants cannot be allergic to carboplatin, paclitaxel and/ or cisplatin. Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
NCT00980954 STU00021457 |
NU 99G8: Northwestern Ovarian Cancer Early Detection and Prevention Program: A Specimen and Data Study…
RATIONALE: To improve strategies for detection and prevention of early-stage disease.
PURPOSE: This research study is collecting specimens and data to develop better methods for
early detection and prevention of ovarian cancer among the high risk population and those
who have the disease.
NCT00005095 STU00005421 |
NCI 01X1: Breast Cancer Program: Tissue and Specimen Collection FacilityThe purpose of this research study is to help advance the scientific understanding of breast cancer. A portion of breast or skin tissue and a sample of blood, along with clinical information, will be collected and stored in a database for research purposes only. Only tissue or fluid in excess … The purpose of this research study is to help advance the scientific understanding of breast cancer. A portion of breast or skin tissue and a sample of blood, along with clinical information, will be collected and stored in a database for research purposes only. Only tissue or fluid in excess of that required for clinical diagnosis and/or staging will be collected. Specific clinical data will include: treatment for cancer (surgical procedures, chemo or hormone therapy, radiation), cancer outcome (recurrence, metastases, death due to disease, and death without disease, alive, alive with disease). You may be eligible for this research study if you are a woman with breast cancer undergoing biopsy or surgical procedures for the diagnosis, treatment, or prevention of your cancer.
NCT00898131 STU00023488 |
Peripheral Neuropathy Research Registry (PNRR)National Peripheral Neuropathy Research Registry (PNRR), a collection of different types ofinformation, such as patient medical, family, and social histories and blood samples. Theinformation is carefully maintained so that it can be studied repeatedly in the future. The registryaims to help researchers’ access large amounts of information about people with … National Peripheral Neuropathy Research Registry (PNRR), a collection of different types ofinformation, such as patient medical, family, and social histories and blood samples. Theinformation is carefully maintained so that it can be studied repeatedly in the future. The registryaims to help researchers’ access large amounts of information about people with PN. By using thisregistry, researchers will facilitate both basic and clinical research studies that will bring improvedunderstandings of the etiology (origination) and pathogenesis (development) of PN. They willspecifically ask why some patients with peripheral neuropathy develop neuropathic pain and othersdo not, and what the characteristics of patients with painful peripheral neuropathy are in terms oftheir symptoms, examination findings, and blood tests. Ultimately this research may result inimproved diagnosis, more effective treatments, and possibly prevention. Inclusion criteria: 1. Diabetic Peripheral Neuropathy 2. Chemo-therapy Induced Peripheral Neuropathy 3. HIV-induced Peripheral Neuropathy 4. Idiopathic Peripheral Neuropathy; Exclusion criteria: Any other type of Peripheral Neuropathy
STU00048864 |
NU 04H7: Molecular Mechanisms of Disease Progression in Myeloid MalignancyIn this research project, samples of blood and bone marrow will be studied in the laboratory to learn more about the nature of chronic myelogenous leukemia (CML) cells and how various medications and chemical agents affect them.The purpose of this study is to learn about how CML leukemia cells … In this research project, samples of blood and bone marrow will be studied in the laboratory to learn more about the nature of chronic myelogenous leukemia (CML) cells and how various medications and chemical agents affect them. The purpose of this study is to learn about how CML leukemia cells become resistant to medications or progress to acute leukemia (blast crisis). This may prove to be helpful in the design of new more effective drugs for the treatment of CML in the future. |
NCI 12H13: Molecular Mechanisms of Relapse After Therapy Discontinuation in Chronic Myeloid LeukemiaIn this research study, samples of bone marrow or peripheral blood will be collected from patients with chronic myeloid leukemia (CML) to learn more about the effect of some new drugs on CML cells in the laboratory. The purpose of this study is to understand how these new drugs stop … In this research study, samples of bone marrow or peripheral blood will be collected from patients with chronic myeloid leukemia (CML) to learn more about the effect of some new drugs on CML cells in the laboratory. The purpose of this study is to understand how these new drugs stop leukemia cells from growing. This research may prove to be helpful in the design of new and more effective treatments for leukemia in the future. |
NUDB 13C03: Northwestern Brain Tumor Institute Research DatabaseThe Northwestern Brain Tumor Institute (NBTI) currently uses an electronic database to collect and store information about patients who come to the NBTI for evaluations, including diagnosis, treatment, follow-up, and/or to obtain additional opinions. This database is called the Northwestern Brain Tumor Institute Database or NBTIDB, and it … The Northwestern Brain Tumor Institute (NBTI) currently uses an electronic database to collect and store information about patients who come to the NBTI for evaluations, including diagnosis, treatment, follow-up, and/or to obtain additional opinions. This database is called the Northwestern Brain Tumor Institute Database or NBTIDB, and it was developed to replace older paper methods for collecting and storing information. The purpose of this study is to allow researchers involved with the NBTIDB to use data stored in it for future research studies and projects. The NBTIDB also allows researchers to track whether or not patients have agreed to allow their information to be linked to their leftover tissue samples, which are kept in the hospital’s pathology department, for future research studies. You may be eligible to take part in the research component of the NBTIDB if you are either a new or returning patient, over the age of 18, who is being seen by one of the clinicians at the NBTI and are or will be entered into the NBTIDB, or a patient who is not coming to the NBTI for evaluation, but would still like to participate in the NBTIDB.
STU00087359 |
Development of a Kidney Cancer Patient Outcomes DatabasePurpose
This study is evaluating an on-line registry for kidney cancer patients called ‰ÛÏMyQOL,‰Û which stands for My Quality of Life.
Overview
A registry is a repository (database) of information about a group of people who share a common characteristic - in this case, kidney cancer. MYQOL registry participants enter … Purpose
This study is evaluating an on-line registry for kidney cancer patients called ‰ÛÏMyQOL,‰Û which stands for My Quality of Life.
Overview
A registry is a repository (database) of information about a group of people who share a common characteristic - in this case, kidney cancer. MYQOL registry participants enter information about their disease, treatment, symptoms, health status, and quality of life into an on-line, password-protected database on a regularly scheduled basis. Participants can use the registry to track many of their symptoms and their health status over time and to compare themselves (anonymously) with other groups of people (for example, how their level of fatigue compares with the average level of fatigue reported by other participants in the registry). Participants can also choose to share relevant information about themselves (from the registry) with their health care provider(s), by printing copies of their completed forms. Registry participants will be offered opportunities to join in other research studies when available.
Description of Treatment
Participants in this study will be asked to do the following for a 1-year trial period: 1) enroll in the on-line registry; 2) complete questionnaires about their health and treatment every 3 months ; and 3) be willing to have MYQOL researchers contact them confidentially about participating in other research studies. This does not mean that participants are obligated to participate in future research studies; only that they agree to be contacted. Some of the eligibility criteria include: - Participants must have a kidney cancer diagnosis. - Participants must be 18 or older. - Participants must be able to read English well enough to complete questionnaires. Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
STU00070200 |
Ex vivo interactions between high-density-like nanoparticles and human bloodThis research is significant because the high-density lipoprotein like nanoparticles (HDL-NPs) being investigated have been shown to have tremendous therapeutic properties when evaluated in in vitro and in vivo settings. Prior to initiating large-scale in vivo animal and human studies it is imperative that we obtain an … This research is significant because the high-density lipoprotein like nanoparticles (HDL-NPs) being investigated have been shown to have tremendous therapeutic properties when evaluated in in vitro and in vivo settings. Prior to initiating large-scale in vivo animal and human studies it is imperative that we obtain an in-depth knowledge of the interaction of the HDL-NPs with human blood cells using safe ex vivo experiments. |
NCI 15H01: Triad1 Regulates Myelopoiesis and Functions as a Leukemia SuppressorResearchers have found that about 60% of patients with acute myeloid leukemia (AML) will obtain a remission following treatment with combinations of chemotherapy drugs. However, relapse after treatment remains a problem, and can be as high as 80% in some types of AML patients. Therefore, it would be beneficial to … Researchers have found that about 60% of patients with acute myeloid leukemia (AML) will obtain a remission following treatment with combinations of chemotherapy drugs. However, relapse after treatment remains a problem, and can be as high as 80% in some types of AML patients. Therefore, it would be beneficial to identify specific treatment approaches for patients at a high risk for relapse. One characteristic associated with high relapse rates is an increase in proteins that are referred to as Hox proteins in the leukemia cells. Increase in Hox proteins prevents production of some other proteins, including a protein referred to as Triad1. An increase in Triad1 protein in bone marrow cells may be important to control the growth of such cells. Decreased Triad1 in leukemia cells may therefore promote their growth, but this has not been previously studied. The purpose of this study is to investigate if the lack of Triad1 in leukemia cells contributes to resistance of some leukemias to chemotherapy drugs. This research may prove to be helpful in the design of new and more effective treatments for leukemia in the future. At a time when you are having a bone marrow biopsy and aspirate performed as part of your standard medical care, about an additional 2.5 teaspoons (12.5 mL) of bone marrow will be collected for this research study. |
A large-scale multicenter phase II study evaluating the protective effect of a tissue selective estrogen complex (TSEC) in women with newly diagnosed ductal carcinoma in situ.…
The main purpose of this study is to determine if taking the study drug, conjugated
estrogens/bazedoxifene (Duavee®) causes any changes in the proliferation markers within the
breast tissue of the study subjects. The study drug is approved by the US Food and Drug
Administration in healthy postmenopausal women to treat certain symptoms of menopause such
as hot flashes. Since it is not approved in women with DCIS, its use in this study is
experimental. This study will also look at whether taking the study drug causes any
significant or undesirable side effects in women with DCIS. The researchers hope that this
study will help them determine if taking the study drug is safe in women taking DCIS and if
it can possibly reduce the risk of developing breast cancer in women with DCIS.
Some of the eligibility criteria include: - Participants must be postmenopausal women with newly diagnosed DCIS scheduled to undergo surgical therapy. - Patients must be able to swallow the oral medication. - Patients must be able to understand and the willing to sign a written informed consent document and comply to all procedures. Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
NCT02694809 STU00202100 |
NU 15N01: Head and Neck Tissue BankResearchers would like to create a bio-specimen bank of tissue, blood, urine and saliva, which would then be used to study cancer and find better ways to detect, prevent, diagnose, treat and provide better care for future patients. Some of these studies may be about how genes affect the … Researchers would like to create a bio-specimen bank of tissue, blood, urine and saliva, which would then be used to study cancer and find better ways to detect, prevent, diagnose, treat and provide better care for future patients. Some of these studies may be about how genes affect the development of cancer, response or resistance to treatment as well as prognosis (course of disease and overall outcome including survival). Other studies may aim to identify measurable substances in the blood and/or urine (known as biomarkers) that can indicate early development of cancer, worsening or relapse of disease and response to treatment. Some studies may lead to new products, such as drugs or tests for detection of cancer. You may be eligible to take part in our head and neck specimen banking study if you have one of the following conditions: a) You have a tumor or an abnormal area in the head and neck area, suspicious for cancer, or pre-cancerous condition or other pathology of interest, and you’re scheduled to have biopsy and/or surgery at Northwestern Memorial Hospital. b) You will receive treatment and/or regular follow up for further management for your head and neck cancer or precancerous condition, or other pathology at Northwestern Memorial Hospital and/or Northwestern Medicine Developmental Therapeutics Institute (NMDTI).
STU00202177 |
NU 15N02: Northwestern Head and Neck Cancer RegistryThe purpose of this registry is to collect clinical information on all consenting head and neck cancer patients seen at the Northwestern Medical Group (NMG) or Northwestern Memorial Hospital (NMH). With this information, researchers will conduct studies to learn more about the subtypes of head and neck cancers and determine … The purpose of this registry is to collect clinical information on all consenting head and neck cancer patients seen at the Northwestern Medical Group (NMG) or Northwestern Memorial Hospital (NMH). With this information, researchers will conduct studies to learn more about the subtypes of head and neck cancers and determine the most effective treatments. The registry will also allow us to identify possible subjects for future studies. |
ECOG-ACRIN 6141: Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma…
This randomized phase II/III trial studies the side effects and best dose of nivolumab and
ipilimumab when given together with or without sargramostim and to see how well they work in
treating patients with stage III-IV melanoma that cannot be removed by surgery. Monoclonal
antibodies, such as ipilimumab and nivolumab, may kill tumor cells by blocking blood flow to
the tumor, by stimulating white blood cells to kill the tumor cells, or by attacking
specific tumor cells and stop them from growing or kill them. Colony-stimulating factors,
such as sargramostim, may increase the production of white blood cells. It is not yet known
whether nivolumab and ipilimumab are more effective with or without sargramostim in treating
patients with melanoma.
NCT02339571 STU00202372 |
NU 16B06: Investigation of Blood-Based Prognostic Biomarkers in Patients with Advanced Breast Cancer for Molecular Mechanisms Underlying Circulating Tumor Cell ClustersThis study is being done to help improve the knowledge on the biology of breast cancer in the future. Blood specimens from patients with breast cancer will be collected and utilized for future research projects known as biomarker studies. These blood based laboratory tests will ultimately evaluate molecules present in … This study is being done to help improve the knowledge on the biology of breast cancer in the future. Blood specimens from patients with breast cancer will be collected and utilized for future research projects known as biomarker studies. These blood based laboratory tests will ultimately evaluate molecules present in the blood of patients with breast cancer. These molecules could be, for example, a protein, tumor DNA, or tumor cells circulating in the blood. As research technology advances, blood samples from patients with breast cancer may help in understanding the course of disease and to check as to how effective a treatment is. |
NUDB 16Z01: The OncoSET Program Database and Biobank - Combining Clinical Outcomes with Next Generation Sequencing and other Advanced Molecular Testing for Genetic Aberrations in Patients with Advanced Solid MalignanciesThe purpose of the study is to gather information about your cancer and the treatment you receive as a part of your routine clinical care. In this study, we are developing a research registry, which is a bank of information about many patients.We are interested in learning about the … The purpose of the study is to gather information about your cancer and the treatment you receive as a part of your routine clinical care. In this study, we are developing a research registry, which is a bank of information about many patients. We are interested in learning about the relationship between your cancer and the different types of tests available to identify the best treatment option for you. That is, we are interested in the tests that identify possible ‘mutations’ (e.g., changes) or ‘drivers’ within your tumor, what treatments you receive after getting these tests, and how your cancer responds to the treatments. The tests known as next generation sequencing or “NGS” are usually done on your cancer tissue or blood samples as a part of your routine clinical care. Your doctor can use the information to identify the best treatment option for you after discussing it with other doctors. These routine tests will be performed whether you participate in this study or not, but we want to collect the information about this process for this study. If you participate in this study, extra samples of your blood will be collected and stored, and your health information from your medical record and NGS lab results will be collected and stored. |
NU 16U05: A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate CancerPurpose
The purpose of this research is to study two US FDA approved drugs alone or in combination with each other in people who have metastatic castration-resistant prostate cancer and specific changes in their DNA, to see which one is best at keeping prostate cancer from growing. Metastatic castration-… Purpose
The purpose of this research is to study two US FDA approved drugs alone or in combination with each other in people who have metastatic castration-resistant prostate cancer and specific changes in their DNA, to see which one is best at keeping prostate cancer from growing. Metastatic castration-resistant prostate cancer means the cancer is spreading outside of the prostate and does not stop or go away with hormone therapy or surgery to reduce testosterone. One of the drugs, Olaparib, is not FDA approved for prostate cancer, which means it is experimental or investigational.
Overview
Once prostate cancer has progressed to metastatic castration-resistant prostate cancer, standard treatment focuses on extending life, delaying disease progression, and improving symptoms and quality of life. The purpose of this research is to study two US FDA approved drugs alone and in combination with each other in people who have metastatic castration-resistant prostate cancer and DNA repair defects. One of the drugs, Olaparib, is not FDA approved for prostate cancer. People who take part in this research study have been diagnosed with metastatic castration-resistant prostate cancer and either their body or the the cancer have a genetic defect (flaw) that causes problems with their body‰Ûªs ability to repair damage to their DNA.
Description of Treatment
Participants will be placed into one of four groups. The treatment that each group will receive is as follows. Group 1 will receive Abiraterone (1000 mg by mouth once per day) and prednisone (5 mg by mouth twice per day). Group 2 and 4 will receive Olaparib (300 mg by mouth twice per day). Group 3 will receive Olaparib (300 mg by mouth twice per day), Abiraterone (1000 mg by mouth once per day) and prednisone (5 mg by mouth twice per day). Treatment may continue until disease progression, severe or unacceptable side effects, or until the participant or study doctor think the treatment should stop. Some of the eligibility criteria include: - participants must have been diagnosed with prostate cancer that is metastatic (has spread outside of the prostate region) and castration-resistant (means the cancer is still growing even when testosterone levels are close to zero) - participants must be males 18 years of age or above Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
NCT03012321 STU00203960 |
Physical activity and DNA methylation among women with high breast densityThe purpose of this study is to learn more about how physical activity may influence your genes through a mechanism called DNA methylation. Our goal is to determine if being physically active may be associated with a healthy pattern of DNA methylation in your immune system cells. Exercising and being … The purpose of this study is to learn more about how physical activity may influence your genes through a mechanism called DNA methylation. Our goal is to determine if being physically active may be associated with a healthy pattern of DNA methylation in your immune system cells. Exercising and being physically active are believed to be important for preventing cancer. It may be particularly important for women with high breast density, and may help reduce risk for breast cancer. However, we do not understand what physical activity changes within the body to alter risk of breast cancer. DNA methylation is a biological process that may help explain the relationship between physical activity and cancer risk. |
Melanoma and Skin Cancer Tissue RepositoryThe purpose of this study is to allow researchers studying and treating melanoma and other cancers to have access to tissue for research purposes only. Northwestern University may use your medical record information, as well as tumor, blood, saliva, urine, and fecal samples (collectively called “tissue”) for research studies to … The purpose of this study is to allow researchers studying and treating melanoma and other cancers to have access to tissue for research purposes only. Northwestern University may use your medical record information, as well as tumor, blood, saliva, urine, and fecal samples (collectively called “tissue”) for research studies to help us understand melanoma and other skin cancers. Biopsies and surgery of your cancer will not be a part of this study but will be performed as part of your standard care. |
The Role of Positron Emission Tomography and Magnetic Resonance Imaging (without Fluorodeoxyglucose or Gadolinium) in Yttrium-90 Radioembolization Treatment Planning for Patients with Liver MalignanciesPatients who are already scheduled to receive Y90 radioembolization, will first be treated with Y90 radioembolization for liver cancer or metastasis in the liver. They will then have a Positron Emission Tomography (PET/MR) scan done a few hours after the treatment. You will be placed inside a small … Patients who are already scheduled to receive Y90 radioembolization, will first be treated with Y90 radioembolization for liver cancer or metastasis in the liver. They will then have a Positron Emission Tomography (PET/MR) scan done a few hours after the treatment. You will be placed inside a small tube for 2-3 hours for the PET/MR scan. There is no contrast or radiation involved in the PET/MR scan. The purpose of the PET/MR scan is to capture specific images of the liver to see where the Y90 radioactive particles are a few hours after treatment. These images will be used to compare determine how much of the radioactive particles went to the tumor(s) compared to how much of them went to healthy liver tissue. We hope to use this information to help develop care that is more specific to the patient. Inclusion Criteria (patients must meet these criteria): 1. 18 years of age or older. 2. Diagnosed with primary liver cancer or metastasis in the liver. 3. Planning to have Y90 radioembolization treatment at Northwestern Medicine. 4. Be able to have an MRI- not claustrophobic or have any other contraindications to MRI. STU00205918 |
Clinical Database of Prostate Cancer at Northwestern UniversityThe goal of this study is to create a database of prostate cancer patients at Northwestern Memorial Group to better understand, learn about, prevent, treat or cure prostate cancer. |
The effect of inflammatory bowel disease flares on serum prostate specific antigenThis study will measure PSA values in men with IBD before, during, and following a flare. In addition, the effect of any PSA increase will be analyzed and correlated to the location of the disease (rectal vs. other). Study findings may help men with IBD by identifying pitfalls in prostate … This study will measure PSA values in men with IBD before, during, and following a flare. In addition, the effect of any PSA increase will be analyzed and correlated to the location of the disease (rectal vs. other). Study findings may help men with IBD by identifying pitfalls in prostate cancer screening for this population and help to stratify and understand the effect IBD has on the prostatic milieu. By optimizing how men with IBD are screened for prostate cancer, future unnecessary healthcare encounters and expenditures may be reduced for this patient group. Men with a confirmed diagnosis of inflammatory bowel disease (IBD) between the ages of 40-69 years old. NCT03558048 STU00207583 |
Mobile – PrOmoting Wellness after cancER Study: M-POWER Feasibility StudyM-POWER is an 8-week weight loss study in the Department of Preventive Medicine at Northwestern University. The participant will be given a smartphone application and have weekly telephone calls with health coaches. Participants will be asked to track their weight, diet, and activity through the smartphone application and … M-POWER is an 8-week weight loss study in the Department of Preventive Medicine at Northwestern University. The participant will be given a smartphone application and have weekly telephone calls with health coaches. Participants will be asked to track their weight, diet, and activity through the smartphone application and will be asked to recruit a "Buddy" to support them throughout their time in the study. Participants will be compensated for their time in the study. If you are interested in participating, please complete our eligibility here: https://tinyurl.com/2p86cm5a You are a cancer survivor (breast, melanoma, prostate or colorectal) between the ages of 18 and 84 years old. You own a smartphone; you are living with obesity and willing to participate in a weight-loss research study that focuses on health behavior changes.
STU00207968 |
(xIRB NCI CIRB) CCTG MA.39: TAILOR RT: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast CancerIn addition to endocrine therapy and possibly chemotherapy, many women with node positive breast cancer will also receive radiotherapy to the whole breast/chest area and the surrounding lymph glands (called regional radiotherapy). Because no one really knows whether patients with low risk breast cancer need to receive regional radiotherapy, … In addition to endocrine therapy and possibly chemotherapy, many women with node positive breast cancer will also receive radiotherapy to the whole breast/chest area and the surrounding lymph glands (called regional radiotherapy). Because no one really knows whether patients with low risk breast cancer need to receive regional radiotherapy, it is possible that some women who get it may not actually need it. These women may be exposed to the side effects of their treatment without benefit. The purpose of this study is to learn if not giving regional radiotherapy is just as good as using regional radiotherapy by comparing any good and bad effects of both approaches. The study has two randomly assigned study groups; Group 1 will receive regional radiotherapy and Group 2 will not. Patients who are of 40 years of age or older may be able to take part in this study if they have newly diagnosed breast cancer that has been treated with breast-conserving surgery or mastectomy and has not spread to other parts of the body.
NCT03488693 STU00208897 |
(xIRB NCI CIRB) NRG GY012: A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women with Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women with Recurrent or Persistent Endometrial Cancer.This is a study to look at a different approach to treating endometrial cancer. It is being done to answer the following question: Can we lower the chance of your endometrial cancer growing or spreading by giving a combination of two experimental drugs or one experimental drug rather than the … This is a study to look at a different approach to treating endometrial cancer. It is being done to answer the following question: Can we lower the chance of your endometrial cancer growing or spreading by giving a combination of two experimental drugs or one experimental drug rather than the usual approach? The purpose of this study is to compare any good and bad effects of using experimental study drugs cediranib alone, olaparib alone, or a combination of cediranib and olaparib. These drugs could shrink your cancer but they could also cause side effects. This study will allow the researchers to know whether one of these approaches is better, the same, or worse than the usual approach. The usual approach is defined as care most people get for endometrial cancer. You may be eligible for this research study if you have endometrial cancer which has grown or has returned after earlier treatment.
NCT03660826 STU00208995 |
An Open Label, Pilot Study Evaluating the Effect of Low-Dose Oral Minoxidil as Treatment of Permanent Chemotherapy-Induced AlopeciaThis study will test if low-dose oral minoxidil has an effect on permanent chemotherapy-induced alopecia (defined as hair loss after the completion of a chemotherapy regimen that persists for over six months). In this study, you will receive the study drug; there is no placebo option. The effectiveness … This study will test if low-dose oral minoxidil has an effect on permanent chemotherapy-induced alopecia (defined as hair loss after the completion of a chemotherapy regimen that persists for over six months). In this study, you will receive the study drug; there is no placebo option. The effectiveness and safety of the treatment will be determined by a range of assessments, including biopsies, images, and subjective evaluation of perceived hair growth. Age 18 and above with a diagnosis of permanent chemotherapy-induced alopecia and agree to use contraception for the duration of the study.
NCT03831334 STU00206882 |
NU 18B05: A Phase II Study of the Determinants of Transdermal Drug Delivery to the Normal and the Radiated BreastThe benefits of anti-estrogen medications taken by mouth as pills (such as tamoxifen) are well-proven to reduce the risk of breast cancer in studies with more than 10 years of follow up. However, because tamoxifen is taken by mouth, it circulates through the whole body and may cause … The benefits of anti-estrogen medications taken by mouth as pills (such as tamoxifen) are well-proven to reduce the risk of breast cancer in studies with more than 10 years of follow up. However, because tamoxifen is taken by mouth, it circulates through the whole body and may cause harmful effects to other organs. When tamoxifen is taken by mouth, it is broken down by the liver into two main active forms, one of which is 4-hydroxytamoxifen, also called 4-OHT. Tamoxifen is approved by the Food and Drug Administration (FDA) while 4-OHT is not and is, therefore, considered investigational. However, 4-OHT has anti-cancer activity, and has been developed as a quick drying medicated gel that can be applied to the breast skin. Early results from two previous studies show that 4-OHT gel, when applied to the skin, gets into the breast and blocks breast cancer cell growth as effectively as oral tamoxifen. Unlike oral tamoxifen, the gel is concentrated in the breasts and therefore very little tamoxifen reaches the blood or other parts of the body. Also, some women lack the proteins that are responsible for the break-down of tamoxifen. It is possible that the use of 4-OHT gel will be more effective than oral tamoxifen in these women. Patients who had radiation for breast cancer in one breast and their other breast has not undergone radiation
NCT04009044 STU00208708 |
Characterization of the microbiome in cutaneous T cell lymphomaThe purpose of this study is to investigate the organisms that reside on the skin, in the gut, and nasal cavity and study their relationship with Cutaneous T-Cell Lymphoma (CTCL).
STU00209226 |
(xIRB NCI) SWOG 1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast CancerThe purpose of this study is to determine if including thedrug olaparib taken along with radiation treatment decreases the recurrence of cancerin patients who have inflammatory breast cancer and have already hadchemotherapy and surgery to remove the cancer. The drug olaparib is already approved by the Food and DrugAdministration (FDA) … The purpose of this study is to determine if including thedrug olaparib taken along with radiation treatment decreases the recurrence of cancerin patients who have inflammatory breast cancer and have already hadchemotherapy and surgery to remove the cancer. The drug olaparib is already approved by the Food and DrugAdministration (FDA) for use in ovarian, fallopian tube, peritoneal cancer, andgBRCA mutated her2-negative metastatic breast cancer, however olaparib is notapproved for inflammatory breast cancer. inflammatory breast cancer who have already had chemotherapy and surgery to remove the cancer
NCT03598257 STU00209490 |
(xIRB) NRG-BN005 A Phase II Randomized Trial of Proton vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients with IDH Mutant, Low to Intermediate Grade Gliomas.The purpose of this study is to compare any good and bad effects of using proton therapy to using photontherapy. Photon therapy is the usual treatment approach for brain cancer. Proton therapy uses a beam ofproton particles to send radiation inside the body to the tumor. This study will allow … The purpose of this study is to compare any good and bad effects of using proton therapy to using photon therapy. Photon therapy is the usual treatment approach for brain cancer. Proton therapy uses a beam of proton particles to send radiation inside the body to the tumor. This study will allow the researchers to know whether proton therapy is better, the same, or worse than the usual approach. Proton therapy may have less negative effects on brain function than photons because less brain is exposed to radiation when proton therapy is used. However, proton therapy might also be associated with more frequent tumor recurrences. -Participants must be 18 years of age or older -Participants must be diagnosed with a brain tumor
NCT03180502 STU00209631 |
A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)… The purpose of this study is to test your tumor tissue for certain biomarker (which may be the cause of your cancers, such as specific mutations in certain proteins). This will help determine your eligibility to participate in either matched sub-studies involving investigational agents that targets the specific mutated protein or alternatively to un-matched sub-studies.
NCT03851445 STU00209659 |
(xIRB NCI CIRB) ETCTN 10183: A Pilot Study of Tazemetostat and MK-3475 (Pembrolizumab) in Advanced Urothelial CarcinomaThe purpose of this study is to see how peoplewith advanced urothelial carcinoma respond to an approved treatment for thistype of cancer (MK-3475) in combination with the study drug tazemetostat(MK-3475 with tazemetostat). Tazemetostat is an investigational drug, whichmeans it is not approved by the FDA. Laboratory research … The purpose of this study is to see how peoplewith advanced urothelial carcinoma respond to an approved treatment for thistype of cancer (MK-3475) in combination with the study drug tazemetostat(MK-3475 with tazemetostat). Tazemetostat is an investigational drug, whichmeans it is not approved by the FDA. Laboratory research indicates thatcombining the two drugs has the potential to have a better response thanMK-3475 alone.
This study will help the study doctors findout the safest and most effective dose for tazemetostat when combined withMK-3475. It will also help doctors determine if the combination treatment has abetter anticancer effect than treatment with MK-3475 alone. To decide if it isbetter, the study doctors will be looking to see if adding tazemetostatimproves the response rates of patients compared to the usual approach. Diagnosis ofadvanced urothelial carcinoma · Age of at least 18 years NCT03854474 STU00209918 |
NU MTBC 18M02: International Melanoma Tissue Bank Consortium Site at Northwestern UniversityThe purpose of this research study is to create a MTBC biorepository (the “MTBC Biobank”) of human biospecimens (the “Biospecimens”) and medical and health history information, for example, test and treatment results, age, gender, history of sun exposure (the “Annotating Data”). This part of the project is called the “Biobanking … The purpose of this research study is to create a MTBC biorepository (the “MTBC Biobank”) of human biospecimens (the “Biospecimens”) and medical and health history information, for example, test and treatment results, age, gender, history of sun exposure (the “Annotating Data”). This part of the project is called the “Biobanking Study”. The second purpose is for MTBC to provide the Biospecimens and/or Annotating Data from the MTBC Biobank to researchers around the world for them to use in specific studies in order to study melanoma (“Future Use Study). Melanoma is a lethal form of skin cancer and more research is necessary to help scientists to understand what causes it, how to diagnose it, how it can be prevented, and how it can be treated. To do this research, scientists need biospecimens (like biopsied tissue and blood samples) from people who have been diagnosed with melanoma and other skin disorders. This study will help scientists learn about melanoma and the projects being conducted on behalf of the Melanoma Tissue Bank Consortium(“MTBC”).
We are asking you to take part in this research study because you have melanoma or another skin disorder.Your participation is completely voluntary. You may choose not to take part.Your decision to sign this informed consent and authorization form in order to participate in the Biobanking Study and to allow the use of your Biospecimens and Annotating Data in a Future Use Study will not change the treatment you receive for your skin disorder.
STU00209847 |
DRUG KRT-232-103: A Phase 1b/2, Open-Label Study Evaluating the Safety and Efficacy of KRT-232 in Patients with p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy, or in Combination with Avelumab in MCC Patients who are Anti-PD-1 or Anti-PD-L1 Treatment NaïveWe are asking you to take part in this research study because you have been diagnosed with Merkel cell carcinoma (MCC) and your prior treatment with a specific immunotherapy (a type of therapy called anti-PD-1 or anti-PD-L1) was not or is no longer effective for your … We are asking you to take part in this research study because you have been diagnosed with Merkel cell carcinoma (MCC) and your prior treatment with a specific immunotherapy (a type of therapy called anti-PD-1 or anti-PD-L1) was not or is no longer effective for your disease. The purpose of this study is to evaluate how well tolerated KRT-232 is when given to participants with Merkel cell carcinoma, and whether KRT-232 can improve your MCC. In order to participate in this study, your Merkel cell carcinoma cells must be a certain type of cell, called “p53 wild type” cells (p53wt). NCT03787602 STU00209401 |
A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)This study is being done to answer the following questions:1. Is adding a new anti-cancer drug (venetoclax) to the usual treatment (ibrutinib plusobinutuzumab) better, the same as, or worse than the usual treatment alone for untreatedolder patients with CLL?2. Can patients who have no detectable CLL after … This study is being done to answer the following questions:1. Is adding a new anti-cancer drug (venetoclax) to the usual treatment (ibrutinib plusobinutuzumab) better, the same as, or worse than the usual treatment alone for untreatedolder patients with CLL?2. Can patients who have no detectable CLL after a year of receiving the usual treatmentplus the new anti-cancer drug discontinue therapy? Some of the eligibility criteria include: - Participants must have intermediate or high-risk chronic lymphocyticleukemia that has not been treated before - Participants must be 18 or older - Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
NCT03737981 STU00210225 |
Yttrium-90 Radiation Lobectomy: Dose Optimization and Prediction of FLR Hypertrophy to Enable Resection of Hepatic MalignanciesIn the study, there will be many patients, like you, with hepatocellular carcinoma (HCC) who are eligible to receive a treatment called Y90 radioembolization and who may also be liver resection candidates.Y90 radioembolization is a non-invasive, out-patient treatment that uses radioactive beads (microspheres), which are tiny glass … In the study, there will be many patients, like you, with hepatocellular carcinoma (HCC) who are eligible to receive a treatment called Y90 radioembolization and who may also be liver resection candidates. Y90 radioembolization is a non-invasive, out-patient treatment that uses radioactive beads (microspheres), which are tiny glass particles that are loaded with radiation. The beads are injected into an artery of the liver that supplies blood to the tumor(s). The beads flow to the tumor(s) and become trapped inside. The beads release the Y90 radiation inside the tumor(s). Liver resection is used to remove the part of the liver that has the liver tumor(s). It has been shown that Y90 radioembolization can increase the untreated liver’s size and volume. Patients with HCC may be liver resection candidates if they have a large enough liver. The purpose of this research is to determine if there is an ideal Y90 dose to increase liver volume. This research may help determine the best Y90 dose for future patients who need a larger liver to have a liver resection. If you participate in this study, you will have standard-of-care Y90 radioembolization as well as study-specific imaging and two optional liver biopsies. You will participate in the study for up to 3 months. Your health status will continue to be followed for up to 5 years. Patients enrolled in the study will receive up to $195.00 for their participation. You are eligible to participate in this study if: 1. You are an adult 18 years of age or older 2. You have been diagnosed with hepatocellular cancer and may be a liver resection candidate to remove your disease
NCT04390724 STU00209629 |
Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder CancerThepurpose of this study is to compare the effects, good and/or bad, ofchemotherapy and radiation therapy with or without the use of atezolizumab,which is used to treat bladder cancer. The combination of chemotherapy,radiation therapy and the immunotherapy atezolizumab is consideredexperimental.… Thepurpose of this study is to compare the effects, good and/or bad, ofchemotherapy and radiation therapy with or without the use of atezolizumab,which is used to treat bladder cancer. The combination of chemotherapy,radiation therapy and the immunotherapy atezolizumab is consideredexperimental.
NCT03775265 STU00210415 |
A randomized, controlled, multi-center, safety and efficacy study of FCR001 cell-based therapy relative to a tacrolimus and mycophenolate-based regimen in de novo living donor renal transplant recipients, and safety in FCR001 donorsResearch study which involves the use of a combination of an Enriched Hematopoetic Stem Cell Infusion (stem cells, produced by the bone marrow, generate the cells that form the blood elements, help fight infection and assist in clotting) and kidney transplantation from the same donor to try to avoid the … Research study which involves the use of a combination of an Enriched Hematopoetic Stem Cell Infusion (stem cells, produced by the bone marrow, generate the cells that form the blood elements, help fight infection and assist in clotting) and kidney transplantation from the same donor to try to avoid the need for long-term anti-rejection drug therapy. The desired result of this study is to allow your body to develop "tolerance" to the transplanted kidney. Tolerance means that your body would see the transplanted kidney as part of you and not try to get rid of, or reject it. To prevent rejection, drugs called immunosuppressive agents must be taken on a daily basis. The purpose of this study is to determine if this procedure is safe and to try to substantially reduce or even eliminate the need for anti-rejection medications. NCT03995901 STU00209928 |
(XIRB) DRUG IMSA101-101: Phase I/IIA Safety and Efficacy Study of IMSA101 in Patients with Advanced Treatment-Refractory MalignanciesThe purpose of this research is to find a safe and tolerable dose of the study drug, IMSA101, for the treatment of your type of cancer and other types of cancer. … The purpose of this research is to find a safe and tolerable dose of the study drug, IMSA101, for the treatment of your type of cancer and other types of cancer. All adult subjects ages 18 and above with advanced cancer that is no longer responding to standard of care treatment are eligible to participate.
NCT04020185 STU00210768 |
BTCRC HN17-111: Phase II trial of androgen deprivation therapy (ADT) and pembrolizumab for advanced stage androgen receptor-positive salivary gland carcinomaThis study is being done to study two investigational drugs called pembrolizumab and goserelin to see if they shrink your cancer or stop it from growing. … This study is being done to study two investigational drugs called pembrolizumab and goserelin to see if they shrink your cancer or stop it from growing. You may be eligible for this research study if you have salivary gland carcinoma that has grown or has come back after treatment.
NCT03942653 STU00210435 |
PD-inhibitor (Nivolumab) and Ipilimumab followed by nivolumab vs. VEGF TKI cabozantinib with nivolumab in metastatic untreated REnal Cell CancEr [PDIGREE]This study is being done to answer the following question: Can we prolong life for patients withadvanced kidney cancer, by adding a drug called cabozantinib to another treatment afterreceiving the standard treatment?We are doing this study because we want to find out if this approach isbetter or worse than … This study is being done to answer the following question: Can we prolong life for patients with advanced kidney cancer, by adding a drug called cabozantinib to another treatment after receiving the standard treatment? We are doing this study because we want to find out if this approach isbetter or worse than the usual approach for your advanced kidney cancer. The usual approach is defined as care mostpeople get for advanced kidney cancer. -Participants must be 18 years of age or older -Participants must be diagnosed with advanced kidney cancer
NCT03793166 STU00210884 |
(xIRB) NCI CIRB NRG GY019: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or PeritoneumThe purpose of this study is to compare the treatment of carboplatin/paclitaxel and letrozole hormonal therapy to letrozole alone. The use of the hormonal therapy drug letrozole without chemotherapy may shrink or stabilize cancer in the same way that chemotherapy also does, but without the added side effects of … The purpose of this study is to compare the treatment of carboplatin/paclitaxel and letrozole hormonal therapy to letrozole alone. The use of the hormonal therapy drug letrozole without chemotherapy may shrink or stabilize cancer in the same way that chemotherapy also does, but without the added side effects of chemotherapy. Letrozole is a drug called an aromatase inhibitor, which indirectly stops the body from producing estrogen. This study will investigate if this approach is better, the same, or worse than the usual approach. In order to determine if the use of letrozole alone helps to improve treatment for patients with low-grade serous ovarian or peritoneal cancer compared to combined chemotherapy and letrozole, half of patients in this study will receive letrozole with paclitaxel/carboplatin and the other half will receive letrozole alone. The study doctors will be looking to see if the letrozole alone prolongs the time cancer is in remission, or the duration of time participants are alive after treatment. Letrozole is approved by the FDA for breast cancer, but is not FDA approved for ovarian cancer and is therefore considered experimental in this setting. Participants will get either the combination of paclitaxel and carboplatin for four and a half months followed by letrozole or letrozole alone. Patients who are assigned to letrozole monotherapy will continue taking the letrozole for as long as they are tolerating the drug (i.e., have not developed any allergies or severe side effects with the medication) and have not experienced a recurrence or progression of their disease. After participants finish their study treatment, their doctor and study team will continue to follow their condition and watch for side effects during clinic visits or by phone. Participants will be checked every 3 months for the first 3 years after treatment. After that, this will happen every 6 months for two years.
NCT04095364 STU00211055 |
(xIRB) NCI CIRB: Alliance A071701: Genomically-Guided Treatment Trial in Brain Metastases… The purpose of this study is to test good and bad effects of different drugs against metastatic brain tumors with altered genes. This trial is trying to see if tumor genetic testing would be helpful at guiding treatment in patients such as you. Researchers have looked at the DNA material (genes) that can be affected in brain metastases and have found several genes that are altered, or mutated. There are medications that target these genes.
We are doing this study because we want to find out if this approach is better or worse than the usual approach for your metastatic cancer. The usual approach is defined as care most people get for your metastatic cancer.
NCT03994796 STU00211229 |
(xIRB) NCI CIRB ECOG-ACRIN 2182: A Randomized Phase II Study of De-Intensified ChemoRadiation for EarlyStage Anal Squamous Cell Carcinoma (DECREASE)This study will helpthe study doctors find out if this different approach is the same as the usualapproach. To decide if it is aseffective, the study doctors will be looking to see if the study approach showsat least the same results as the normal approach. This study has 2 studygroups. · … This study will helpthe study doctors find out if this different approach is the same as the usualapproach. To decide if it is aseffective, the study doctors will be looking to see if the study approach showsat least the same results as the normal approach. This study has 2 studygroups. · Participants in groupA will get the standard dose of chemoradiation therapy: this includesMitomycin-C and 5-Fluorouracil or Capecitabine, as well as radiation. Therewill be 28 radiation treatment sessions in this group. · Group 2 (Arm B) Participants in group2 you will get the lower dose of chemoradiation therapy: this includesMitomycin-C and 5-Fluorouracil or Capecitabine, as well as radiation. Therewill be 20 or 23 radiation treatment sessions in this group, depending on thesize of the tumor. Participants who are 18 years of age or older with anal cancer will beinvited to participant in this study.
NCT04166318 STU00211554 |
NU 19H08: Signal Transduction of Type I Interferons in Malignant CellsThis is a lab study of a group of diseases called myeloproliferative neoplasms (MPN). MPN is abnormal blood coagulation (abnormal or irregular blood clotting) and includes polycythemia vera (PV) and essential thrombocytosis (ET). The purpose of this research is to learn more about how a drug called interferon stops the … This is a lab study of a group of diseases called myeloproliferative neoplasms (MPN). MPN is abnormal blood coagulation (abnormal or irregular blood clotting) and includes polycythemia vera (PV) and essential thrombocytosis (ET). The purpose of this research is to learn more about how a drug called interferon stops the growth of MPN blood cells in the laboratory. Alpha-interferon is a natural protein present in the body in small amounts. Treatment with interferon is known to have significant activity in MPN, but the way that this drug works is not fully known. |
Randomized controlled trial assessing transperineal prostate biopsy to reduce infection complicationsProstate cancer is the most commonly diagnosed malignancy in U.S. men. There are approximately 1 million prostate biopsy performed annually in the U.S. Almost all biopsies are performed as an office based procedure in under 15 minutes. The precision of biopsy has improved over the last decade with … Prostate cancer is the most commonly diagnosed malignancy in U.S. men. There are approximately 1 million prostate biopsy performed annually in the U.S. Almost all biopsies are performed as an office based procedure in under 15 minutes. The precision of biopsy has improved over the last decade with the introduction of MRI guidance/targeting of suspicious lesions within the prostate. However, significant limitations remain with this approach, including a significantly increasing risk of post-biopsy infection. This arises because more than 97% of all prostate biopsy are performed via a transrectal approach that introduces rectal bacteria with each pass of the biopsy needle into the sterile urinary tract. The current risk of post-transrectal biopsy infection, even with antimicrobial prophylaxis, is high at approximately 7% overall with 3% (30,000 men) requiring hospitalization annually. Transperineal biopsy is an alternate approach that eliminates the direct introduction of bacteria from the rectum to the prostate. This approach, which is perfomed without antimicrobial prophylaxis, instead passes the biopsy needle through the perineal skin and pelvic floor. Transperineal biopsy has not been widely adopted for several reasons. Historically, it has been considered too painful for patients in the clinic and thus was traditionally performed under general anesthesia. The added time, inconvenience and cost has limited its national adoptance. Second, when transrectal biopsy was initially adopted over 40 years ago, antibiotic resistance of rectal flora was not a challenge. Beyond the potential for in-office transperineal biopsy to significantly reduce or eliminate biopsy infections, transperineal biopsy may also improve cancer detection: studies of transperineal biopsy (performed under general anesthesia) demonstrate higher detection rates for prostate cancer, particularly for anterior zone tumors, compared to transrectal biopsy. This is notable, as anterior tumors are difficult to sample with transrectal. Anterior tumors are also twice as likely to occur in African American men. In fact, our research demonstrates that some of the outcomes disparities in African American men may stem from an underdiagnosis of anterior prostate cancers. Although transrectal biopsy is used widely, it is associated with a significant and increasing risk of biopsy infections due to growing antibiotic resistance, highlighting the urgent need for a safer alternative approach to prostate biopsy. The study investigators have refined a transperineal approach under local anesthesia with MRI-targeting/guidance without the need for antibiotic prophylaxis. The investigators hypothesize that transperineal MRI targeted biopsy will: (1) largely eliminate post-biopsy infections and costly hospitalizations for urosepsis; (2) be performed in the office with similar discomfort and non-infectious complications compared to transrectal MRI targeted biopsy; and (3) have significantly better detection of prostate cancer. This multi-center randomized controlled trial will be conducted to evaluate in-office transperineal MRI targeted vs. transrectal MRI targeted biopsy, the current gold standard. This has transformative impact to change current standard of practice. This study will include allmen who are recommended to undergo prostate biopsy as part of routine clinicalcare. NCT04815876 STU00211699 |
DRUG CKAZ954A12101: A Phase I/IB, Open-label, Multi-Center, Study of KAZ954 as a Single Agent and in Combination With Spartalizumab, NZV930 and NIR178 in Patients with Advanced Solid TumorsThe purpose of the study is to identify the best dose and treatment schedule of KAZ954 alone,and with Spartalizumab (PDR001), NIR178 or NZV930 that can be given safely to patients with cancer.… The purpose of the study is to identify the best dose and treatment schedule of KAZ954 alone,and with Spartalizumab (PDR001), NIR178 or NZV930 that can be given safely to patients with cancer. All patients age 18 and above who have advanced cancers are eligible to participate.
NCT04237649 STU00211372 |
(xIRB) DRUG JCAR017-FOL-001: A Phase 2, Open-Label, Single-Arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of jcar017 in Adult Subjects with Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma (NHL) (Transcend FL)The purpose of this research study is to determineif the experimental therapy called JCAR017 is effective and safe to treatFollicular Lymphoma or Marginal Zone Lymphoma.This study will have 4 cohorts or patientgroups. Assignment to one of these patient groups depends on if you haveFollicular Lymphoma or Marginal Zone Lymphoma … The purpose of this research study is to determineif the experimental therapy called JCAR017 is effective and safe to treatFollicular Lymphoma or Marginal Zone Lymphoma. This study will have 4 cohorts or patientgroups. Assignment to one of these patient groups depends on if you haveFollicular Lymphoma or Marginal Zone Lymphoma and the number and type oftreatments that you have received in the past, as well as how long it took foryour lymphoma to return after your last treatment. Everyone in all 4 patientgroups will receive the same dose of JCAR017 T cells. JCAR017 is a type oftherapy known as chimeric antigen receptor (CAR) T cell therapy which isco-developed with Juno Therapeutics. The visit schedule will also be the samefor all 4 patient groups. At the time you decide to take part in the study andgo through the screening procedures, it will be determined which patient groupyou will be assigned to. In this study, your immunecells will be collected from your blood in a procedure called leukapheresis.The T cells will be separated from the collected immune cells and will bemodified in a laboratory. In the laboratory, a new gene will be put into your Tcells using genetic modification techniques. After they have been modified, thecells will be grown in the laboratory to reach the expected dose for thetreatment. Adding in the new gene may enable your T cells (now called JCAR017 Tcells) to bind to the CD19 protein, which your type of cancer cells carry ontheir surface. Binding to these cells activates the JCAR017 T cells, and theyattack the cancer cells. The JCAR017 T cells will persist in your body afterattacking the cancer cells, you will be monitored during the study to evaluatehow long these JCAR017 T cells persist. The JCAR017 T cells will be given backto you via infusion (IV).
Note:This is only a partial description of treatment. Please contact the Robert H.Lurie Comprehensive Cancer Center of Northwestern University if you areinterested in the trial. Age of at least 18 years Diagnosis of Follicular Lymphoma or Marginal Zone Lymphoma, which has either returned or is not responding toyour current treatment. Follicular Lymphoma and Marginal Zone Lymphoma are twotypes of non-Hodgkin lymphoma (NHL). Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT04245839 STU00212069 |
A PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF OQL011 ON VEGFR INHIBITOR-ASSOCIATED HAND-FOOT SKIN REACTION IN CANCER PATIENTSThis study is trying to determine whether an ointment is safe and effective for the treatment of hand-foot skin reaction induced by VEGRF inhibitors. Participants must be over the age of 18 and have hand-foot skin reaction after taking anti-cancer medications calls VEGRF inhibitors.
NCT04088318 STU00211322 |
NU COVID-19 MSK20H04: Examining COVID19 Course and Outcomes in Patients Previously Diagnosed with Chronic Lymphocytic Leukemia (CLL)This multicenter, retrospective cohort study will include patientstreated at national and international medical centers. Patients will be included if they have a prior diagnosis of CLL, havebeen diagnosed with COVID19, and received care at a participating medicalcenter. Primary Aim: To determine the 28-daymortality rate from the time of COVID … This multicenter, retrospective cohort study will include patientstreated at national and international medical centers. Patients will be included if they have a prior diagnosis of CLL, havebeen diagnosed with COVID19, and received care at a participating medicalcenter. Primary Aim: To determine the 28-daymortality rate from the time of COVID 19 diagnosis for CLL patients infectedwith SARS-CoV2 at MSKCC and other institutions. Secondary Aims: To describe baseline characteristics, prior and current CLL directed therapies, COVID19 clinical course and outcomes for CLL patients infected with SARS-CoV2. To examine relationships between CLL directed therapy and COVID19 disease course and outcomes. To examine current practices regarding management of CLL directed therapy in CLL patients infected with SARS-CoV2. |
NU FC19L02: Phase II randomized trial of carboplatin + pemetrexed + bevacizumab, with or without atezolizumab in stage IV non-squamous NSCLC patients who harbor a sensitizing EGFR mutation or have never smokedThe purpose of this research study is to determine if the combination therapy of carboplatin, pemetrexed, bevacizumab (Avastin) and atezolizumab (Tecentriq) is better at controlling disease progression in patients with sensitizing EGFR mutation induced NSCLC or patients with NSCLC who are never-smokers as compared to the combination without Tecentriq. … The purpose of this research study is to determine if the combination therapy of carboplatin, pemetrexed, bevacizumab (Avastin) and atezolizumab (Tecentriq) is better at controlling disease progression in patients with sensitizing EGFR mutation induced NSCLC or patients with NSCLC who are never-smokers as compared to the combination without Tecentriq. All prospective patients will undergo screening tests to determine if they are eligible to take part in the study. A computer will by chance assign patients to one of the two arms in the study. This is called randomization. •Arm A: Carboplatin + Pemetrexed + Avastin + Tecentriq •Arm B: Carboplatin + Pemetrexed + Avastin Arm A: Participants will receive carboplatin, pemetrexed, Avastin and Tecentriq for 4 cycles in the treatment phase, followed by pemetrexed, Avastin and Tecentriq for the rest of the cycles, called the maintenance phase. Arm B: Participant will receive carboplatin, pemetrexed and Avastin for 4 cycles in treatment phase, followed by pemetrexed and Avastin during the following cycles of the maintenance phase. Participants will be asked to take the study drugs as long as they are benefitting from the treatment or their disease does not get worse. Participants will be removed from the study if the study doctor thinks that they have unacceptable toxicities due to the study drug/s and it is in their best interest to stop participating in the study. All the drugs will be administered intravenously on Day 1 of each cycle. Each cycle is made of 21 days. The number of cycles will depend on how participants respond to treatment. During the study, participants will have a CT scan every 6 weeks (every 9 weeks during the maintenance phase). Participants will also undergo a physical exam, blood tests, performance status, and vital signs. Blood will be collected during the study. A biopsy for tissue will be collected if the participant agrees. Note: This is only a partial description of treatment. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Some of the eligibility criteria include: •Stage IV advanced non-small cell lung cancer (NSCLC) with a sensitizing EGFR mutation or without a history of smoking •Age of at least 18 years Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT03786692 STU00211923 |
Immune checkpoint inhibitor-associated acute kidney injurySince 2011, six immune checkpoint inhibitors (ICIs), a type of immunotherapy, have been approved by the Federal Drug Administration for use in patients with cancer. These medications have been demonstrated to have great promise for treating a variety of cancers. However, there are toxicities associated with these agents, … Since 2011, six immune checkpoint inhibitors (ICIs), a type of immunotherapy, have been approved by the Federal Drug Administration for use in patients with cancer. These medications have been demonstrated to have great promise for treating a variety of cancers. However, there are toxicities associated with these agents, known as immune-related adverse events (AKI), some of which can be fatal. Affected organs include the skin (rash), gastrointestinal tract(diarrhea), and the kidneys (acute kidney injury [AKI]). This study, led by Drs. Shruti Gupta and David Leaf at Brigham and Women’s Hospital, has the goal of collecting data on over 300 ICI-associated acute kidney injury cases from more than 30 academic medical centers worldwide. We will characterize the clinical features of ICI-associated AKI in the hope that this will help us to determine predictors of toxicity and best practices for management. STU00212602 |
(xIRB) DRUG AVM-003-HC: Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR-105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant.The purpose of this study is to determine if the study drug, ALVR-105, is safe and works well in the treatment for HC. The study will compare ALVR-105 to placebo in reducing your bladder pain, reducing the amount of blood in your urine, and seeing if specific viruses … The purpose of this study is to determine if the study drug, ALVR-105, is safe and works well in the treatment for HC. The study will compare ALVR-105 to placebo in reducing your bladder pain, reducing the amount of blood in your urine, and seeing if specific viruses are lowered in your blood and urine. This is a randomized double-blind study. “Randomized” means that you will be randomly assigned (like the flip of a coin) to receive either ALVR-105, or placebo (inactive substance). You will have a 60% chance of receiving ALVR-105 and a 40% chance of receiving placebo. Your participation in this study will last approximately 6 months and include about 10 study visits to the study site. Some of these study visits will occur when you are already in the hospital in which case the study team will visit you to complete the study visit. In healthy people, T-cells defend the body against viruses. Because of the early stage / premature engraftment and /or immune suppressing therapy given for the HCT, T-cell numbers are low, and it is more difficult for the body to control viruses that are already in your body, but are not active. If you have low T-cell numbers and your body cannot control viruses, some of these viruses can cause HC. Viralym-M (ALVR-105) is a research study medicine that contains T-cells made from healthy human donors to potentially help defend your body against specific viruses. The research study medicine is “investigational.” It has not been approved by the United States Food and Drug Administration (FDA), the health authority that approves new medicine being prescribed for use in the United States. This means that it is not approved to treat patients with hemorrhagic cystitis or any other disease. All prospective patients will undergo screening tests to determine if they are eligible to take part in the study. If you qualify, the research study medicine (ALVR-105 or placebo) will be given to you by an infusion into a vein (IV injection). You will receive a second dose of research study medicine about two weeks after your first dose. Note: This is only a partial description of treatment. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Some of the eligibility criteria include: •Age of at least 18 years •Diagnosis of hemorrhagic cystitis (HC) caused by a viral infection after your allogeneic hematopoietic cell transplant (HCT) Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. NCT04390113 STU00213027 |
(xIRB) NCI CIRB ECOG-ACRIN 2185: Comparing the Clinical Impact of Pancreatic Cyst Surveillance ProgramsThe purpose of this study is tocompare the two approaches for monitoring pancreatic cysts. The doctors want tosee if less frequent monitoring is better or worse than more frequentmonitoring for patients with pancreatic cysts. This study has 2 study groups: Group 1Participants in this group willget less frequent monitoring. Participants … The purpose of this study is tocompare the two approaches for monitoring pancreatic cysts. The doctors want tosee if less frequent monitoring is better or worse than more frequentmonitoring for patients with pancreatic cysts. This study has 2 study groups: Group 1 Participants in this group willget less frequent monitoring. Participants will receive an MRI or CT imagingscan at the beginning of the study and repeat the scan 1 year after joining thestudy. If the scans show normal results, scans will be repeated every 2 years.If the scans show abnormal results, participants will receive an endoscopicultrasound. Group 2 Participants in this group willget more frequent monitoring. Participants will receive an MRI or CT imagingscan at the beginning of the study. . The frequency of repeat imaging couldrange from every 6 months to every 2 years, based on the size of theparticipant's pancreatic cyst. Participants will be enrolled forup to five years.
Participants between the ages of 50and 75 who have pancreatic cysts will be enrolled into this study.
NCT04239573 STU00213102 |
Phase 1/2 trial of blood-brain barrier opening with the SonoCloud-9 implantable ultrasound device and treatment with albumin-bound paclitaxel in patients with recurrent glioblastomaEligible patients will undergo craniotomy for tumor resection. During the tumor resection and when possible, an initial low dose of albumin-bound paclitaxel will be given following sonication. In select patients, the sonication procedure may occur immediately after the test dose of chemotherapy is administered. The sonication device will be … Eligible patients will undergo craniotomy for tumor resection. During the tumor resection and when possible, an initial low dose of albumin-bound paclitaxel will be given following sonication. In select patients, the sonication procedure may occur immediately after the test dose of chemotherapy is administered. The sonication device will be implanted at the end of the procedure. In phase 1, about two weeks after surgery, patients will undergo sonication and albumin-bound paclitaxel administration with MRI to quantify extent of blood brain barrier opening. Sonication and administration of albumin-bound paclitaxel will continue every 3 weeks until disease progression. The planned albumin-bound paclitaxel starting dose is 40 mg/m2, to be escalated in the absence of significant toxicity up to 260 mg/m2. Blood samples for circulating tumor DNA will also be collected before and after each sonication. In phase 2, pre-sonication carboplatin at AUC 5 will be added to the regimen, with a safety run-in for the first 6 patients. Inclusion Criteria: Measurable or evaluable disease For patients with a childbearing potential Exclusion Criteria: Have multifocal disease that cannot be encompassed in the ultrasound fields:
NCT04528680 STU00212298 |
NRG HN006: Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity CancerThis study is being done to answer the following questions: 1) will neck and shoulder function and discomfort be better if you have a procedure called sentinel lymph node (SLN) biopsy instead of the usual surgery for this type of cancer; and 2) is SLN biopsy the same as the … This study is being done to answer the following questions: 1) will neck and shoulder function and discomfort be better if you have a procedure called sentinel lymph node (SLN) biopsy instead of the usual surgery for this type of cancer; and 2) is SLN biopsy the same as the usual surgery in extending the time you have without cancer returning? The usual approach is defined as care most people get for this cancer. This study has 2 parts. In the first part,doctors will try to learn the answer to question #1 above. If the answer shows that neck and shoulder function and discomfort is better in patients who have the SLN biopsy, then the study will go on to the second part, and doctors will try to answer question #2.
NCT04333537 STU00213298 |
(xIRB) NCI CIRB ECOG-ACRIN 2186: A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)The purpose of this study is to determine whether Gemcitabine and Nab-paclitaxel or 5-Fluorouracil,Leucovorin, and Liposomal Irinotecan are more effective treatments for vulnerable patients over the age of 70 with newly diagnosed metastatic pancreatic cancer (mPCA). These drugs are already approved by the FDA for use in … The purpose of this study is to determine whether Gemcitabine and Nab-paclitaxel or 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan are more effective treatments for vulnerable patients over the age of 70 with newly diagnosed metastatic pancreatic cancer (mPCA). These drugs are already approved by the FDA for use in pancreatic cancer. But, it is unknown which combination is the most effective for vulnerable mPCA patients over the age of 70. This study will help the study doctors find out which approach is better at prolonging the life of patients over 70 with mPCA. To determine this, the study doctors will be looking to see which of the two approaches shows better results. Participants who participate will be randomized to either get Gemcitabine and Nab-paclitaxel every other week or 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan every other week. This study has 2 study groups. Group 1 (Arm A) Participants in this group will get the combination treatment of Gemcitabine and Nab-paclitaxel. Group 2 (Arm B) Participants in this group will get the combination treatment of 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan. Your doctor will continue to follow your condition for up to 2 years after you start the study, and watch you for side effects and monitor your cancer. Vulnerable patients over the age of 70 with newly diagnosed metastaticpancreatic cancer (mPCA).
NCT04233866 STU00213326 |
Prospective Molecular Profiling To Guide Therapeutic Decision-making in Patients with Advanced Hepatocellular Cancer (HCC): An Insight to Next Generation Sequencing-Matched Systemic Therapy in Liver Cancer (PROTOLIGHT STUDY)Hepatocellular carcinoma (HCC) is the most common form of liver cancer, making up approximately 90% of all liver cancers. It is the fourth largest contributor to cancer-related deaths worldwide. HCC is considered to be a complex tumor. Despite recent drug approvals for HCC, it has become clear that only … Hepatocellular carcinoma (HCC) is the most common form of liver cancer, making up approximately 90% of all liver cancers. It is the fourth largest contributor to cancer-related deaths worldwide. HCC is considered to be a complex tumor. Despite recent drug approvals for HCC, it has become clear that only some populations of patients benefit from certain drugs. This leads researchers to suspect that treatment for HCC would be more effective if we could match specific characteristics of a patient’s tumor with a drug that targets them best. Genomic analysis using an FDA-approved method called Next Generation Sequencing (NGS) could be used to potentially help physicians make such treatment decisions. The purpose of this study is to see how long patients will benefit if genomic analysis of their tumors is used to recommend more targeted treatments for HCC from a number of FDA-approved drugs. Eligible participants are at least 18 years of age and have advanced hepatocellular cancer (HCC) or recurrent HCC for which they have not yet received systemic therapy for, and are are not candidates for resection, transplant or liver-directed therapies.
STU00212975 |
Impact of immunotherapy-related skin diseases on quality of lifeThe purpose of this study is to characterize the effects of cutaneous side effects from immunotherapies on quality of life. Participants will complete a one time survey. |
(xIRB NCI CIRB) ECOG-ACRIN 1181: Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer) (CompassHER2-pCR)This study isbeing done to answer the following question: Can participantswith HER2-positive breast cancer who have no cancer remaining at surgery(either in the breast or underarm lymph nodes) after 12 weeks of chemotherapyand two HER-targeted therapies eliminate further chemotherapy after surgery? This would be adecrease in the … This study isbeing done to answer the following question: Can participantswith HER2-positive breast cancer who have no cancer remaining at surgery(either in the breast or underarm lymph nodes) after 12 weeks of chemotherapyand two HER-targeted therapies eliminate further chemotherapy after surgery? This would be adecrease in the total number of chemotherapy drugs and the amount ofchemotherapy typically received to treat this type of cancer. We are doing thisstudy because we want to find out if this approach can enable you to take fewerchemotherapy drugs than the usual approach for your type of breast cancerwithout compromising your outcome. The usual approach is defined as care mostpeople get for HER2-positive breast cancer. Usual treatment includes additional chemotherapy drugs that might not benecessary, since the HER2-targeted drugs are so effective. The names of thestudy drugs involved in this study are:
All chemotherapy drugs will be givenintravenously through vein for 4 cycles. A cycle consists of 3 weeks. Before surgery, paclitaxel will be givenweekly for 12 weeks; pertuzumab will be given once every cycle; and trastuzumabonce every cycle or once weekly for 12 weeks. Alternatives to paclitaxel include docetaxel that will be given once percycle or nab-paclitaxel that would be given weekly for 12 weeks.
Note: This is only apartial list of eligibility criteria. Please contact the Robert H. LurieComprehensive Cancer Center of Northwestern University for complete screeninginformation if you are interested in this clinical trial.
NCT04266249 STU00213352 |
DRUG CCTL019B2003I: Managed Access Program (MAP) Cohort Treatment Plan CCTL019B2003I to provide access for patients with out of specification leukapheresis product and/or out of specification manufactured tisagenlecleucel (CTL019; Kymriah®).The purpose of this Managed Access Program(MAP), which is an intermediate size patientpopulation Expanded Access, is to allowtreatment with tisagenlecleucel (CTL019) for eligiblepatients diagnosed with B-cell acutelymphoblastic leukemia (ALL) or large B-cell lymphomas who meet all of thefollowing criteria: are 1) consistent with the approved prescribing information,… The purpose of this Managed Access Program(MAP), which is an intermediate size patient population Expanded Access, is to allowtreatment with tisagenlecleucel (CTL019) for eligible patients diagnosed with B-cell acutelymphoblastic leukemia (ALL) or large B-cell lymphomas who meet all of thefollowing criteria: are 1) consistent with the approved prescribing information,2) unable to receive commercially manufactured product due to failure of the incomingapheresis material to meet acceptance specifications or final outgoing productto meet the commercial release specifications or other specification within theprescribing information, and 3) where no overwhelming safety concerns has beenidentified for manufacture and release of the out of specification product. Participation inthis treatment plan involves an experimental approach called gene transfer forALL or large B-cell lymphoma that involves cells in your blood called B cells(your tumor cells and also normal antibody-producing cells). During thistreatment, some of your own white blood cells (T cells) will be taken andchanged to turn against your tumor cells. T cells from your body will bechanged in a way that may allow them to identify and kill your tumor cells.This change may allow your T cells to go to the tumor cells, turn"on" and potentially kill the tumor cells. The modification is doneby gene transfer and results in a genetic change to your T cells. This mayallow the changed T cells to recognize your tumor cells but also normalantibody-producing cells called B cells. These changed cells are calledtisagenlecleucel cells. If you are eligible andchoose to participate in this MAP, you will be asked to come to the doctor’soffice/clinic/study site at least 3 times in order to make sure you areeligible to receive the tisagenlecleucel cells, and to prepare you for theexperimental treatments. Once you receive the tisagenlecleucel cells, acaregiver, relative, or friend should be in your presence at all times for thefirst 10 days to monitor your well-being and contact your study physician incase of fever or changes in your condition. If you become ill, immediatelycontact your study physician. Additionally, you may be required to spend about4 weeks after you have received tisagenlecleucel cells in close proximity tothe trial treatment center while the doctor and study team see how thetreatment is working and monitor your safety.
Note:This is only a partial description of treatment. Please contact the Robert H.Lurie Comprehensive Cancer Center of Northwestern University if you areinterested in this Managed Access Plan (MAP). Some of the eligibility criteria include: · Age of at least 18 years Diagnosis of acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse or have been diagnosed with relapsed or refractory large B-cell lymphoma after two or more lines of therapies including diffuse large B cell lymphoma not otherwise specified, high grade B cell lymphoma and Diffuse large B-cell lymphoma (DLBCL) arising from follicular lymphoma.
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this Managed Access Plan (MAP).
NCT03601442 STU00213101 |
(xIRB) DRUG 209626: A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants with Relapsed or Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Renal Function (DREAMM 12)The purpose of this study is to find out the relationship between kidney function and safety and pharmacokinetics of the study drug. Pharmacokinetics means study of the movement of drug through the body, and this study will be looking to see if kidney disease affects that movement. Patients with well-… The purpose of this study is to find out the relationship between kidney function and safety and pharmacokinetics of the study drug. Pharmacokinetics means study of the movement of drug through the body, and this study will be looking to see if kidney disease affects that movement. Patients with well-functioning kidneys will be invited into the study as well as patients with kidneys that do not work well (or not at all). This is a study in people with relapsed (returning)and/or refractory (not responding to treatment) multiple myeloma (RRMM) with normal or reduced kidney function to test how the study drug belantamab mafodotin impacts kidney function. There are 2-parts to the study. Participants with RRMM from 4 groups based on how well your kidneys work will be enrolled. The study will include three phases. A Screening phase, a Study Treatment phase, and a Follow-up phase.
The screening assessment will be performed within 21 days before the first dose. After your screening period, if you are eligible, you will need to visit the study site repeatedly (at least every 3 weeks) to receive the study treatment and take part in additional exams, tests, or procedures. Study drug will be infused through a vein over approximately 30 minutes. Study visits will take as little as 3 hours or as much as 12 hours of your time.
Participants who are at least 18 years of age or older who have been diagnosed with relapsed or refractory multiple myeloma and who have impaired renal function will be enrolled into this study.
NCT04398745 STU00213490 |
(xIRB) NCI CIRB ETCTN 10300: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1 (BLAST MRD AML-1): A Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy as Frontline Therapy in Patients with Acute Myeloid LeukemiaThe purpose of this study is to compare theusual treatment alone to adding immune system activating therapy, Pembrolizumab(MK-3475), to the usual treatment. This study will help the study doctors findout if this different approach is better than the usual approach. To decide if it is better, the study … The purpose of this study is to compare theusual treatment alone to adding immune system activating therapy, Pembrolizumab(MK-3475), to the usual treatment. This study will help the study doctors findout if this different approach is better than the usual approach. To decide if it is better, the study doctorswill be looking to see if the addition of pembrolizumab results in fewerdetectable leukemia using new methods. Pembrolizumab (MK-3475), is already approvedby the FDA for use in several cancers, including advanced or metastaticsmall-cell and non-small cell lung cancer, melanoma, head and neck cancer,urothelial cancer, hepatocellular carcinoma, gastric cancer, among others. However, Pembrolizumab (MK-3475) is notapproved by the FDA or known to be safe for use in AML either alone or incombination with standard chemotherapy. This study has 2 study groups. You will be putinto a group by chance. You will have anequal chance of being in Group 1 or Group 2 Group 1 Participants in group 1 will get the usualstudy drugs, cytarabine on Days 1-7 and either daunorubicin or idarubicin onDays 1-3. If you have evidence ofresidual leukemia in the bone marrow at Day 14, you will receive a second roundof the first part of therapy (5+2 chemotherapy), which means cytarabine on Days1-5 and either daunorubicin or idarubicin on Days 1-2. If you have a complete remission after thefirst part of therapy, you will continue with the second part of therapy thatconsists of up to four cycles of high dose cytarabine. If you remain in complete remission aftersecond part of therapy, you will be monitored without further therapy for up to3 years. If you proceed with atransplant, you will forgo any remaining protocol-defined therapy. Group 2 Participants in group 2 will get the usualstudy drugs, cytarabine on Days 1-7 and either daunorubicin or idarubicin onDays 1-3. If you have evidence ofresidual leukemia in the bone marrow at Day 14, you will receive second dose ofthe first part of therapy (5+2 chemotherapy), which means cytarabine on Days1-5 and either daunorubicin or idarubicin on Days 1-2. Regardless of your bone marrow findings onDay 14, you will receive Pembrolizumab (MK-3475) IV on Day 8. If you have a complete remission after thefirst part of therapy, you will continue with the second part of therapy thatconsists of up to four cycles of high dose cytarabine with Pembrolizumab(MK-3475). If you remain in completeremission after the second part of therapy, you will be monitored withoutPembrolizumab (MK-3475) therapy on Day 1 of each 21-day cycle for up to 2years. If you proceed with a transplant,you will forgo any remaining protocol-defined therapy. Participants between the ages of 18 and 75 who have newly diagnosed AML willbe enrolled into this study.
NCT04214249 STU00213544 |
NU MSK19H03 : Combination Therapy with Entinostat and Pembrolizumab in Relapsed and Refractory LymphomasAlmost allpatients with relapsed and refractory Hodgkin lymphoma require additionaltreatment. Typical treatments for relapsed or refractory Hodgkin lymphoma inthe United States can include additional chemotherapy regimens such asbrentuximab vedotin, or nivolumab. Webelieve that the addition of entinostat to pembrolizumab may provide benefit tothese patients and without having the need to … Almost allpatients with relapsed and refractory Hodgkin lymphoma require additionaltreatment. Typical treatments for relapsed or refractory Hodgkin lymphoma inthe United States can include additional chemotherapy regimens such asbrentuximab vedotin, or nivolumab. Webelieve that the addition of entinostat to pembrolizumab may provide benefit tothese patients and without having the need to undergo a stemcell transplant ( SCT) Pembrolizumab has already been approved by theUS Food and Drug Administration (FDA) to treat relapsed or refractory classicalHodgkin lymphoma and other cancers. The combination of Entinostat andPembrolizumab has been tested in patients with lung cancer and has been foundto be safe. · Participantsmust be 18 years or older The target populationfor this study is patients relapsed and refractory Hodgkin lymphoma
NCT03179930 STU00212107 |
(xIRB) NCI CIRB SWOG 1823: A Prospective Observational Cohort Study to Assess mRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell TumorsThe purpose of this study is for the study doctors to learn if miRNA 371 is useful for predicting relapse in patients with germ cell cancer. A germ cell tumor is a type of cancer that occurs in the ovaries (for females) or the testes (for males). This tumor may … The purpose of this study is for the study doctors to learn if miRNA 371 is useful for predicting relapse in patients with germ cell cancer. A germ cell tumor is a type of cancer that occurs in the ovaries (for females) or the testes (for males). This tumor may also be found in the pelvis along the tailbone, the chest, the abdomen and in other structures of the body, generally along the midline of the body. A sample of your blood will be collected during regular clinic visits to look for the presence of a tumor marker called miRNA 371. The study doctors do not know if the test is as good as the usual care (tumor scans and bloodwork) in predicting when cancer will return (relapse) in patients with germ cell cancer. If better, this blood test could change the way patients are monitored for relapse in the future. If you decide to take part in this study, an extra tube of blood will be collected during your regular clinic visits for miRNA 371 analysis for up to 3 years from enrollment into the study. Participants 18 years of age or older who have germ cell cancer will be enrolled.
NCT04435756 STU00213585 |
Alliance A021806: A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic CancerThis study is being done to answer the following question: Can we increase the chance of your pancreatic cancer staying away by giving you chemotherapy before and after surgery? We are doing this study because we want to find out if this approach is better or worse than the usual … This study is being done to answer the following question:
Can we increase the chance of your pancreatic cancer staying away by giving you chemotherapy before and after surgery?
We are doing this study because we want to find out if this approach is better or worse than the usual approach for your pancreatic cancer. The usual approach is defined as care most people get for removable pancreatic cancer.
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT04340141 STU00213664 |
(xIRB NCI CIRB) ECOG-ACRIN Q172: Optimizing Immunosuppression for Steroid-Refractory Anti-PD-1/PD-L1 PneumonitisThis study is being done to answer the following question: Can treatment with either infliximab or Intravenous Immunoglobulin (IVIG) result in improvement in pneumonitis in patients whose pneumonitis has not improved with corticosteroids?We are doing this study because we want to find out if this approach is better or … This study is being done to answer the following question: Can treatment with either infliximab or Intravenous Immunoglobulin (IVIG) result in improvement in pneumonitis in patients whose pneumonitis has not improved with corticosteroids?We are doing this study because we want to find out if this approach is better or worse than the usual approach for the management of pneumonitis. We also want to find out if either infliximab or IVIG will help patients with pneumonitis that is not improving with corticosteroids.
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT04438382 STU00213713 |
Optimization of a mHealth Physical Activity Promotion Intervention with Mindful Awareness for Adolescent and Young Adult Cancer SurvivorsAbout the StudyOpt2Move is a 6-month smartphone-based study to help adolescent and young adult cancer survivors become more active.What’s involved? AssessmentsComplete before starting study and at 3 and 6 months: 45-min online surveyWear activity monitor 24/7 for 7 days You will be compensated for … About the Study Opt2Move is a 6-month smartphone-based study to help adolescent and young adult cancer survivors become more active. What’s involved? Assessments Complete before starting study and at 3 and 6 months:
Physical Activity Program All Participants
How can I learn more? For questions: Phone: 312-503-3465; Email: O2M@nm.org To complete online screening: https://redcap.link/opt2move Who can participate?
NCT05375162 STU00210628 |
ECOG-ACRIN 6192: A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)This study is being done to answer the following question:Can we safely shorten the use of standard of care anti-PD1 therapy for advanced melanoma by using biomarkers seen on PET/CT imaging and tumor biopsy?… This study is being done to answer the following question:Can we safely shorten the use of standard of care anti-PD1 therapy for advanced melanoma by using biomarkers seen on PET/CT imaging and tumor biopsy?
NCT04462406 STU00213767 |
Serial Monitoring of Circulating Tumor Cells During Radiotherapy for Women with Non-Metastatic Breast Cancer: A Prospective Observational Cohort StudyThe purpose of this research is to determine whether radiotherapy after surgery to remove a breast cancer can help decrease the number of circulating tumor cells (CTCs) in the blood. Circulating tumor cells are cancer cells that are shed from the tumor into the blood stream and are believed to … The purpose of this research is to determine whether radiotherapy after surgery to remove a breast cancer can help decrease the number of circulating tumor cells (CTCs) in the blood. Circulating tumor cells are cancer cells that are shed from the tumor into the blood stream and are believed to be one of the first indicators that breast cancer cells may remain after surgery. Approximately 20% of women with early-stage breast cancer can be found to have CTCs in a small sample of blood taken several weeks after surgery. Radiotherapy is used after surgery to remove a breast cancer in order to sterilize any cancer cells that may be remaining in the breast. It is not known if radiotherapy can help decrease or eliminate CTCs that are found in the blood. This study aims to find out if testing for CTCs can be clinically useful for guiding radiotherapy treatment decisions. Another aim of this study is to evaluate whether CTCs can be used to measure the effectiveness of radiotherapy in an individual patient. |
(xIRB) DRUG 20190135: A Phase 1b, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib in Subjects With Advanced Solid Tumors With KRAS p.G12C MutationPURPOSE: The purpose of this study isto evaluate the safety and tolerability of sotorasib (AMG 510) in combinationwith other cancer treatments in patients with advanced tumors. Sotorasib is an investigationalanticancer drug that is being developed for tumors with a specific mutationcalled KRAS p.G12C. There are threedifferent sub-studies named … PURPOSE: The purpose of this study isto evaluate the safety and tolerability of sotorasib (AMG 510) in combinationwith other cancer treatments in patients with advanced tumors. Sotorasib is an investigationalanticancer drug that is being developed for tumors with a specific mutationcalled KRAS p.G12C. There are threedifferent sub-studies named I, J, and K.
Sub-study I:This research studyis being done to evaluate the effects of a new combination of sotorasib andpembrolizumab that is being investigated for adult subjects with advancedNon-small Cell Lung Cancer (NSCLC) with a specific mutation called KRAS p.G12C.
Sub-study J:This study is being done to learn moreaboutsotorasib in combination with palbociclib in participants with advanced solidtumors with KRAS P.G12C mutation.
Sub-study K:This research study is being done to test theeffects of a new combination of sotorasib with everolimus that is beinginvestigated for adult subjects with certain cancer types with a specificmutation called KRAS p.G12C. Note: This is only a partial description of treatment. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete treatment information if you are interested in this clinical trial. OVERVIEW:Sub-study I:If you meet the study requirements and are enrolledyou will be in this study for about 4 years, which includes screening ofup to 28 days, study procedures of approximately 8 months, safetyfollow-up visit 30 (plus 3) days after the last dose of study drugs and up to 3years of long-term follow-up (LTFU). However, this may vary depending on how well you tolerate or respond totherapy.
Sub-study J:If you meet the study requirements and are enrolledyou will be in this study for about 4 years which will include screeningperiod of up to 28 days, a study procedure period of approximately8 months, a 30 (plus 3) days safety follow‑up (SFU), afterthe last dose of investigational product or protocol mandated therapies. Following SFU, you will enter a long‑termfollow‑up period (LTFU), in which you will be followed up in clinic or viatelephone every 12 weeks (± 2 weeks) for assessment of survival anddocumentation of anti‑cancer treatment for up to 3 years.
Sub-studyK:If you meet the studyrequirements and are enrolled, you will be in this study for about4 years. This includes up to 28days of screening, approximately 8 months of study procedures (which may varydepending on how well you tolerate or respond to the study drugs), a safetyfollow-up visit about 30 (plus or minus 3) days after your lastdose of study drugs, and up to 3 years of long-term follow-up.
· · · · Sub-studyK: diagnosis of certain cancer types with a specific mutation called KRASp.G12C. Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT04185883 STU00213909 |
(xirb) DRUG DEK-DKK1-P205: A Phase 2a, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as FirstLine or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (DisTinGuish)This is a Phase 2anonrandomized, open-label, multicenter study to be conducted concurrently in 2Parts (Parts A and B). Both parts are designed to evaluate safety,tolerability, and efficacy of the combination therapy of intravenous (IV)DKN-01 and tislelizumab ± CAPOX in G/GEJ adenocarcinoma patients. Treatmentcontinues in repeating 21-… This is a Phase 2anonrandomized, open-label, multicenter study to be conducted concurrently in 2Parts (Parts A and B). Both parts are designed to evaluate safety,tolerability, and efficacy of the combination therapy of intravenous (IV)DKN-01 and tislelizumab ± CAPOX in G/GEJ adenocarcinoma patients. Treatmentcontinues in repeating 21-day cycles until patient meets criteria fordiscontinuation or is no longer deriving clinical benefit. Parts A and B willbe enrolled concurrently. Two doses of DKN-01 will be evaluated in Part B (PartB1 and Part B2)
Approximately72 patients aged 18 years or older with inoperable, histologically confirmedlocally advanced or metastatic G/GEJ adenocarcinoma with measurable disease(RECIST v1.1) requiring therapy will be enrolled in the study.
NCT04363801 STU00214015 |
NU 20H07: Social Correlates of Variation in Intestinal and Oral Microbiome Among Hematopoietic Stem Cell Transplant Patients: A Geographic Exploration in the City of ChicagoThis study is being done to learn how the microbiome evolves through stem cell transplantation, how it can be shaped by socioeconomic status, the neighborhoods that people reside in, and their diet, as well as certain clinical factors (such as antibiotic usage). Study participants will be asked to provide a … This study is being done to learn how the microbiome evolves through stem cell transplantation, how it can be shaped by socioeconomic status, the neighborhoods that people reside in, and their diet, as well as certain clinical factors (such as antibiotic usage). Study participants will be asked to provide a saliva sample and complete a questionnaire. You may be eligible for this study if you have been diagnosed with a hematologic malignancy (also known as a blood cancer) and are being considered for an allogeneic hematopoietic stem cell transplantation (sometimes also referred to as a bone marrow transplant). STU00213358 |
DRUG Q702-ONC-P1-US001 A Phase 1 Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic, Pharmacokinetic Study of Q702 with a Cohort Expansion at the RP2D in Patients with Advanced Solid TumorsThe major purpose of this study is to determine the highest dose of Q702 that does not result in severe side effects, the dose that is tolerated, and once this dose is found, if it has any effect against the cancer in patients with solid cancer tumors. This study is … The major purpose of this study is to determine the highest dose of Q702 that does not result in severe side effects, the dose that is tolerated, and once this dose is found, if it has any effect against the cancer in patients with solid cancer tumors. This study is being done:
This research is being performed because improvements are needed in the treatment of patients with cancer. We are asking you to take part in this research study because you have cancer that has continued to grow despite the treatments you have already received. Either the standard drugs and therapies used to treat your disease are no longer working or there are no known treatments which work because your tumor cells may be resistant to available treatments or you are not a candidate for or intolerant of available treatment. Your cancer had been confirmed by a pathologist (a person who studies the causes and effects of diseases). This clinical trial tests a study drug, Q702. The study drug, Q702, targets certain molecules present in cancer cells that may help activate your body's immune system to fight the cancer. The study drug, Q702, is not approved for sale by the FDA.
NCT04648254 STU00213510 |
NU MDA20L01: An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLCThe purpose of this study is to compare the usual treatment osimertinib alone to ramucirumabplus the usual treatment (osimertinib). The addition of ramucirumab to the usual treatment could help osimertinib control the abnormal EGFR protein for a longer duration and in turn, for you tohave a longer period of … The purpose of this study is to compare the usual treatment osimertinib alone to ramucirumabplus the usual treatment (osimertinib). The addition of ramucirumab to the usual treatment could help osimertinib control the abnormal EGFR protein for a longer duration and in turn, for you tohave a longer period of time that your disease is inactive.We are doing this study because we want to find out if this approach is better or worse than theusual approach for your cancer. The usual approach is defined as care most people get for thetreatment of non-small cell lung cancer. Age ≥ 18 years at the time of consent, Histologically or cytologically confirmed non-squamous, nonsmall cell lung cancer, Locally advanced or metastatic disease, not amenable tocurative surgery or radiotherapy.
NCT03909334 STU00212727 |
(xIRB) NCI CIRB NRG BN009: Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS With Brain Metastasis Velocity >/= 4 Brain Metastases/YearThe purpose of this study is to compare the usual treatment of SRS alone to SRS plus HA-WBRT (whole brain radiation therapy with hippocampus avoidance) and memantine for patients with cancer that has spread to the brain and come back in other areas of the brain after earlier treatment … The purpose of this study is to compare the usual treatment of SRS alone to SRS plus HA-WBRT (whole brain radiation therapy with hippocampus avoidance) and memantine for patients with cancer that has spread to the brain and come back in other areas of the brain after earlier treatment with SRS. The addition of HA-WBRT and memantine to the usual treatment could better control your brain cancer. This study will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. Memantine is FDA approved for treating dementia and is commonly used off-label (that is, for a purpose for which it is not FDA approved) for patients receiving whole-brain radiation therapy for cancer that has spread to the brain. This study has 2 study groups. You will be told which group you are in. Group 1 If you are in this group, you will get the usual treatment, SRS. In addition to the usual SRS treatment, you will also receive HA-WBRT. You will also be given the drug memantine, which has also been shown to preserve memory function. Memantine will be taken for up to 6 months. Group 2 If you are in this group, you will get the usual treatment of SRS. After you finish your treatment, your doctor and study team will watch you for side effects and follow your condition. They will check you every 2 to 3 months for at least 1 year after you finish SRS. If you are receiving memantine, your doctor will continue to see you in the clinic as needed. Participants age 18 years or older who have receivedstereotactic radiosurgery to treat cancer that spread to the brain, and now thecancer has returned in other areas of the brain will be enrolled into thisstudy.
NCT04588246 STU00214371 |
DRUG JCAR017-EAP-001: Expanded Access Protocol (EAP) for Patients Receiving Lisocabtagene Maraleucel That Is Nonconforming for Commercial ReleaseThe purpose of this expanded access protocol is to allow patients to receive lisocabtagene maraleucel T cells that did not meet all of the prespecified release criteria (nonconforming) to be used as a routine prescription drug. The study will evaluate the safety and effectiveness of this therapy through the collection … The purpose of this expanded access protocol is to allow patients to receive lisocabtagene maraleucel T cells that did not meet all of the prespecified release criteria (nonconforming) to be used as a routine prescription drug. The study will evaluate the safety and effectiveness of this therapy through the collection of information. Participation in this treatment plan involves receiving the nonconforming product and performing tests as part of your routine clinical care. The information or results from these evaluations will be collected for research purposes. If you are eligible and choose to participate in this EAP, you will be asked to complete test as part of routine care, you will undergo lymphodepleting therapy (chemotherapy administered to help prepare your bone marrow and immune system to receive lisocabtagene maraleucel), and receive the nonconforming lisocabtagene maraleucel product through your vein as an intravenous (IV) infusion. Approximately 3 months after receiving your nonconforming lisocabtagene maraleucel, your participation in this study will end. Note: This is only a partial description of treatment. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Some of the eligibility criteria include: •Age of at least 18 years
NCT04400591 STU00214152 |
(xIRB) DRUG VS-6766-202: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC)(RAMP 202)The main aims of this clinical study are to:•Find out if the best course of cancer treatment is to take either VS-6766 alone (monotherapy) or to take VS-6766 together (in combination) with defactinib.•Understand the safety of VS-6766 taken alone or taken together with defactinib.•Describe … The main aims of this clinical study are to: •Find out if the best course of cancer treatment is to take either VS-6766 alone (monotherapy) or to take VS-6766 together (in combination) with defactinib. •Understand the safety of VS-6766 taken alone or taken together with defactinib. •Describe how well and how long the study treatment with VS-6766 alone or in combination with defactinib works. •Measure the amount of VS-6766, defactinib and compounds related to the two study drugs in your blood at different times (this is called pharmacokinetics).
This study will look at a potential treatment for KRAS-mutant or BRAF-mutant NSCLC by comparing VS-6766 taken alone, versus VS-6766 taken in combination with defactinib. The study will be conducted in two parts, Part A and Part B. Participants will only be taking part in one of these two parts, not both. The type of KRAS or BRAF mutation will determine which group participants will be enrolled in. Participants could be randomized (like the flip of a coin, with a 50:50 chance) to one of two study treatment groups or could be assigned to a study treatment group. The 2 study treatment groups: - Monotherapy: VS-6766 4.0 mg by mouth, twice weekly (for example: Monday/Thursday, Tuesday/Friday or Wednesday/Saturday), 3 weeks on and 1 week without study drug (each 4-week period is considered a cycle). - Combination Therapy: VS-6766 3.2 mg by mouth, twice weekly (for example: Monday/Thursday, Tuesday/Friday or Wednesday/Saturday) and defactinib 200 mg by mouth, twice a day, 3 weeks on and 1 week without study drug (each 4- week period is considered a cycle). For participants with BRAF-Mutant NSCLC, study treatment group is: - Combination therapy: VS-6766 3.2 mg by mouth, twice weekly (for example: Monday/Thursday, Tuesday/Friday, Wednesday/Saturday) and defactinib 200mg by mouth, twice a day, 3 weeks on and 1 week without study drug (each 4-week period is considered a cycle). Note: This is only a partial description of treatment. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Some of the eligibility criteria include: •Age of at least 18 years •Diagnosis of have KRAS-mutant non-small cell lung cancer (NSCLC) or BRAF-Mutant NSCLC. Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT04620330 STU00214623 |
(xIRB) NCI CIRB ECOG-ACRIN 2176: A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer PatientsThe purpose of this study is to compare the usual treatment (chemotherapy) alone to using nivolumab plus the usual treatment. This study will help the study doctors find out if this different treatment (chemotherapy plus nivolumab) is better, the same, or worse than the usual approach of chemotherapy alone. To … The purpose of this study is to compare the usual treatment (chemotherapy) alone to using nivolumab plus the usual treatment. This study will help the study doctors find out if this different treatment (chemotherapy plus nivolumab) is better, the same, or worse than the usual approach of chemotherapy alone. To decide if it is better, the study doctors will be looking to see if nivolumab when given with the usual treatment will slow the progression of cancer. The study drug nivolumab, is already approved by the FDA for use in different types of cancer, including lung, skin (melanoma), kidney, bladder, colorectal, and some types of liver cancers. Participants who decide to take part in this study will either get chemotherapy for up to 6 months or get chemotherapy plus a drug called nivolumab for 6 months. After the 6 months of chemotherapy, participants will continue to receive nivolumab until their cancer gets worse or up to 2 years. All of these treatments have been approved by the Food and Drug Administration (FDA), but the use of nivolumab with chemotherapy to treat this type of cancer is considered investigational. After treatment, participants will be followed for up to 2 years to check for side effects. Participants will visit the clinic once every 3 months for the first year, then every 6 months for the second year. Participants ages 18 years or olderwho have anal canal cancer that has spread to some other areas in the body willbe enrolled into this study.
NCT04444921 STU00214628 |
(xIRB) NCI CIRB NRG GU009: Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)Participants ages 18 years or older who have high-risk prostate cancer will be enrolled into this study. This study is being done to answer the following questions: If you have high risk prostate cancer, a low gene risk score and plan to receive radiation therapy, is a shorter hormone … Participants ages 18 years or older who have high-risk prostate cancer will be enrolled into this study.
This study is being done to answer the following questions:
If you have high risk prostate cancer, a low gene risk score and plan to receive radiation therapy, is a shorter hormone therapy treatment as effective at controlling your cancer compared to the usual 24 month hormone therapy treatment?
If you have high risk prostate cancer, a high gene risk score and plan to receive radiation therapy, does adding two new hormone therapy drugs to the usual treatment increase the length of time without your prostate cancer spreading as compared to the usual treatment?
The study doctors want to find out if these approaches are better, similar, or worse than the usual approach for your type of prostate cancer.
This study has 4 study groups.
If you have a low Decipher risk score, you will be randomly assigned to one of these two study groups:
· Group 1: If you are in this group, you will get the usual approach, hormone therapy and radiation therapy, used to treat this type of cancer.
· Group 2: If you are in this group, you will get the usual radiation treatment and a shorter period of hormone therapy used to treat this type of cancer.
If you have a high Decipher risk score and/or positive pelvic node(s), you will be randomly assigned to one of these two study groups:
· Group 3: If you are in this group, you will get the usual approach, hormone therapy and radiation therapy, used to treat this type of cancer.
· Group 4: If you are in this group, you will get study drugs called apalutamide and abiraterone acetate with prednisone plus the usual approach (hormone therapy and radiation therapy) used to treat this type of cancer.
After you finish your study treatment, your doctor will continue to follow your condition for at least annually and watch you for side effects. NCT04513717 STU00214649 |
(xIRB) NCI CIRB ETCTN 10384: A Phase 1b/2 Study of Hu5F9-G4 (Magrolimab) in Combination with Mogamulizumab in Relapsed/Refractory Treated T-Cell LymphomaThe purpose of phase 1 of this study is to test the safety of a drug called Hu5F9-G4 (magrolimab) in combination with mogamulizumab. This combination of drugs has been tested in animals, but has not been tested in people and is not approved by the FDA for treatment of … The purpose of phase 1 of this study is to test the safety of a drug called Hu5F9-G4 (magrolimab) in combination with mogamulizumab. This combination of drugs has been tested in animals, but has not been tested in people and is not approved by the FDA for treatment of this type of cancer. This study tests different doses of Hu5F9-G4 (magrolimab) to see which dose is safer for people when given together with mogamulizumab.
Participants enrolled into phase 1will get the study drug Hu5F9-G4 (magrolimab) in combination with mogamulizumab for up to 1 year or until the side effects become too severe or their cancergets worse.
The purpose of phase 2of this study is to compare mogamulizumab alone to using Hu5F9-G4 (magrolimab) plus mogamulizumab. This study will help the study doctors find out if this different approach is better than the usual approach. The study drug, Hu5F9-G4 (magrolimab) is not approved by the FDA for treatment of this type of cancer. Mogamulizumab is approved by the FDA for treatment of this type of cancer.
Phase 2 has two study groups:
Group 1 – participants in this group will get the usual drug used to treat this type of cancer, mogamulizumab, plus a study drug called Hu5F9-G4 (magrolimab).
Group 2 – participants in this group will get the usual drug used to treat this type of cancer, mogamulizumab. In both phases, after the last treatment, participants will be followed for 2years until their cancer gets worse, or until the start of any significant treatment. This study has two phases. In phase1, participants ages 18 years or older who have T-cell (a type of immune cell) lymphoma that has returned after or does not respond to treatment will be enrolled. In phase 2, participants ages 18 years or older who have T-cell lymphoma affecting the skin that has returned after or does not respond to treatment will be enrolled. Participants will participate in either phase 1 or phase 2.
NCT04541017 STU00214653 |
(xIRB) DRUG M-2018-344: A multi-center single arm Phase II study to evaluate the safety and efficacy of genetically engineered autologous cells expressing anti-CD20 and anti-CD19 specific chimeric antigen receptor in subjects with relapsed and/or refractory diffuse large B cell lymphomaThe purpose of this research study is to evaluate an investigational cell and gene treatment called MB-CART2019.1 that may help to eliminate cancer cells in subjects who have relapsed (responded to treatment but then returns) and/or refractory (has not responded to initial treatment) DLBCL. In order to … The purpose of this research study is to evaluate an investigational cell and gene treatment called MB-CART2019.1 that may help to eliminate cancer cells in subjects who have relapsed (responded to treatment but then returns) and/or refractory (has not responded to initial treatment) DLBCL. In order to produce the investigational treatment, white blood cells (T-cells) will be collected at the study center by a process called leukapheresis.
Participation in this study is for up to two years, and additionally subjects must enroll in the separate Gene Therapy Long-Term Follow Up protocol for 13 years (total study participation to equal up to 15 years). The T‑cells (obtained from blood) will be modified in order for them to express molecules called chimeric antigen receptors (CARs) on their surfaces. When the modified cells, called CAR T‑cells, are reinfused into the body, the new receptors will enable them to bind onto specific antigens on cancer cells and by doing so destroy them. The CAR T-cells act as a “living drug” against your cancer cells.
Before your cells are reinfused, participants will first receive a conditioning regimen consisting of two chemotherapy drugs, fludarabine and cyclophosphamide. The conditioning regimen helps make room in the bone marrow for new blood stem cells to grow, and helps prevent rejection of the transplanted cells, as well as helps kill any cancer cells that are in the body.
Note: This is only a partial description of treatment. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Some of the eligibility criteria include: · Age of at least 18 years · Diagnosis of diffuse large B cell lymphoma (DLBCL).
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT04792489 STU00214654 |
(xIRB) NCI CIRB ECOG-ACRIN 8185: Phase 2 Study of Bladder-SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage 3, Node PosItive BladdeR CancEr (INSPIRE)The purpose of this study is to compare the usual treatment of chemotherapy and radiation to adding MEDI4736 (durvalumab) immunotherapy to the usual treatment. This study will help determine if this different approach is better than the usual approach. To decide if it is better, the study doctors will be … The purpose of this study is to compare the usual treatment of chemotherapy and radiation to adding MEDI4736 (durvalumab) immunotherapy to the usual treatment. This study will help determine if this different approach is better than the usual approach. To decide if it is better, the study doctors will be looking to see if the study approach increases the life of patients compared to the usual approach. This immunotherapy drug,MEDI4736 (durvalumab), is already approved by the FDA for use in metastatic bladder cancer.
Participants who decide to take part in this study will either get chemotherapy and radiation for 6-8weeks, or will get MEDI4736 (durvalumab) immunotherapy in addition to chemotherapy and radiation for 6.5-8 weeks. Participants in the MEDI4736(durvalumab) Group 1 whose bladder cancer has responded (shrunk, gone away or remained stable) to treatment with chemotherapy, radiation and MEDI4736(durvalumab) will be offered more treatments with MEDI4736 (durvalumab) alone for up to 9 months.
Participants who are in the arm with chemotherapy and radiation, and whose cancer has responded, will be watched closely without any additional chemotherapy and radiation treatments. Participants whose cancer has not responded, may be offered surgery or some other treatment.
After study treatment is finished, participants will be followed by the study doctor for up to 3 years. Participants ages 18 years or older who have bladder cancer that has spread from the bladder to the lymph nodes will be enrolled into this study.
NCT04216290 STU00214716 |
(xIRB) NCI CIRB ETCTN 10285: Phase 1/2 Study of an EZH2 Inhibitor (Tazemetostat) in Combination with Dual BRAF/MEK Inhibition in Patients with BRAF- Mutated Metastatic Melanoma Who Progressed on Prior BRAF/MEK Inhibitor TherapyParticipants 18 years or older who have metastatic melanoma, and the cancer has a change in the gene called the BRAF, and is not responsive to treatment with MEK and BRAF inhibitors will be enrolled. This study has two phases. Phase 1 and Phase 2. The purpose of Phase 1 … Participants 18 years or older who have metastatic melanoma, and the cancer has a change in the gene called the BRAF, and is not responsive to treatment with MEK and BRAF inhibitors will be enrolled.
This study has two phases. Phase 1 and Phase 2.
The purpose of Phase 1 is to test the safety of the study drug, tazemetostat, in combination with the usual treatment, dabrafenib and trametinib. This study tests different doses of tazemetostat with the usual dose of dabrafenib and trametinib to see which dose of tazemetostat is safest for people. Tazmetostatis not approved by the FDA for treatment of this type of cancer.
All people taking part in this study will get the same dose of the usual intervention, dabrafenib and trametinib. However, people in this study will get different doses of the study drug, tazemetostat. Once the highest safe dose is found, phase 1 of the study is stopped.
The purpose of Phase II is to compare the combination of tazemetostat, dabrafenib, and trametinib to tazemetostat alone. This study will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. Another purpose of this study is for the study doctors to learn if a genetic test is helpful to decide if tazemetostat is more effective in patients whose cancer has an abnormal EZH2 gene. The combination of tazemetostat, trametinib, and dabrafenib, has not been administered together in patients and the combination of these agents are not FDA approved for the treatment of this type of cancer.
Participants who take part in this study will either get a combination of usual approach of dabrafenib and trametinib, and the study drug, tazemetostat or will get the study drug, tazemetostat alone, until their disease gets worse or the side effects become too severe. Patient must be ≥18 years. Patient must have a diagnosis of BRAFV600E/K-mutated metastatic melanoma.
NCT04557956 STU00214795 |
(xIRB) NCI CIRB SWOG 1925: Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL StudyThe purpose of this study is to compare the early treatment(before you have symptoms) of venetoclax and obinutuzumab (V-O) to the usual treatment of V-O after you have symptoms. This study will help the study doctors find out if this different approach is better, the same, or … The purpose of this study is to compare the early treatment(before you have symptoms) of venetoclax and obinutuzumab (V-O) to the usual treatment of V-O after you have symptoms. This study will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. Another purpose of this study is to find out how early V-O treatment affects patients’ physical, social, and emotional well-being, compared to patients receiving the standard delayed V-O treatment.
The antibody, obinutuzumab, and the drug, venetoclax are already approved by the FDA for use in patients with previously untreated CLL or SLL. Most of the time these drugs are not used until a patient has symptoms that make treatment necessary.
Participants who decide to take part in this study will either get treatment with venetoclax and obinutuzumab (V-O) that starts before symptoms start (now), or participants will get treatment with venetoclax and obinutuzumab (V-O) that will start after symptoms start (later). For all patients, the treatment with V-O will continue for 12 months or until the cancer gets worse, or the side effects are too great.
After treatment is finished, participants will be followed for up to 10 years after enrollment. Participants ages 18 years or older who have chronic lymphocytic leukemia or small lymphocytic lymphoma and who do not have symptoms and do not need to start treatment now will be enrolled into this study.
NCT04269902 STU00214799 |
(xIRB) NCI CIRB Alliance A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and TucatinibThe purpose of this study is to compare the usual treatment with T-DM1 alone toT-DM1 plus tucatinib. This study will help the study doctors find out if this different approach is better than the usual approach. T-DM1 is already approved by the FDA for use in patients … The purpose of this study is to compare the usual treatment with T-DM1 alone toT-DM1 plus tucatinib. This study will help the study doctors find out if this different approach is better than the usual approach. T-DM1 is already approved by the FDA for use in patients with HER2-positive cancer. Tucatinib has not been FDA-approved to treat breast cancer.
Participants who decide to participate will either get treatment with T-DM1 and placebo (a pill that looks like the study drug but contains no medication) or T-DM1 and tucatinib, for up to 14 cycles, unless the breast cancer returns or the side effects become too severe. After study treatment is finished, the study doctor will follow participants to watch for side effects and for signs of breast cancer returning. This may include a clinic visit every 6 months for 10 years. Participants age 18 years or older who have HER2-positive breast cancer, and who have already received treatment with chemotherapy and anti-HER2 targeted therapies followed by surgery. At the time of the surgery, cancer was still present in the breast and/or lymph nodes and was removed by a surgeon, will be enrolled into this study.
NCT04457596 STU00214807 |
NU MSK20C04: PROTECT Study: A Phase II, Open-Label Trial of PROphylactic Skin Toxicity ThErapy with Clindamycin and Triamcinolone in Glioblastoma Patients Treated with Tumor Treating FieldsStudyparticipants are being treated with Tumor Treating Fields (TTFields) formalignant glioma. The TTFields device uses low-intensity electrical fields totreat cancer, and this type of therapy can cause skin side effects, such asitching, sores, or infections. Researchers want to know if using clindamycingel and triamcinolone topical (on the skin) lotion … Studyparticipants are being treated with Tumor Treating Fields (TTFields) formalignant glioma. The TTFields device uses low-intensity electrical fields totreat cancer, and this type of therapy can cause skin side effects, such asitching, sores, or infections. Researchers want to know if using clindamycingel and triamcinolone topical (on the skin) lotion before these side effectsoccur may be able to prevent their appearance, so that TTFields can be usedwith less need for interruptions Key eligibility criteria include:
All prospective patients will undergo screening tests to determine if they are eligible to take part in the study. Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT04469075 STU00213944 |
NU UM20I04 : Phase 1/2 Trial to Evaluate Cabozantinib in Patients with Advanced Hepatocellular Carcinoma with Child Pugh Class B Cirrhosis after First-Line TherapyPatients with unresectable Hepatocellular carcinoma (HCC) with underlying Child-Pugh classB cirrhosis have no options for systemic therapy based on current guidelines and available evidence.The aim of this study is to determine the safety and efficacy of cabozantinib in the management of HCCin this patient population… Patients with unresectable Hepatocellular carcinoma (HCC) with underlying Child-Pugh classB cirrhosis have no options for systemic therapy based on current guidelines and available evidence.The aim of this study is to determine the safety and efficacy of cabozantinib in the management of HCCin this patient population Patients must have a radiologically consistent (early enhancement and delayed enhancement washout) or pathologically confirmed diagnosis of hepatocellular carcinoma that is not eligible for curative resection, transplantation, or ablative therapies Prior radiation, liver directed therapy (including bland, chemo- or radioembolization, or ablation), orhepatic resection are permitted if >4 weeks from start of therapy. Extra-hepatic palliative radiation is permitted if completed >2 weeks prior to first dose of study therapy and the patient has recovered to <grade 1 toxicity. Patients must have radiographically measurable disease (RECIST1.1) in at least one site not previously treated or with progression after radiation or liver directed therapy Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested inthis clinical trial. All prospective patients will undergo screening tests to determine if they are eligible to take part in the study NCT04497038 STU00214060 |
DRUG KN035SAR201: ENVASARC: A Pivotal Trial of Envafolimab, and Envafolimab in Combination with Ipilimumab, in Patients with Advanced or Metastatic Undifferentiated Pleomorphic Sarcoma or Myxofibrosarcoma Who Have Progressed on Prior ChemotherapyThe purposeof this study is to determine the effectiveness (how well the experimentaldrugs work) and safety of envafolimab, when given alone or in combination withipilimumab to patients with advanced or metastatic undifferentiated pleomorphicsarcoma (UPS) or myxofibrosarcoma (MFS) in order to stimulate the immune systemto attack cancer cells. Undifferentiatedpleomorphic sarcoma (UPS) … The purposeof this study is to determine the effectiveness (how well the experimentaldrugs work) and safety of envafolimab, when given alone or in combination withipilimumab to patients with advanced or metastatic undifferentiated pleomorphicsarcoma (UPS) or myxofibrosarcoma (MFS) in order to stimulate the immune systemto attack cancer cells. Undifferentiatedpleomorphic sarcoma (UPS) is a rare type of cancer that begins mostly in thesoft tissues of the body and myxofibrosarcoma (MFS) is a type of cancer thattypically appears as a slow-growing, painless lump on one of your legs or arms.
NCT04480502 STU00214197 |
(XIRB) Drug R5668-ONC-1938: Phase 1/2 Study of REGN5668 (MUC16 X CD28, a Costimulatory Bispecfic) Administered in Combination with Cemiplimab OR REGN4018 (MUC16 X CD3)The main purposes of this study are to learn about the safety and profile of any side effects from the study drugs and to determine the highest, safe dose that can be given to patients with ovarian cancer and to look for signs that the study drugs can treat ovarian … The main purposes of this study are to learn about the safety and profile of any side effects from the study drugs and to determine the highest, safe dose that can be given to patients with ovarian cancer and to look for signs that the study drugs can treat ovarian cancer Age of at least 18 years Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. All prospective patients will undergo screening tests to determine if they are eligible to take part in the study.
NCT04590326 STU00214950 |
(xirb) Drug BGB-11417-101: A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell MalignanciesThis study will look at the safety and tolerability of an investigational anticancer drug currently known as BGB-11417. In addition, this study also aims to look at the safety of BGB-11417 when given in combination with zanubrutinib (also known as BGB-3111). BGB-11417 is made by BeiGene, … This study will look at the safety and tolerability of an investigational anticancer drug currently known as BGB-11417. In addition, this study also aims to look at the safety of BGB-11417 when given in combination with zanubrutinib (also known as BGB-3111).
BGB-11417 is made by BeiGene, Ltd. BGB-11417 is an experimental drug. This means that it has not been approved for treatment by the Food and Drug Administration (FDA) in the United States or other regulatory agencies outside the United States where the Sponsor seeks approval of BGB-11417. As of 04 February 2021, BGB-11417 as a single drug has been given to over 9 participants enrolled in this research study.
This study aims to determine the range of BGB-11417 doses that can safely be used, the safest dosing schedule to minimize side effects when first taking BGB-11417, what side effects may be experienced when taking this drug, how your body processes this drug, and if this drug is effective against your cancer. Key eligibility criteria include:
· · Age of at least 18 years
Allprospective patients will undergo screening tests to determine if they areeligible to take part in the study
Note: This is only a partial list of eligibility criteria. Pleasecontact the Robert H. Lurie Comprehensive Cancer Center of NorthwesternUniversity for complete screening information if you are interested in thisclinical trial.
NCT04277637 STU00214957 |
NU NCI 20C06: Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients with Recurrent Select Rare CNS CancersBackground:More than 130 primary tumors of the central nervous system (CNS) have been identified. Most affect less than 1,000 people in the United States each year. Because these tumors are so rare, there are few proven therapies. This study will test whether the immunotherapy drug nivolumab is an … Background: More than 130 primary tumors of the central nervous system (CNS) have been identified. Most affect less than 1,000 people in the United States each year. Because these tumors are so rare, there are few proven therapies. This study will test whether the immunotherapy drug nivolumab is an effective treatment for people with rare CNS tumors. Objectives: To learn if stimulating the immune system using the drug nivolumab can shrink tumors in people with rare CNS (brain or spine) tumors or increase the time it takes for these tumors to grow or spread. Eligibility: Adults whose rare CNS tumor has returned. Design: Participants will be screened:
At the start of the study, participants will have blood tests. They will answer questions about their symptoms and their quality of life. Participants will get nivolumab in a vein every 2 weeks for up to 64 weeks. Participants will have monthly blood tests. Every other month they will have an MRI and a neurologic function test. They will also answer questions about their quality of life. Genetic tests will be done on participants' tumor tissue. Participants will be contacted if any clinically important results are found. After treatment ends, participants will be monitored for up to 5 years. They will have a series of MRIs and neurological function tests. They will be asked to report any symptoms they experience....
NOTE: Based on the evidence cited in Nivolumab IB ver. 20, given that nivolumab is not a genotoxic agent, and that relevant systemic concentrations sufficient to produce a risk of fetal toxicity are not expected in WOCBP partners from exposure to a male participant s seminal fluid, male study participants will not be required to use contraceptive measures and/or a latex or other synthetic condom during sexual activity with a WOCBP partner. EXCLUSION CRITERIA: Severe, active co-morbidity defined as follows: Unstable angina within the last 6 months prior to Step 2 registration. Transmural myocardial infarction within the last 6 months prior to Step 2 registration Evidence of recent myocardial infarction or ischemia by the findings of S-T elevations of (Bullet) 2 mm using the analysis of an EKG performed within 14 days prior to Step 2 registration. New York Heart Association grade II or greater congestive heart failure requiring hospitalization within 12 months prior to Step 2 registration. History of stroke, cerebral vascular accident (CVA) or transient ischemic attack within 6 months prior to Step 2 registration, with the exception of pericavitary ischemia due to tumor resection. Serious and inadequately controlled cardiac arrhythmia. Significant vascular disease (e.g., aortic aneurysm, history of aortic dissection) or clinically significant peripheral vascular disease. Evidence of bleeding diathesis or coagulopathy. Serious or non-healing wound, ulcer, or bone fracture or history of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess, major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Step 2 registration, with the exception of the craniotomy for tumor resection. Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration. Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration. Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects. Known acquired immune deficiency syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude participants with AIDS is based on the lack of information regarding the safety of nivolumab in patients with active HIV infection. Active connective tissue disorders, such as lupus or scleroderma, which in the opinion of the treating physician may put the patient at high risk for immunologic toxicity. Participants with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids, should be excluded. These include but are not limited to participants with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome or CIDP, myasthenia gravis; systemic autoimmune disease such as SLE, connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn s, ulcerative colitis, hepatitis; and participants with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease. --Of note, participants with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible. Participants with rheumatoid arthritis and other arthropathies, Sj(SqrRoot)(Delta)gren s syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible. However, patients with vitiligo, diabetes mellitus, and Hashimoto thyroiditis on appropriate replacement therapy may be enrolled. 10. Participants with contraindications to COVID-19 vaccination will not be eligible. 11. Participants unable to have MRIs.
NCT03173950 STU00214301 |
DRUG AN2025H0301: The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaThe purpose of this open-label research study is to assess the effectiveness and safety of once-daily buparlisib in combination with weekly paclitaxel compared to weekly paclitaxel alone in subjects with refractory, (a disease or condition which does not respond to previous forms of treatment) recurrent, or metastatic (disease … The purpose of this open-label research study is to assess the effectiveness and safety of once-daily buparlisib in combination with weekly paclitaxel compared to weekly paclitaxel alone in subjects with refractory, (a disease or condition which does not respond to previous forms of treatment) recurrent, or metastatic (disease that has returned or spread) head and neck cancer that has progressed after prior immunotherapy (treatment that uses the immune system to attack cancer, such as antiPD1/antiPDL1 treatments) with or without prior platinum-based chemotherapy. The study will consist of the following parts: •A preliminary (screening) period of up to 4 weeks (28 days) to determine eligibility •A treatment period of up to 15 cycles (1 cycle is 21 days) •End-of-treatment visit •A follow-up visits 30 days after the end-of-treatment visit •Continued follow-up to monitor health status every 3 months for up to 5 years Participants will continue to receive the study drug until they are no longer benefiting, or experience unacceptable side effects or withdraw from the study. Participants will be assigned into one of two study treatment groups: •80 mg/m2/week paclitaxel intravenous infusion in combination with 100 mg/day buparlisib given orally in 21-day cycles •80 mg/m2/week paclitaxel intravenous infusion Study treatment assignment will be random. Participants will be assigned to the study treatment groups in a 2:1 ratio, which means 2 out of 3 subjects will be in the buparlisib group and 1 out of 3 subjects placed in the paclitaxel only study treatment group. Note: This is only a partial description of treatment. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Some of the eligibility criteria include: •Age of at least 18 years •Diagnosis of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT04338399 STU00214841 |
(xIRB) NU MC21B04: Genetic Risk Estimation of Breast Cancer Prior to Decisions on Preventive Therapy Uptake, Risk Reducing Surgery or Intensive Imaging Surveillance: A Study to Determine if a Polygenic Risk Score Influences the Decision Making Options Amongst High Risk WomenThe purpose of this research is to determine whether providing an individual polygenic risk score (PRS), in addition to the Breast Cancer Risk Assessment Tool (BCRAT) or Tyrer-Cuzick (IBIS) score, to women at high risk of breast cancer will improve their ability to make a better informed decision to … The purpose of this research is to determine whether providing an individual polygenic risk score (PRS), in addition to the Breast Cancer Risk Assessment Tool (BCRAT) or Tyrer-Cuzick (IBIS) score, to women at high risk of breast cancer will improve their ability to make a better informed decision to accept preventive therapy and/or supplemental breast cancer screening. Study participation involves: 2 separate visits at which you will be asked to complete surveys and blood draws; and 8 annual visits of which you will be asked to complete surveys remotely. Some of the eligibility criteria include: •Adult woman of at least 18 years of age •Have been determined to be at risk of developing breast cancer. Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
STU00215127 |
Training Swallowing Initiation during Expiration: Impact on Safety and Efficiency Following Treatment for Oropharyngeal Head and Neck CancerDr. Bonnie Martin-Harris and her team are studying a new swallowing therapy to improve eating, drinking, health, and quality-of-life of individuals with head and neck cancer. Therapy will be conducted remotely. … Dr. Bonnie Martin-Harris and her team are studying a new swallowing therapy to improve eating, drinking, health, and quality-of-life of individuals with head and neck cancer. Therapy will be conducted remotely. If you were recently diagnosed with head and neck cancer, you might be eligible to participate in this study. NCT05278039 STU00214730 |
(XIRB) Drug MORAb 202-G000-201: A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) in Subjects With Selected Tumor TypesThere are two parts to this study: The Dose Escalation part, was toidentify the highest tolerable safe dose of MORAb-202 and is now complete.The DoseConfirmation part is to further evaluate the safety, tolerability and effectivenessof MORAb-202 in subjects with ovarian cancer and endometrial cancer at selecteddoses.… There are two parts to this study: The Dose Escalation part, was toidentify the highest tolerable safe dose of MORAb-202 and is now complete. The DoseConfirmation part is to further evaluate the safety, tolerability and effectivenessof MORAb-202 in subjects with ovarian cancer and endometrial cancer at selecteddoses. Ovarian cancer or primary peritoneal cancer orfallopian tube cancer and had progression of disease after previous treatmentwith a platinum-containing chemotherapy regimen. · · Age of at least 18 years.
Note: This is only apartial list of eligibility criteria. Please contact the Robert H. LurieComprehensive Cancer Center of Northwestern University for complete screeninginformation if you are interested in this clinical trial.
Allprospective patients will undergo screening tests to determine if they areeligible to take part in the study NCT04300556 STU00215228 |
NU 21B01: Volumetric Lumpectomy Specimen Image Visualization for Intraoperatively Directing Cavity Shaves, a Phase II Study (VIVID)The purpose of this study is to assess if the use of a 3D imaging device called the Clarix Imaging Volumetric Specimen Imager (VSI) can help guide and assist surgeons in identifying and removing all positive margins while in the operating room for breast conservation surgery.If you are undergoing … The purpose of this study is to assess if the use of a 3D imaging device called the Clarix Imaging Volumetric Specimen Imager (VSI) can help guide and assist surgeons in identifying and removing all positive margins while in the operating room for breast conservation surgery. If you are undergoing breast conservation surgery and meet all criteria, the 3D imaging device, VSI, will be used to guide and assist the surgeon in identifying and removing all positive margins while in the operating room. The lumpectomy procedure will be performed per standard practice. If eligible, the lumpectomy procedure will be performed per standard practice. Promptly after excision, the tumor specimen will be imaged using the VSI device to take additional 3D images of the removed tissue during the standard of care surgery.
During surgery, after the tumor has been removed, the investigators will use the VSI device to identify the margins on the main sample. The surgeon will use this information to remove additional tissue from the cavity. The surgeon will then complete the standard of care surgery according to standard of care practices which may include additional shaves of the remaining issue. The amount of tissue removed as a result of VSI-directed shaving will not be more than the amount that your surgeon would normally remove as part of standard of care.
Participants will be asked to come for a post-operative visit as per standard of care and will be followed-up up to 2 months after surgery.
Note: This is only a partial description of the study procedures. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Some of the eligibility criteria include: · Age 18 or older · Must have histologically confirmed invasive breast cancer, ductal carcinoma in situ (DCIS), or invasive breast cancer with a DCIS component · Planning to undergo breast conservation surgery with planned localization and intraoperative imaging for the management of invasive breast cancer
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT05545150 STU00214652 |
Drug GS-US-546-5857: A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine versus Physician’s Choice of Venetoclax in Combination with Azacitidine or Intensive Chemotherapy in Previously Untreated Patients with TP53 Mutant Acute Myeloid Leukemia… The primary objective of this study is to compare the efficacy of magrolimab + azacitidine versus venetoclax + azacitidine in adults with previously untreated TP53 mutant acute myeloid leukemia (AML) who are appropriate for non-intensive therapy as measured by overall survival (OS).
• Individuals with confirmation of AML by World Health Organization criteria, previously untreated for AML, and who have presence of at least 1 TP53 gene mutation that is not benign or likely benign based on evaluation by either central laboratory or an approved local laboratory (after central review of the bone marrow TP53 mitigation next-generation sequencing test results) (individuals with biallelic 17p deletions, loss of both 17p alleles, are eligible based on locally evaluated cytogenetics/karyotype/fluorescence in situ hybridization (FISH) report) • Age of at least 18 years Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. NCT04778397 STU00215715 |
(xIRB) DRUG CAAA617C12301:An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)This study is being conducted to determine if a new experimental Radioligandtherapeutic agent drug named [177Lu]Lu-PSMA-617 given with androgen deprivation therapy(also called ADT) and androgen receptor targeted therapy (called ARDT) is safe and effectiveas a treatment for men with metastatic hormone-sensitive prostate cancer (mHSPC). … This study is being conducted to determine if a new experimental Radioligandtherapeutic agent drug named [177Lu]Lu-PSMA-617 given with androgen deprivation therapy(also called ADT) and androgen receptor targeted therapy (called ARDT) is safe and effectiveas a treatment for men with metastatic hormone-sensitive prostate cancer (mHSPC). Patients must be adults ≥18 years of age. Patients must have metastatic prostate cancer with histologically or cytologicallyconfirmed adenocarcinoma (current or prior biopsy of the prostate and/or metastatic site).
NCT04720157 STU00215972 |
NU MSK20H06: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study of Ibrutinib in Combination with Rituximab in Subjects with Treatment Naïve Marginal Zone LymphomaThe purpose of this study is to see if the combination of rituximab and ibrutinib can help people with marginal zone lymphoma (MZL) who have not received treatment in the past. The study will also compare the combination of rituximab and ibrutinib with the combination of rituximab and placebo to … The purpose of this study is to see if the combination of rituximab and ibrutinib can help people with marginal zone lymphoma (MZL) who have not received treatment in the past. The study will also compare the combination of rituximab and ibrutinib with the combination of rituximab and placebo to see which combination works better. In addition, the study will look at the safety of both combinations.
The FDA has approved rituximab for the treatment of B-cell lymphomas, including low grade (or indolent) lymphomas. The FDA has not approved rituximab as a treatment by itself for MZL, but doctors commonly use the drug for this purpose.
The FDA has approved ibrutinib for the treatment of MZL after a patient has received one past therapy.Giving the combination of rituximab and ibrutinib to people with MZL who have not received a treatment in the past is an investigational use a use that has not been approved by the FDA.. Key eligibility criteria include:
· Histologically documented marginal zone lymphoma, including splenic, nodal, and extranodal sub-types at the enrolling institution. · No prior systemic therapy for MZL with the exception of the following: o a. Prior antibiotic therapy for H. pylori, C. psittaci, and B. burgdorferi o b. Prior antiviral therapy for HCV. · Age of at least 18 years
All prospective patients will undergo screening tests to determine if they are eligible to take part in the study
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT04212013 STU00215286 |
NU 20H09: Phase II, Single-arm, Open-label, Multicenter study Evaluating the Efficacy of Adjunctive Zanubrutinib and CAR T-cell therapy in Aggressive B-cell Non-Hodgkin’s LymphomaWe are asking you to take part in this research studybecause you have and aggressive B-cell Non-Hodgkin’s Lymphoma that couldbenefit from standard of care , chimeric antigen receptor (CAR) T-cell therapy.CAR T-cell therapy is a promisingtreatment where immune cells originally collected from your body called … We are asking you to take part in this research studybecause you have and aggressive B-cell Non-Hodgkin’s Lymphoma that couldbenefit from standard of care , chimeric antigen receptor (CAR) T-cell therapy.CAR T-cell therapy is a promisingtreatment where immune cells originally collected from your body called T-cells (a type of white blood cell), are modifiedand then reintroduced into your body to fight and destroy lymphoma cells.However, CAR T-cell therapy can sustain anti-cancer response beyond 6 months in only 30-40% ofcases. Thus, there is need to enhanceefficacy of CAR T-cell therapy in lymphoma. Lymphoma cells are also known to make a protein called Burton’s TyrosineKinase (“BTK” ), that helps in the proliferation of these cancers. Zanubrutinib is targeted drug that is FDAapproved for a related lymphoma called “Mantel Cell Lymphoma” ( MCL). It isknown to inhibit the BTK protein ( BTK inhibitor ) and can enhance T cell function. Thus, it is expected that it couldenhance CAR T-cell therapy. The investigators of his clinical trialhypothesize that the administration of Zanubrutinib before CAR T-cell therapy and after CAR T-cell therapy can enhance itsanti-cancer effect for your lymphoma · Participantsmust be 18 years or older The target populationfor this study is patients with aggressive B-cell Non-Hodgkin’s Lymphoma
NCT05202782 STU00215064 |
NU SARC041: Phase 3 Randomized Double-Blind Study of Abemaciclib versus Placebo in Patients with Advanced Dedifferentiated LiposarcomaDedifferentiated liposarcoma often has a protein called CDK4 that is over-active. Researchers think that abemaciclib (the study drug), which blocks CDK4, may slow or stop the growth of the liposarcoma tumors. This study is being done to see if the study drug can slow or prevent liposarcoma from growing. … Dedifferentiated liposarcoma often has a protein called CDK4 that is over-active. Researchers think that abemaciclib (the study drug), which blocks CDK4, may slow or stop the growth of the liposarcoma tumors. This study is being done to see if the study drug can slow or prevent liposarcoma from growing. The US Food and Drug Administration (FDA) has not approved abemaciclib for liposarcoma, although it is approved for breast cancer. The use of abemaciclib in this study is considered investigational. Key eligibility criteria include: · Histologically confirmed diagnosis of dedifferentiated liposarcoma which is locally recurrent and/or metastatic. · At least one site of measurable disease on CT/MRI scan as defined by RECIST 1.1 criteria. Baseline imaging must be performed within 28 days of Day 1 of study · Age of at least 18 years All prospective patients will undergo screening tests to determine if they are eligible to take part in the study. Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. NCT04967521 STU00215929 |
DRUG DT2216-001: A Phase 1, Open-Label, Dose Escalation, and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Clinical Activity of DT2216, an Antiapoptotic Protein Targeted Degradation Compound, in Subjects with Relapsed or Refractory MalignanciesThe main purpose of this study is to determine if the investigational drug, called DT2216, is safe, and to determine the anti-cancer activity. This is the first time that the study drug has been used in people.The study will consist of the following parts: •A preliminary (screening) period … The main purpose of this study is to determine if the investigational drug, called DT2216, is safe, and to determine the anti-cancer activity. This is the first time that the study drug has been used in people. The study will consist of the following parts: •A preliminary (screening) period of up to 28 days to determine eligibility •A treatment period of up to 1 year •A follow-up visit 28 days after the last dose of drug •Continued follow-up to monitor health status every 3 months for up to 2 years Participants will continue to receive the study drug until they are no longer benefiting, or experience unacceptable side effects or withdraw from the study. On the first day of the study treatment period (Day 1), the study doctor will perform some tests before participants receive the first dose of study drug. After these are completed, participants will receive a single dose of study drug by intravenous (IV) line on Day 1 and again on Day 4 each week for at least 4 weeks (this is known as 1 cycle of study treatment). During each cycle clinic visits, the study doctor will perform some tests to check for health status. Note: This is only a partial description of treatment. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Some of the eligibility criteria include: •Age of at least 18 years •Diagnosis of advanced cancer, which has returned after your most recent treatment regimen (relapsed) or has not responded to your most recent treatment regimen (refractory). Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT04886622 STU00215654 |
(xIRB) DRUG TAK-007-2001: A Phase 2, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients With Relapsed or Refractory Non-Hodgkin LymphomaThe purpose of this study is to determine how safe, at what dose and how well TAK-007 works as a therapy in participants with worsened or refractory B-cell Non Hodgkin Lymphoma. If you meet all the eligibility criteria for being in this study, the study consists of two … The purpose of this study is to determine how safe, at what dose and how well TAK-007 works as a therapy in participants with worsened or refractory B-cell Non Hodgkin Lymphoma. If you meet all the eligibility criteria for being in this study, the study consists of two parts: Part 1: You will be given one of two dose levels to determine the safety and tolerability of TAK-007. The information from this part of the study will help the Sponsor determine what dose level to explore in a larger number of participants. Both doses expected to be safe. Part 2: You will be given the recommended phase 2 dose, determined in part 1 of the study, to further evaluate the safety and effectiveness of TAK-007. Some of the eligibility criteria include:
NCT05020015 STU00216463 |
NU 21C01: A phase 1/1b adaptive dose escalation study of mycophenolate mofetil (MMF) in combination with standard of care for patients with glioblastomaThe purpose is to determine if mycophenolate motfetil (MMF) combine with temozolomide (TMZ) can stop glioblatoma. Mycophenolate Mofetil is an antimetabolite immunosuppressant and is FDA approved for the prophylaxis of organ rejection in recipients of allogeneic kidney, heart or liver transplant, and is used in combination with other immunosuppressants.Group … The purpose is to determine if mycophenolate motfetil (MMF) combine with temozolomide (TMZ) can stop glioblatoma. Mycophenolate Mofetil is an antimetabolite immunosuppressant and is FDA approved for the prophylaxis of organ rejection in recipients of allogeneic kidney, heart or liver transplant, and is used in combination with other immunosuppressants. Group S (Pre-surgical): Window of Opportunity Study, pre-operative MMF and temozolomide (TMZ) Participants with suspected newly diagnosed or recurrent glioblastoma who plan to have surgical resection are eligible. Study treatment must begin within 7 days after registration. Group S will open in Part 1 after one participant in Group 1 has successfully completed the first dose level DLT period and subsequent DSMB review. The MMF dose for Group S will be adjusted each time DSMB has approved a subsequent dose escalation. The MMF dose for Group S will always be 1 dose level below the current enrolling dose level (the last safe dose level as indicated by the DSMB) in Group 1. Participants will have 5 days of pre-operative MMF (BID) and TMZ (200 mg/m2 QD) Group 1 (Adjuvant): Adjuvant therapy+ MMF (dose escalation) Four to six weeks after the completion of chemoradiation, participants will be registered to the study. Study treatment must begin within 7 days after registration. On study, participants will receive maintenance TMZ and MMF. Each maintenance cycle is 28 days long. TMZ will be taken orally once a day on Days 1-5, at a dose of 150 mg/m2, for up to 6 cycles. On Cycles 2-6, the TMZ dose may be increased to 200 mg/m2 in the absence of toxicity. Starting Cycle 1 Day 1, MMF will be taken orally twice daily for up to 6 cycles (each cycle is 28 days). The dose of MMF will depend on the dose level each participant is accrued to. See MMF Dose Level table in Section 4.2. The DLT period for Group 1 is the duration of Cycle 1 (28 days), and 7 days thereafter. Group 2 (Chemoradiation): RT + MMF for MGMT unmethylated tumors (dose escalation) About 4 weeks after surgical resection, participants confirmed to have unmethylated glioblastoma will be registered and treated with concurrent MMF and TMZ (75 mg/m2 daily) and 6 weeks of focal radiation therapy (60 Gy). Study treatment must begin within 7 days after registration. MMF will be taken twice daily for the entire 6 week period of focal radiation therapy. The dose of MMF will depend on the dose level each participant is accrued to. After radiation therapy, participants will start adjuvant treatment with TMZ. TMZ will be taken orally once a day on Days 1-5, at a dose of 150 mg/m2, for up to 6 cycles. On Cycles 2-6, the TMZ dose may be increased to 200 mg/m2 in the absence of toxicity The DLT period for Group 2 is the duration of radiation therapy (6 week period), and 7 days thereafter. Group 3 (Expansion): MMF during RT and during adjuvant phase. Enrollment to begin only AFTER the completion of groups 1 and 2. About 4 weeks after surgical resection, participants will be registered and treated with concurrent MMF and 6 weeks of focal radiation therapy (60Gy) and concurrent TMZ at a dose of 75 mg/m2 daily. Study treatment must begin within 7 days after registration. After completion of chemoradiation, participants will go on to have adjuvant TMZ (at a dose of 150 mg/m2 on days 1-5 of each cycle, may be up to 200 mg/m2 during cycles 2-6) with concurrent twice-daily MMF for a total of 6 planned cycles (each cycle is 28 days). The dose of MMF during radiation therapy and during adjuvant treatment will be the RP2D determined in dose escalation Groups 1 and 2. Optune® Device (Tumor Treating Fields) Concurrent use of the Optune® device (TTFields) is permitted, but not required for participation on this study. It’s use will be according to standard of care. Some of the eligibility criteria include: •Participants must be 8 years of age or older. •For Groups 1-3: Histologically confirmed glioblastoma (GBM), IDH wild-type (by IHC R132H neg or sequencing). Astrocytoma with molecular features of GBM are eligible. •For Groups 1-3: Newly diagnosed glioblastoma and: a) Group 1: Received surgical resection or biopsy followed by chemoradiation; b) Group 2: Received surgical resection or biopsy only and have documented unmethylated glioblastoma (may have been done at an outside facility); c) Group 3: Received surgical resection or biopsy only •For Group S: Newly suspected glioblastoma or recurrent glioblastoma, and scheduled to undergo a standard of care surgical resection or biopsy Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT05236036 STU00215766 |
(xIRB) DRUG 676: A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette- Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is either Persistent or Recurrent Following BCG Induction or that is Naïve to BCG Treatment (KEYNOTE-676)The purpose of this study is to: • Test the safety of the study drugs, pembrolizumab/MK-3475 in combination with Bacillus Calmette-Guérin (BCG) • See how well the drugs work • See how the body handles pembrolizumab and BCG • See how well pembrolizumab in combination with different doses of BCG … The purpose of this study is to: • Test the safety of the study drugs, pembrolizumab/MK-3475 in combination with Bacillus Calmette-Guérin (BCG) • See how well the drugs work • See how the body handles pembrolizumab and BCG • See how well pembrolizumab in combination with different doses of BCG works compared to BCG alone • See if pembrolizumab helps patients getting BCG have a better quality of life • See if pembrolizumab helps patients getting BCG live longer Pembrolizumab has been approved for patients with certain types of bladder cancer; however, it has not been approved for your type of bladder cancer, and is therefore considered experimental in this study. Have locally and BICR-confirmed histological diagnosis of high-risk non-muscle invasive (T1, high-grade Ta and/or CIS) UC of the bladder.
Have been treated with one adequate course of BCG induction therapy for the treatment of HR NMIBC defined as at least 5 intravesical instillations of BCG within a 10-week period of time. If more than one induction course or any maintenance therapy of BCG has been received, the participant is not eligible for this study NCT03711032 STU00216667 |
ETCTN 10466: A Phase 2 Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell CancerThe purpose of this study is to see if using a combination of bevacizumab, atezolizumab, and erlotinib is safe and will cause your tumors to shrink. The use of bevacizumab and atezolizumab in this study is considered investigational which means this combination has not been approved by the U.S. … The purpose of this study is to see if using a combination of bevacizumab, atezolizumab, and erlotinib is safe and will cause your tumors to shrink.
The use of bevacizumab and atezolizumab in this study is considered investigational which means this combination has not been approved by the U.S. Food and Drug Administration (FDA) to treat kidney cancer. However, the FDA has given us permission to use bevacizumab and atezolizumab in this study. Some of the key eligibility criteria include: · Patients with cytologically or histologically confirmed RCC and a diagnosis of HLRCC (Cohort 1) or sporadic/non-HLRCC papillary RCC (Cohort 2). · Age ≥12 years · Adequate organ and marrow function
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
All prospective patients will undergo screening tests to determine if they are eligible to take part in the study. NCT04981509 STU00216677 |
Site for (xIRB) BMT ACCESS: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation (HCT) with Post-Transplantation Cyclophosphamide for Patients with Hematologic MalignanciesThe purpose of this study is to see how well transplant works in adults with a mismatched unrelated donor using stem cells from a donor’s blood. We’ll look at how well the transplant treats your disease, what the side effects may be, and what your life looks like … The purpose of this study is to see how well transplant works in adults with a mismatched unrelated donor using stem cells from a donor’s blood. We’ll look at how well the transplant treats your disease, what the side effects may be, and what your life looks like after your transplant. The study will also help us give better care to future patients. This study treatment does not include any investigational drugs. Before you begin the study, your doctor will review your test results to decide if it’s safe for you to be in the study. If you join the study, you will have tests and evaluations to closely watch your health and safety. Most of these tests and evaluations are considered part of the standard care you would get if you receive a transplant and weren’t in this study. You may have had some of them done already. Your study doctor will determine if any of these tests or procedures will need to be repeated for you to participate in the study. There are some surveys we will ask you to fill out before and after the transplant that are not part of routine care. The medicines and procedures in this study are also standard for transplant. You may still receive these medicines and procedures if you are not part of the study and receive a transplant. Transplant day On your transplant day (Day 0), the donor cells will be given to you through your central line, like a blood transfusion. The cells will travel to your bone marrow where they will start to make healthy, new blood cells after several weeks. After your transplant Graft-versus-host disease (GVHD) is a common complication of transplant. It happens because of differences between the donated cells (graft) and your body’s cells (host). Your new cells from your donor might see your body’s cells as different and attack them. You’ll get standard medicines to lower your risk of getting graft versus host disease (GVHD). You’ll start these medicines around the time of your transplant, and continue taking them for many months afterwards. They may not completely prevent GVHD and you may need more medicines to treat GVHD if you develop it. The Survey Research Group (SRG) team of the Center for Blood and Marrow Transplant Research (CIBMTR) will contact you to do the surveys 4 times during the 1 year you’re in the study. Each survey will take between 15 and 25 minutes to complete. oBefore transplant oAbout 3 months after transplant oAbout 6 months after transplant oAbout 1 year after transplant Note: This is only a partial description of treatment. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Some of the eligibility criteria include: •Age of at least 18 years (Donor and Recipient) •Normal liver function Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT04904588 STU00216689 |
Drug BNT152-01C: Phase I, first-in-human, open-label, dose escalation trial to evaluate safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of BNT152+153 in patients with solid tumorsThis research study is ultimately designed to evaluate a new drug called BNT152+153. Since this drug is a combination of two investigational drugs called BNT152 and BNT153, the sponsor must first evaluate each of the two drugs separately (called “monotherapy”). “Investigational” means that BNT152 and BNT153, whether given as … This research study is ultimately designed to evaluate a new drug called BNT152+153. Since this drug is a combination of two investigational drugs called BNT152 and BNT153, the sponsor must first evaluate each of the two drugs separately (called “monotherapy”). “Investigational” means that BNT152 and BNT153, whether given as monotherapy or combination therapy, are not approved by the United States (U.S.) Food and Drug Administration (FDA) or by any regulatory authority in the world.
In this research study, BNT152 monotherapy, BNT153 monotherapy, and BNT152+153 combination therapy will be tested in humans for the first time.
The overall purpose of this research study is to assess the safety and to establish a safe and effective dose of BNT152 and BNT153 when each is given alone (monotherapy) and when given in combination (BNT152+153). The study will also collect information about how well the drug(s) works against cancer. • Histologically or cytologically confirmed solid tumor that is metastatic (Stage IV) or unresectable and for whom there is no available standard therapy likely to confer clinical benefit, or patient who is not a candidate for such available therapy. If there is no contraindication, patients should have exhausted all SoC therapies before entering the trial. • Measurable or evaluable disease per RECIST1.1. NCT04710043 STU00216003 |
DRUG CYTB323A12101: Phase I, open label, multicenter, dose escalation study of YTB323 in adult patients with CLL/SLL and DLBCLThis is a first-in-human study to evaluate the feasibility, safety and preliminary antitumor efficacy of autologous T cells genetically engineered with a CD19-specific chimeric antigen receptor (CAR) and manufactured with a new process. CAR-T cells will be investigated in combination with ibrutinib in chronic lymphocytic leukemia (… This is a first-in-human study to evaluate the feasibility, safety and preliminary antitumor efficacy of autologous T cells genetically engineered with a CD19-specific chimeric antigen receptor (CAR) and manufactured with a new process. CAR-T cells will be investigated in combination with ibrutinib in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and as single agent in diffuse large B-cell lymphoma (DLBCL) and in adult acute lymphoblastic leukemia (ALL).
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Some of the eligibility criteria include: •Age of at least 18 years •Diagnosis of DLBCL, or ALL Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT03960840 STU00215546 |
(xIRB NCI CIRB) NRG GU010: Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)PurposeThe purpose of this study is to determine if radiation therapy alone is as effective at controlling unfavorable intermediate risk prostate cancer, cancer compared to the usual combination of radiation and hormone therapy. Who May be Eligible: Some of the key eligibility criteria include: · Cytologically or histologically confirmed diagnosis of … Purpose The purpose of this study is to determine if radiation therapy alone is as effective at controlling unfavorable intermediate risk prostate cancer, cancer compared to the usual combination of radiation and hormone therapy.
Who May be Eligible: Some of the key eligibility criteria include: · Cytologically or histologically confirmed diagnosis of adenocarcinoma of the prostate. · Unfavorable intermediate risk prostate cancer · Age ≥18 years
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
All prospective patients will undergo screening tests to determine if they are eligible to take part in the study.
NCT05050084 STU00216947 |
TELLOMAK: T-cell Lymphoma anti-KIR3DL2 therapy An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell lymphomaThe purpose of this study is to evaluate the effectiveness and safety of a new experimental drug named lacutamab (IPH4102). … The purpose of this study is to evaluate the effectiveness and safety of a new experimental drug named lacutamab (IPH4102).
NCT03902184 STU00215713 |
Phase II Multicenter Study of Ruxolitinib in Relapsed or Refractory T or NK Cell LymphomaThe purpose of this study is to test any good and bad effects of the study drug called ruxolitinib. Ruxolitinib works by blocking a protein called JAK. JAK works along with another protein called STAT and is important for survival of many T or NK-cell lymphomas. By blocking JAK, … The purpose of this study is to test any good and bad effects of the study drug called ruxolitinib. Ruxolitinib works by blocking a protein called JAK. JAK works along with another protein called STAT and is important for survival of many T or NK-cell lymphomas. By blocking JAK, ruxolitinib may cause T or NK-cell lymphomas to shrink.
NCT02974647 STU00216438 |
DRUG ADCT-901-101: A Phase 1, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 as Monotherapy in Patients With Selected Advanced Solid TumorsThe primary objectives of this study are to identify the recommended dose for expansion (RDE) (and recommended schedule) and/or maximum tolerated dose (MTD), and to characterize the safety and the tolerability of ADCT-901. Note: This is only a partial description of the study. Please contact the Robert H. … The primary objectives of this study are to identify the recommended dose for expansion (RDE) (and recommended schedule) and/or maximum tolerated dose (MTD), and to characterize the safety and the tolerability of ADCT-901.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial.
Some of the eligibility criteria include:
Pathologic diagnosis of selected solid tumor malignancy that is locally advanced or metastatic at time of Screening: cholangiocarcinoma, ovarian/fallopian tube cancers, prostate cancer, renal cell carcinoma, and triple negative breast cancer (TNBC). Note: Histologic variants of prostate cancer, including neuroendocrine features and small cell carcinoma of the prostate are permitted. Participants who are refractory to or intolerant to existing therapy(ies) known to provide clinical benefit for their condition per Investigator judgment. Participants with measurable disease as determined by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1: Note 1: Lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft tissue components, that can be evaluated by cross sectional imaging techniques such as computed tomography (CT) or magnetic resonance imaging (MRI) can be considered as measurable lesions only if the soft tissue component meets the definition of measurability per RECIST v1.1. Note 2: Prostate cancer participants without measurable lesions will be accepted, with evidence of bone metastatic disease on radiographic examination, whether from bone scan or other imaging modality, and prostate specific antigen (PSA) ≥2.0 ng/mL. Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT04972981 STU00216671 |
NU 21N05: A Phase II, Multicenter Study of XmAb20717 in Patients with Metastatic Anaplastic Thyroid Cancer with an Exploratory Cohort in Aggressive Hurthle Cell Thyroid CancerThe purpose of this study is to test any good and bad effects of the study drug, XmAb20717, and test how well it works on your type of cancer, anaplastic thyroid cancer (ATC) or Hurthle cell thyroid cancer (HCC). ATC is the most advanced and aggressive thyroid cancer. It is … The purpose of this study is to test any good and bad effects of the study drug, XmAb20717, and test how well it works on your type of cancer, anaplastic thyroid cancer (ATC) or Hurthle cell thyroid cancer (HCC). ATC is the most advanced and aggressive thyroid cancer. It is very rare and is found in less than 2% of patients with thyroid cancer. HCC is another aggressive form of thyroid cancer found in 5% of patients with thyroid cancer. If the study requirements are met, the enrolled patient will be given the study drug, XmAb20717, as treatment. There will be 2 cohorts receiving treatment—patients with ATC and patients with HCC. Each cycle of treatment will be 28 days (4 weeks), and the study drug will be administered on days 1 and 15 of each 28-day cycle. The treatment cycles may repeat until the patient has received treatment for 24 months (2 years).
After the last dose of the study drug, the study doctor will continue to watch the patient for side effects and follow the patient’s condition for up to 5 years. · Age of at least 18 years · Subject ATC or HCC must be metastatic or incurable · Subjects whose ATC carries a known BRAF V600E mutation must previously have received and failed, or be intolerant to, a BRAF/MEK inhibitor (e.g., dabrafenib or trametinib). · Subjects with HCC must previously have received and failed, or be intolerant to, one line of primarily anti-VEGFR tyrosine kinase inhibitor therapy (e.g., levantibib) NCT05453799 STU00216441 |
(xIRB) NCI CIRB ETCTN 10405: Phase I Trial of BAY 1895344 ATR Inhibitor Combined with Stereotactic Body Radiation Therapy and Pembrolizumab for Recurrent Head and Neck Squamous Cell Carcinoma… The purpose of this study is to test the safety and tolerability of a drug called BAY 1895344 given with pembrolizumab and radiation. This study tests different doses of the drug and radiation to see which dose is safest for people as part of the combination treatment. There will be up to 37 people taking part in this study.
Pembrolizumab has already been approved by the FDA to treat your cancer. The combination of BAY 1895344, pembrolizumab, and radiation is not FDA-approved to treat your cancer. BAY 1895344 is not FDA-approved to treat your cancer or any cancer.
If the study requirements are met, the enrolled patient will be enrolled into one of the two parts of this study below:
· Dose escalation part: different patients will get different doses of the study drug BAY 1895344 and different doses of radiation, as well as the same doses of pembrolizumab OR · Dose expansion part: patients will receive the highest dose of BAY 1895344 with manageable side effects, along with pembrolizumab and radiation
The doctor and the study team will watch for side effects during the trial. Patients will also be followed for 5 years after starting the study.
Some of the eligibility criteria include: · At least 18 years of age. · Patients must have histologically confirmed recurrent, unresectable head and neck squamous cell carcinoma, including oral cavity, oropharynx, larynx, hypopharynx, or cervical lymphadenopathy. · Patients must have recurrent disease within a previously irradiated area (radiotherapy to dose ≥40 Gy, i.e., in-field recurrence). · Patients must have competed prior radiotherapy ≥6 months prior to enrollment. · Patients must have received prior cisplatin chemotherapy
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. NCT04576091 STU00217166 |
NU 22H01: Serial Monitoring of Circulating Plasma Cells and Plasma Cell Components in Adults with Plasma Cell DisordersThis study is being done to collect, process, and store blood samples of plasma cell disorder patients. The collected blood samples will be used for research projects to study the abnormal plasma cells and compare the results to current tests being done. This will provide an opportunity to better understand … This study is being done to collect, process, and store blood samples of plasma cell disorder patients. The collected blood samples will be used for research projects to study the abnormal plasma cells and compare the results to current tests being done. This will provide an opportunity to better understand how a patient is responding to treatment and to assess the stage of the patient’s disease. This study will use different tests that are not FDA approved. This test is being studied as a less invasive way to monitor amount of disease in a patient (versus invasive bone marrow biopsy). Current blood tests show the levels of the product of the cancer cell - not the levels of the cells themselves. Sometimes the cancer cells do not make this product and can therefore go undetected in standard tests. This study will show the number of cells. These tests will help identify, and analyze circulating plasma cells (CPCs), which are cells that have escaped into the bloodstream (a characteristic of plasma cell disorders). We will also look at any plasma cell components, such as genes in the DNA and RNA. Part of your samples will be used for Next Generation Sequencing (NGS) to evaluate any changes in your genes. NGS is a useful tool that determines the sequence of your DNA. You may be eligible for this research study if you have a plasma cell disorder. STU00216869 |
(xIRB) DRUG PTC596-ONC-008-LMS: A Phase 2/3 Study to Evaluate the Efficacy and Safety of Unesbulin in Unresectable or Metastatic, Relapsed or Refractory LeiomyosarcomaThe purpose of this study is to evaluate the effectiveness and safety of an investigational drug, unesbulin. This study drug is used to treat unresectable (can’t be removed with surgery) or metastatic (spread to other parts of the body), relapsed (has come back after treatment or refractory (did not … The purpose of this study is to evaluate the effectiveness and safety of an investigational drug, unesbulin. This study drug is used to treat unresectable (can’t be removed with surgery) or metastatic (spread to other parts of the body), relapsed (has come back after treatment or refractory (did not respond to prior treatment) leiomyosarcoma along with Dacarbazine (DTIC). Dacarbazine is a drug that is United States Food and Drug Administration (FDA)-approved for the treatment of other types of cancer and recommended by the cancer treatment guidelines for sarcomas. Laboratory studies showed the combination of unesbulin and dacarbazine was significantly more effective than either agent alone in suppressing tumor growth. If the study requirements are met, patients will be assigned to one of the two groupgs:
· Unesbulin in combination with Dacarbazine: Subjects will receive Unesbulin twice a week in 3-week study treatment cycles, and Dacarbazine once every 21 days OR · Placebo in combination with Dacarbazine: Subjects will receive placebo (pill with no active medicine) twice a week in 3-weeks study treatment cycles, and Dacarbazine once every 21 days.
Twice the number of the subjects will be in the unesbulin arm vs the placebo. As a result, you are more likely to be on the unesbulin group than the placebo group. After treatment, the study doctor will also call you every 3 months via telephone for up to 2 years to monitor your health. Some of the eligibility criteria include:
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. NCT05269355 STU00217413 |
NU DF21B07: Evaluation of talazoparib, a PARP inhibitor, in patients with somatic BRCA mutant metastatic breast cancer: genotyping based clinical trial… In this research study, we are examining how effective talazoparib is in patients with metastatic breast cancer with a BRCA mutation in their tumor.
The U.S. Food and Drug Administration (FDA) has not approved talazoparib for your specific disease but it has been approved for metastatic breast cancer with a germline (inherited) BRCA mutation. Talazoparib is a study drug that inhibits (stops) the normal activity of certain proteins called “poly (ADP-ribose) polymerases” also called “PARPs”. PARPs are proteins (made from genes which are part of your DNA) that are found in all normal and cancer cells that are involved in the repair of DNA. PARPs are needed to repair mistakes that can happen in DNA when cells divide. If the mistakes are not repaired, the defective cell will usually die and be replaced. Cells with mistakes in their DNA that do not die can become cancer cells. Cancer cells may be killed by a study drug, like talazoparib, that stops the normal activity of PARPs. In clinical trials, the use of talazoparib and other PARP inhibitors have shown that these drugs can reduce tumor size and slow tumor growth in some cancer patients with BRCA1 or BRCA2 mutations
Key eligibility criteria include:
· Metastatic breast cancer with deleterious somatic BRCA 1 or 2 mutations detectable by cell-free circulating tumor DNA or tumor tissue, by CLIA certified clinical assay (including but not restricted to MGH-Snapshot cfDNA assay, Guardant360, Foundation One).
· Patients with germline BRCA 1 or 2 mutations will not be eligible.
· Patients with only a Variant of Unknown Significance or non-functional BRCA mutation, without a deleterious somatic BRCA 1 or 2 mutation will not be eligible.
· The following disease subtypes are eligible:
· Triple negative breast cancer (defined as ER < 1%, PR < 1%, HER2 negative, as per ASCO CAP guidelines), with disease progression on at least one prior chemotherapy regimen in the metastatic setting.
· Hormone receptor positive, HER2 negative disease with disease progression on at least one prior endocrine therapy in the metastatic setting or be considered inappropriate for endocrine therapy
· Patients must have evaluable or measurable disease. All prospective patients will undergo screening tests to determine if they are eligible to take part in the study
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT03990896 STU00217331 |
(xIRB) DRUG D8241C00001: A Modular Phase I/II, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD0466 Monotherapy or in Combination in Patients with Advanced Haematological MalignanciesThe purpose of the study is to the evaluate safety, tolerability, pharmacokinetics (PK), and efficacy of AZD0466 as monotherapy in participants with advanced haematological malignancies and also to assess drug-drug interaction (DDI) potential between AZD0466 and the azole antifungal voriconazole. Note: This is only a partial description of the … The purpose of the study is to the evaluate safety, tolerability, pharmacokinetics (PK), and efficacy of AZD0466 as monotherapy in participants with advanced haematological malignancies and also to assess drug-drug interaction (DDI) potential between AZD0466 and the azole antifungal voriconazole.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Some of the eligibility criteria include:
· Participants must have a diagnosis of advanced hematological malignancies including higher-risk myelodysplastic syndrome
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT04865419 STU00217566 |
(xIRB NCI CIRB) ECOG-ACRIN 9213: A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL)This study is being done to answer the following question:Can daratumumab-hyaluronidase reduce the level of MRD in T-ALL patients previously treated with chemotherapy?We are doing this study because we want to find out if this approach is better or worse than the usual approach for your … This study is being done to answer the following question: Can daratumumab-hyaluronidase reduce the level of MRD in T-ALL patients previously treated with chemotherapy? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your T-ALL. The usual approach is defined as care most people get for Acute Lymphoblastic Leukemia (ALL). The usual approach for patients who are not in a study is treatment with chemotherapy, and possibly stem cell transplant. Sometimes, combinations of these treatments are used. Currently there is no SOC treatment for MRD positive T ALL. Many patients if eligible would undergo stem cell transplant, but still have a high risk for T ALL relapse if MRD positive The purpose of this study is to test the good and bad effects of the drug called daratumumab and hyaluronidase. Daratumumab and hyaluronidase could be effective in preventing your cancer from returning, but it could also cause side effects. The study doctors hope to learn if the study drug will be effective in treating patients with MRD positive T-ALL and preventing reoccurrence of your disease.
NCT05289687 STU00217578 |
(xIRB) NU USC22D01: Evaluating the PD-1 checkpoint inhibitor, Cemiplimab, as neoadjuvant therapy in high risk localized, locally recurrent, and regionally advanced cutaneous squamous cell carcinoma: a Phase II pilot study (NeoPOWER)The purpose of this study is to test any good and bad effects of the study drug called Libtayo(cemiplimab) in patients with the diagnosis of Cutaneous Squamous Cell Carcinoma (CSCC,) when given before resection surgery. This investigational approach could shrink your cancer, but it could also cause side effects. … The purpose of this study is to test any good and bad effects of the study drug called Libtayo(cemiplimab) in patients with the diagnosis of Cutaneous Squamous Cell Carcinoma (CSCC,) when given before resection surgery. This investigational approach could shrink your cancer, but it could also cause side effects. Researchers hope to learn if the use of this drug before surgery will reduce the amount of cancer cells by at least 50% compared to the original amount in more than 40% of patients. Libtayo (cemiplimab) is FDA-approved to treat metastatic CSCC. Cemiplimab will be administered as an IV infusion over 30 minutes in an outpatient setting. Cemiplimab will be used at a flat 350 mg IV dose every 21 days for a total of 9 weeks (or 12 weeks). One cycle is 21 days. After discontinuation of treatment, if the tumor is potentially resectable, the patient will proceed with surgical resection.
Note: This is only a partial description of treatment. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete description of treatment. Some of the eligibility criteria include:
· Participants must have a diagnosis of histologically confirmed, measurable, and potentially resectable Cutaneous Squamous Cell Carcinoma · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT04315701 STU00217579 |
(xIRB NCI CIRB) SWOG 2015: Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous MelanomaPatients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the … Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of life.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial.
Some of the eligibility criteria include: · Participants must have a diagnosis of Cutaneous Melanoma, Stage II · Participants must be 18 or older · Patient must be able to give informed consent and comply with the treatment protocol and follow-up plan. · Surgery (which refers to the staging sentinel node biopsy and wide local excision as these are both to be done on the same day) must be completed within 120 days of the original diagnosis.
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT05251038 STU00217691 |
(xIRB NCI CIRB) SWOG 2011: Randomized Phase II Trial of Gemcitabine, Avelumab and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma: SWOG GAP TRIALThis phase II trial studies the effect of avelumab, gemcitabine and carboplatin before surgery compared with surgery alone in treating patients with muscle invasive bladder or upper urinary tract cancer who are not able to receive cisplatin therapy. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's … This phase II trial studies the effect of avelumab, gemcitabine and carboplatin before surgery compared with surgery alone in treating patients with muscle invasive bladder or upper urinary tract cancer who are not able to receive cisplatin therapy. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as gemcitabine and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving avelumab together with gemcitabine and carboplatin before surgery may work better in lowering the chance of muscle invasive urinary tract cancer growing or spreading, in patients who cannot receive cisplatin therapy compared to surgery alone.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Some of the eligibility criteria include:
· Participants must have a diagnosis of muscle-invasive bladder cancer or upper tract urothelial carcinoma · Participants must be 18 or older · All sexes eligible
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. NCT04871529 STU00217759 |
(xIRB NCI CIRB) Alliance A211801: BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline MutationThis phase III trial compares denosumab to placebo for the prevention of breast cancer in women with a BRCA1 germline mutation. A germline mutation is an inherited gene change which, in the BRCA1 gene, is associated with an increased risk of breast and other cancers. Denosumab is a monoclonal antibody … This phase III trial compares denosumab to placebo for the prevention of breast cancer in women with a BRCA1 germline mutation. A germline mutation is an inherited gene change which, in the BRCA1 gene, is associated with an increased risk of breast and other cancers. Denosumab is a monoclonal antibody that is used to treat bone loss in order to reduce the risk of bone fractures in healthy people, and to reduce new bone growths in cancer patients whose cancer has spread to their bones. Research has shown that denosumab may also reduce the risk of developing breast cancer in women carrying a BRCA1 germline mutation. Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial.
Some of the eligibility criteria include:
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT04711109 STU00217826 |
(xIRB NCI CIRB) NRG GU012: Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has spread to other places in … This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has spread to other places in the body (metastatic). Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses of radiation over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, avelumab, and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib, cabozantinib, and lenvatinib are in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving SABR in combination with standard of care immunotherapy may help shrink or stabilize the cancer in patients with renal cell cancer.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial.
Some of the eligibility criteria include:
· Participants must have a diagnosis of renal cell carcinoma prior to registration · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. NCT05327686 STU00217871 |
(xIRB NCI CIRB) SWOG 1900F: A Randomized Phase II Study of Carboplatin and Pemetrexed with or Without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study)This phase II Lung-MAP treatment trial tests whether carboplatin and pemetrexed with or without selpercatinib works to shrink tumors in patients with RET fusion-positive non-small cell lung cancer that is stage IV or has not responded to previous RET directed therapy. Chemotherapy drugs, such as carboplatin and … This phase II Lung-MAP treatment trial tests whether carboplatin and pemetrexed with or without selpercatinib works to shrink tumors in patients with RET fusion-positive non-small cell lung cancer that is stage IV or has not responded to previous RET directed therapy. Chemotherapy drugs, such as carboplatin and pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Selpercatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving selpercatinib in combination with carboplatin and pemetrexed may help lower the chance of the cancer growing and spreading Some of the eligibility criteria include:
NCT05364645 STU00217878 |
(xIRB NCI CIRB) NRG GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)This Phase II/III trial will evaluate what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer. Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center … This Phase II/III trial will evaluate what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Some of the eligibility criteria include:
· Participants must have a diagnosis of histologically/pathologically confirmed Stage IIIA or Stage IIIB colon adenocarcinoma · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. NCT05174169 STU00217884 |
(xIRB NCI CIRB) SWOG 1918: A Phase II/III Randomized Study of R-MiniCHOP With or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas With MYC AND BCL2 and/or BCL6 RearrangementsA Phase II/III Randomized Study of R-MiniCHOP with or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC AND BCL2 and/or BCL6 … A Phase II/III Randomized Study of R-MiniCHOP with or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC AND BCL2 and/or BCL6 Rearrangements Some of the eligibility criteria include:
· Participants must have a diagnosis of lymphoma · Participants must be 75 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT04799275 STU00217891 |
(xIRB NCI CIRB) COG ANHL1931: A Randomized Phase 3 trial of Nivolumab(NSC# 748726) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell LymphomaThis phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the … This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Treatment for PMBCL involves chemotherapy combined with an immunotherapy called rituximab. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving nivolumab with chemo-immunotherapy may help treat patients with PMBCL.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. NCT04759586 STU00217895 |
(xIRB NCI CIRB) NRG GY026: A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or CarcinosarcomaThis phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin HylectaTM) or pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma. Trastuzumab and pertuzumab are monoclonal antibodies and forms … This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin HylectaTM) or pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Some of the eligibility criteria include:
· Participants must have a diagnosis of Federation of Gynecology and Obstetrics (FIGO) 2009 stage IA-IVB, non-recurrent, chemotherapy (chemo)-naive, HER2-positive endometrial serous carcinoma or endometrial carcinosarcoma · Participants must be 18 or older · Patients must be within 8 weeks of primary surgery (or endometrial biopsy in patients who never undergo hysterectomy) at the time of study registration
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. NCT05256225 STU00217949 |
(xIRB) A Phase 2 Study of ANV419 as Monotherapy or in Combination With Anti-PD-1 or Anti-CTLA-4 Antibody Following Anti-PD-1/Anti-PD-L1 Antibody Treatment in Patients With Unresectable or Metastatic Cutaneous MelanomaThe purpose of this study is to compare how safe and effective the investigational medicine, ANV419, is when given alone, or in combination with pembrolizumab or ipilimumab, which are medicines approved for use to treat melanoma.This clinical study has three parts, and you will take part in one of … The purpose of this study is to compare how safe and effective the investigational medicine, ANV419, is when given alone, or in combination with pembrolizumab or ipilimumab, which are medicines approved for use to treat melanoma. This clinical study has three parts, and you will take part in one of these parts: In Part 1, the goal is to understand how effective ANV419 is when given alone at two different doses. In Part 2, the goal is to understand how safe different doses of ANV419 are when given in combination with pembrolizumab or ipilimumab, and to select the best dose of ANV419. In Part 3, the dose of ANV419 selected from Part 2 will be used to further investigate the efficacy and safety of ANV419 in combination with pembrolizumab or ipilimumab. Some of the eligibility criteria include: · Participants must have a diagnosis of unresectable or metastatic cutaneous melanoma · Participants must be 18 or older Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT05578872 STU00217965 |
(xirb) DRUG IMGN853-0420: Multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha positive, recurrent platinum-sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers following 1 prior line of platinum-based chemotherapyIMGN853-0420 is a multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha positive, recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer following 1 prior line of platinum-based chemotherapy. Note: This is only … IMGN853-0420 is a multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha positive, recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer following 1 prior line of platinum-based chemotherapy.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Some of the eligibility criteria include:
· Participants must have a diagnosis of high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancer. · Patients must have relapsed after 1 prior line of platinum-based chemotherapy. · Patients must have platinum-sensitive disease defined as radiographic progression greater than 6 months from last dose of platinum-based chemotherapy. · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT05456685 STU00217980 |
Relugolix Versus Leuprolide in Patients with Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (REPLACE-CV)This is a randomized open-label study to evaluate the risk of MACE in patients with prostate cancer with defined high-risk cardiovascular disease who are appropriate to be treated either withrelugolix or leuprolide acetate for a planned duration of 12 months or more. This study will collect clinical and … This is a randomized open-label study to evaluate the risk of MACE in patients with prostate cancer with defined high-risk cardiovascular disease who are appropriate to be treated either with relugolix or leuprolide acetate for a planned duration of 12 months or more. This study will collect clinical and cardiovascular baseline risk factor data on these patients. 1. Has voluntarily signed and dated the informed consent form prior to baseline visit; 2. Is a male and 18 years of age or older on the day of signing and dating the informed consent form; 3. Patient has sufficient cognitive function in the investigator’s opinion to complete the questionnaires and other activities related to the study; 4. Has histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate; 5. Is, in the opinion of the investigator, a candidate for at least 1 year of continuous ADT for the management of prostate cancer with one of the following clinical disease state presentations: a. Evidence of biochemical (prostate-specific antigen [PSA], confirmed with two measurements at least one week apart) or clinical relapse following local primary intervention with curative intent (such as surgery, radiation therapy, cryotherapy, or high-frequency ultrasound and not a candidate for salvage treatment by surgery); b. Newly diagnosed hormone-sensitive metastatic disease (metastases in regional lymph node[s] are considered N1 and will, therefore, be stratified as non-metastatic); c. Advanced localized disease unlikely to be cured by local primary intervention with curative intent; d. Patients receiving primary or salvage radiation therapy with adjuvant ADT; 6. Patients with high-risk cardiovascular disease defined as prior history of MACE (myocardial infarction, stroke, coronary revascularization [including percutaneous procedures] or revascularization affecting cerebral blood flow [including carotid procedures]) > 1 month before enrollment in the study; OR patients with ≥ 3 of the following cardiovascular risk factors (Okwuosa et al. 2020): − Age ( ≥ 55 years of age); − Hypertension defined as self-reported high blood pressure, or use of a blood pressure-lowering medication; − Diabetes defined as self-reported diabetes or use of hypoglycemic medication for the purposes of lowering blood glucose; − Dyslipidemia defined as high cholesterol or use of a lipid-lowering medication; − Current cigarette use, defined as smoking, within the year prior to the screening visit; − Family history of cardiovascular disease, defined as a myocardial infarction or stroke or coronary revascularization or revascularization affecting cerebral blood flow (ie, carotid procedures) or sudden death in a first-degree relative < 60 years old; 7. Serum testosterone before starting relugolix or leuprolide acetate of ≥ 150 ng/dL (1.50 ng/mL or 5.2 nmol/L) within 6 months prior to screening; 8. Serum PSA concentration of > 2.0 ng/mL (2.0 μg/L), or, when applicable, post radical prostatectomy of > 0.2 ng/mL (0.2 μg/L) within 6 months prior to screening (by medical history); 9. Patients, in the opinion of the investigator, must be equally eligible for either treatment in the study. If either the patient or the physician has a strong preference that one of the treatments be prescribed over the other, the patient must not be enrolled; 10. Patients must not be participating or intending to participate in an interventional therapeutic study.
NCT05605964 STU00218016 |
A Single-Arm, Phase II Study of Autophagy Modulation using Hydroxychloroquine in combination with Encorafenib and Cetuximab or Panitumumab in Metastatic BRAF-mutated Colorectal Cancer Refractory to Standard TherapiesColon and rectal cancer are cancers that involve the lowest part of the digestive system: the large intestine and the rectum. A colorectal cancer that has already spread to distant sites by the time it is diagnosed is referred to as metastatic (stage IV) colorectal cancer (CRC). In colorectal cancer, … Colon and rectal cancer are cancers that involve the lowest part of the digestive system: the large intestine and the rectum. A colorectal cancer that has already spread to distant sites by the time it is diagnosed is referred to as metastatic (stage IV) colorectal cancer (CRC). In colorectal cancer, mutations in the BRAF gene are present in approximately 10% of patients with metastatic disease. Outcomes in these patients are poor relative to patients with non-BRAF mutated colon cancer. Encorafenib and cetuximab are standard of care therapy for metastatic colorectal cancer (CRC) patients who have disease progression (worsening of disease) after a previous line of therapy. Addition of hydroxychloroquine (HCQ) with encorafenib has shown to overcome the tumor’s resistance to encorafenib in laboratory studies. This study examines adding hydroxychloroquine to encorafenib and cetuximab in patients with worsening metastatic colon cancer on previous therapy. HCQ is an oral drug which is approved by the Food and Drug Administration (FDA) for other indications such as for treatment of uncomplicated malaria, preventive against malaria in select geographic regions, and for treatment of rheumatoid arthritis, systemic lupus erythematosus, and chronic discoid lupus erythematosus in adults. It is not currently FDA approved for the indication to be investigated in this study. As such, hydroxychloroquine will be the drug to be investigated (investigational drug) in this study in combination with encorafenib and cetuximab. Another drug named Panitumumab is also FDA approved for treatment of metastatic CRC in combination with other standard therapy. Panitumumab may also be used instead of Cetuximab in the above-mentioned treatment combination, depending on the choice of your doctor. Stage IV colon cancer with progression (disease worsening) on a prior line of therapy
NCT05576896 STU00217727 |
(xIRB NCI CIRB) Phase 2 Study of Rogaratinib (BAY 1163877) in the Treatment of Patients with Sarcoma Harboring Alterations in Fibroblast Growth Factor Receptor (FGFR) 1-4 and SDH-Deficient Gastrointestinal Stromal Tumor (GIST)It is a phase II trial studying the effect of rogaratinib in treating patients with sarcoma with a change in a group of proteins called fibroblast growth factor receptors (FGFRs) or SDH-deficient gastrointestinal stromal tumor (GIST). Rogaratinib may stop the growth of tumor cells by blocking some of the … It is a phase II trial studying the effect of rogaratinib in treating patients with sarcoma with a change in a group of proteins called fibroblast growth factor receptors (FGFRs) or SDH-deficient gastrointestinal stromal tumor (GIST). Rogaratinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This study is being done to answer the following question: Can we lower the chance of sarcoma growth and/or spreading when treated with the anticancer drug rogaratinib (BAY 1163877)? The investigation is also done to determine if this approach is better or worse than the usual approach for sarcoma. The study will focus on two cohorts of sarcomas with alterations in the FGF axis. Cohort A is defined as any sarcoma with documented FGFR alteration as confirmed by NGS. Cohort B is defined as SDH-deficient GIST. Some of the eligibility criteria include: • Participants must have a diagnosis of advanced sarcoma • Participants must be 18 or older Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT04595747 STU00218087 |
(xIRB) DRUG GS-US-576-6220: An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic AlterationsThe primary objectives of the study are to assess the objective response rate (ORR) and to determine the recommended Phase 2 dose (RP2D) of SG in combination with pembrolizumab or pembrolizumab and a platinum agent (carboplatin or cisplatin) in participants with advanced or metastatic non-small-cell lung cancer (NSCLC) … The primary objectives of the study are to assess the objective response rate (ORR) and to determine the recommended Phase 2 dose (RP2D) of SG in combination with pembrolizumab or pembrolizumab and a platinum agent (carboplatin or cisplatin) in participants with advanced or metastatic non-small-cell lung cancer (NSCLC) without actionable genomic alterations. Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Some of the eligibility criteria include:
· Participants must have a diagnosis of Stage IV non-small cell lung cancer (NSCLC) · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT05186974 STU00218091 |
NU 22MH03: Phase II open-label multi-cohort study evaluating CPI-613 (devimistat) in combination with hydroxychloroquine and 5-fluorouracil or gemcitabine in patients with advanced chemorefractory colorectal, pancreatic, or other solid cancersThe primary objective is to estimate the Overall Response Rate (ORR) of treatment with CPI-613 plus HCQ and, depending on the cohort and indication, either 5-FU or gemcitabine. Under this protocol, patients in cohorts 1 and 2 will be treated with combination of 2000 mg/m2 CPI-613 … The primary objective is to estimate the Overall Response Rate (ORR) of treatment with CPI-613 plus HCQ and, depending on the cohort and indication, either 5-FU or gemcitabine.
Under this protocol, patients in cohorts 1 and 2 will be treated with combination of 2000 mg/m2 CPI-613 Day 1 and Day 15, plus 2400 mg/m2 Fluorouracil (5-FU) IV infusion over 46 hours Day 1 and Day 15, plus 400 mg hydroxychloroquine (HCQ) PO BID over 28-day cycles.
Patients in cohort 3 will be treated with combination of 2000 mg/m2 CPI-613 Day 1 and Day 15 plus 400 mg HCQ PO BID and, depending on indication, either 1000 mg/m2 gemcitabine or 2400 mg/m2 5-FU.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial Some of the eligibility criteria include:
· Participants must be 18 or older · Patients in cohort 1 must have colorectal cancer. Patients in cohort 2 must have pancreatic cancer. Patients in cohort 3 may have any of the following cancers:o Biliary o Gastroesophageal o Urothelial o Ovarian o Non-small cell lung (adenocarcinoma only)
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. NCT05733000 STU00218203 |
(xIRB NCI CIRB) NRG BN012: A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain MetastasesThis phase III trial compares the addition of stereotactic radiosurgery before or after surgery in treating patients with cancer that has spread to the brain (brain metastases). Stereotactic radiosurgery is a type of radiation therapy that delivers a high dose of radiation only to the small areas of cancer in … This phase III trial compares the addition of stereotactic radiosurgery before or after surgery in treating patients with cancer that has spread to the brain (brain metastases). Stereotactic radiosurgery is a type of radiation therapy that delivers a high dose of radiation only to the small areas of cancer in the brain and avoids the surrounding normal brain tissue. Surgery and radiation may stop the tumor from growing for a few months or longer and may reduce symptoms of brain metastases.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Some of the eligibility criteria include:
· Radiographic confirmation of 1-4 brain metastases · Participants must be 18 or older · Known active or history of invasive non-central nervous system (CNS) primary cancer based on documented pathologic diagnosis within the past 3 years cancer based on documented pathologic diagnosis within the past 3 years
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. NCT05438212 STU00218228 |
(xIRB NCI CIRB) SWOG 2101: Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot StudyThis phase II trial studies the effects of the combination of cabozantinib and nivolumab in study participants with melanoma or squamous cell head and neck cancer that has spread to other places in the body (advanced). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes … This phase II trial studies the effects of the combination of cabozantinib and nivolumab in study participants with melanoma or squamous cell head and neck cancer that has spread to other places in the body (advanced). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack cancer and interfere with the ability of tumor cells to grow and spread. This trial may help doctors determine how quickly patients can be divided into groups based on biomarkers in their tumors. A biomarker is a biological molecule found in the blood, other body fluids, or in tissues that is a sign of a normal or abnormal process or a sign of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. The two biomarkers that this trial is studying are "tumor mutational burden" and "tumor inflammation signature." Another purpose of this trial is to help doctors learn if cabozantinib and nivolumab shrink or stabilize the cancer and whether patients respond differently to the combination depending on the status of the biomarkers. This is a singlegroup study assignment where participants receive nivolumab IV over 30 minutes on day 1 of each cycle and cabozantinib PO BID. The study cycle is 28 days for 2 years. Some of the eligibility criteria include: • Participants must have a diagnosis of IO Refractory Melanoma or HNSCC • Participants must be 18 or older Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT05136196 STU00218236 |
(xirb) DRUG GS-US-592-6238: A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti PD(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1 (ASCENT-03)The purpose of this study is to see if sacituzumab govitecan can improve lifespans of patients with advanced TNBC and their tumor does not grow or spread when compared to chemotherapy (paclitaxel, or nab-paclitaxel, or the combination of gemcitabine and carboplatin), a commonly used treatment for previously untreated advanced … The purpose of this study is to see if sacituzumab govitecan can improve lifespans of patients with advanced TNBC and their tumor does not grow or spread when compared to chemotherapy (paclitaxel, or nab-paclitaxel, or the combination of gemcitabine and carboplatin), a commonly used treatment for previously untreated advanced TNBC
NCT05382299 STU00218238 |
(xIRB NCI CIRB) SWOG 2200: A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or Without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2)This phase II trial tests whether cabozantinib with or without atezolizumab works to shrink tumors in patients with papillary kidney cancer that has spread to other places in the body (metastatic). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy … This phase II trial tests whether cabozantinib with or without atezolizumab works to shrink tumors in patients with papillary kidney cancer that has spread to other places in the body (metastatic). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib with atezolizumab may prevent papillary kidney cancer from growing or spreading compared to cabozantinib alone.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Some of the eligibility criteria include:
· Participants must have a diagnosis of metastatic papillary renal cell carcinoma (PRCC) · Participants must be 18 or older · All sexes eligible for study
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT05411081 STU00218240 |
(xIRB NCI CIRB) Alliance A082002: A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung CancerThis phase II/III trial compares the addition of radiation therapy to the usual treatment (immunotherapy with or without chemotherapy) versus (vs.) usual treatment alone in treating patients with non-small cell lung cancer that has spread to nearby tissue or lymph nodes (advanced) or has spread to other places … This phase II/III trial compares the addition of radiation therapy to the usual treatment (immunotherapy with or without chemotherapy) versus (vs.) usual treatment alone in treating patients with non-small cell lung cancer that has spread to nearby tissue or lymph nodes (advanced) or has spread to other places in the body (metastatic) whose tumor is also negative for a molecular marker called PD-L1. Stereotactic body radiation therapy (SBRT) is a type of radiation therapy that uses high energy x-rays to kill tumor cells and shrink tumors. This method uses special equipment to position a patient and precisely deliver radiation to tumors with fewer doses over a shorter period and may cause less damage to normal tissue than conventional radiation therapy. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as carboplatin, pemetrexed, paclitaxel and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The addition of radiation therapy to usual treatment may stop the cancer from growing and increase the life of patients with advanced non-small cell lung cancer who are PD-L1 negative. Some of the eligibility criteria include:
· Participants must have a diagnosis of stage IV NSCLC · Participants must be 18 or older · No prior systemic chemotherapy or immunotherapy for advanced NSCLC No prior treatment with checkpoint inhibitors for metastatic lung cancer NCT04929041 STU00218262 |
(xIRB) DRUG SL03-OHD-105: An Open-Label, Phase 1b Study of SL-172154 (SIRPα-Fc-CD40L) Administered with Either Pegylated Liposomal Doxorubicin or Mirvetuximab Soravtansine in Subjects with Platinum-Resistant Ovarian CancersSL03-OHD-105 is an open-label, multicenter, phase 1b trial designed to evaluate SL-172154 administered in combination with pegylated liposomal doxorubicin (PLD) or mirvetuximab soravtansine (MIRV) in patients with platinum resistant ovarian cancer. Approximately 102 participants will be enrolled in this study in two phases: dose escalation and … SL03-OHD-105 is an open-label, multicenter, phase 1b trial designed to evaluate SL-172154 administered in combination with pegylated liposomal doxorubicin (PLD) or mirvetuximab soravtansine (MIRV) in patients with platinum resistant ovarian cancer. Approximately 102 participants will be enrolled in this study in two phases: dose escalation and dose expansion.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Some of the eligibility criteria include:
· Participants must have a diagnosis of: Platinum-resistant Ovarian CancerFallopian Tube CancerEpithelial Ovarian CancerOvarian CancerPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaPrimary Peritoneal Carcinoma · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT05483933 STU00218292 |
(xIRB NCI CIRB) ETCTN 10387: Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients with HIV InfectionThis phase I trial investigates the side effects of cabozantinib and nivolumab in treating patients with cancer that has spread to other places in the body (advanced) and who are undergoing treatment for human immunodeficiency virus (HIV). Cabozantinib may stop the growth of tumor cells by blocking some of the … This phase I trial investigates the side effects of cabozantinib and nivolumab in treating patients with cancer that has spread to other places in the body (advanced) and who are undergoing treatment for human immunodeficiency virus (HIV). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and nivolumab may shrink or stabilize cancer in patients undergoing treatment for HIV.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial.
Some of the eligibility criteria include:
· Participants must have a diagnosis of confirmed advanced solid tumors that are metastatic or recurrent · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT04514484 STU00218321 |
SWOG 2104: Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine TumorsThis study is being done to answer the following question: Can we lower the chance of pNET coming back by giving chemotherapy after surgery? We are doing this study because we want to find out if this approach is better or worse than the usual approach for patients that have … This study is being done to answer the following question: Can we lower the chance of pNET coming back by giving chemotherapy after surgery? We are doing this study because we want to find out if this approach is better or worse than the usual approach for patients that have had surgery for pNET. The usual approach is defined as care most people get after surgery for pNET. If you decide to take part in this study, you will either get the study drugs capecitabine and temozolomide for up to four months or you will receive the usual approach of observation only. Observation means you will not receive treatment for pNET. After the first four months, your doctor will continue to follow your condition for 5 years, watch you for side effects, and see if your tumor comes back. During this time you will need to visit the clinic every 6 months for the first 3 years, then once every 12 months for 2 more years. More Info |
NU 22S08: Northwestern Sarcoma Biorepository and Clinical DatabaseThe purpose of this study is to collect and store tumor tissue samples and clinical data from participants with any type of sarcoma, obtained when participants undergo routine biopsy and/or surgery, for use in future research. Participants will be asked to allow for blood, tissue and archival tissue samples, … The purpose of this study is to collect and store tumor tissue samples and clinical data from participants with any type of sarcoma, obtained when participants undergo routine biopsy and/or surgery, for use in future research. Participants will be asked to allow for blood, tissue and archival tissue samples, and clinical data, to be used for this biorepository. Samples will only be collected during standard of care procedures. Additional blood will be requested at the time of standard of care labs. Leftover tissue will be requested from patients’ standard of care biopsy or surgery. Information related to cancer and its response to therapy, including pathology and radiology results, will be collected. Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Some of the eligibility criteria include:
· Participants must have a diagnosis of any type of known or suspected neoplasm arising from cells of mesenchymal origin. This may be a confirmed malignancy (a sarcoma) or simply an aggressive benign tumor such as a desmoid tumor. · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
STU00218245 |
(XIRB) DRUG ACR-368-201: A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® StatusThis is an open label Phase 1b/2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or in combination with low dose gemcitabine in participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon's OncoSignature® test status. Note: This is only … This is an open label Phase 1b/2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or in combination with low dose gemcitabine in participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon's OncoSignature® test status.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Some of the eligibility criteria include:
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT05548296 STU00218498 |
(XIRB) DRUG GS-US-592-6173: A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1The purpose of this study is to see if sacituzumab govitecan in combination with pembrolizumab can improve lifespans of patients with advanced, PD-L1 positive TNBC and their tumor does not grow or spread when compared to pembrolizumab in combination with chemotherapy (paclitaxel, or nab-paclitaxel, or the combination of … The purpose of this study is to see if sacituzumab govitecan in combination with pembrolizumab can improve lifespans of patients with advanced, PD-L1 positive TNBC and their tumor does not grow or spread when compared to pembrolizumab in combination with chemotherapy (paclitaxel, or nab-paclitaxel, or the combination of gemcitabine and carboplatin), a commonly used treatment for previously untreated advanced TNBC. • Sacituzumab govitecan (Trodelvy®) is currently approved by the United States (U.S.) Food and Drug Administration (FDA) and other regulatory agencies for previously treated advanced TNBC. It is also approved by the U.S. FDA for the treatment of patients with bladder cancer and cancers of the urinary tract. • Pembrolizumab, is approved by the U.S. FDA and other regulatory agencies for the treatment of certain types of TNBC. It is also approved for the treatment of several different types of other cancers. The combination of sacituzumab govitecan and pembrolizumab has not been approved by any health authorities for previously untreated advanced TNBC. This is a randomized, open-label study. Participants will be randomly assigned to receive either the experimental treatment, sacituzumab govitecan in combination with pembrolizumab, OR 1 of the following 3 standard chemotherapy treatment regimens chosen by the doctor: • Pembrolizumab in combination with paclitaxel • Pembrolizumab in combination with nab-paclitaxel • Pembrolizumab in combination with gemcitabine with carboplatin · Participants must have a diagnosis of locally advanced, inoperable, or metastatic triple-negative breast cancer (TNBC) who have not received previous systemic therapy for advanced disease and whose tumors are programmed cell death ligand 1 (PD-L1) positive at screening.
NCT05382286 STU00218523 |
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or FusionsThis study will evaluate erdafitinib administered via an intravesical delivery system for both NMIBC and MIBC. The TAR-210 intravesical delivery system has been developed to providecontinuous intravesical drug delivery for prolonged periods over multiple voiding cycles, thereby minimizing the number of intravesical instillations required and providing sustained drug exposure … This study will evaluate erdafitinib administered via an intravesical delivery system for both NMIBC and MIBC. The TAR-210 intravesical delivery system has been developed to provide continuous intravesical drug delivery for prolonged periods over multiple voiding cycles, thereby minimizing the number of intravesical instillations required and providing sustained drug exposure at the tumor site while minimizing systemic exposure and improving tolerability.
NCT05316155 STU00217656 |
(xIRB NCI CIRB) ETCTN 10492: Phase I/Ib Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer… This phase I/Ib trial tests the safety and best dose of ipatasertib in combination with the usual treatment approach using chemotherapy together with radiation therapy ("chemo-radiation") in patients with stage III-IVB head and neck cancer. Ipatasertib is in a class of medications called protein kinase B (AKT) inhibitors. It may stop the growth of tumor cells and may kill them. Cisplatin which is a chemotherapy used in this trial is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Radiation therapy uses high energy to kill tumor cells and shrink tumors. Giving ipatasertib in combination with chemo-radiation may be better than chemo-radiation alone in treating patients with advanced head and neck cancer.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial.
Some of the eligibility criteria include:
· Participants must have a diagnosis of confirmed HNSCC (including tumors of the oropharynx, hypopharynx, larynx, oral cavity, nasal cavity, maxillary and other paranasal sinuses, and unknown primary of the head and neck), with measurable disease
· Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT05172245 STU00218529 |
DRUG ALKS 4230-007: A Phase 3, Multicenter, Open Label, Randomized Trial of Nemvaleukin Alfa in Combination with Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)… Patients will be centrally allocated in a randomized fashion (3:1:1:3) to receive either: • Arm 1: nemvaleukin and pembrolizumab combination therapy • Arm 2: pembrolizumab monotherapy • Arm 3: nemvaleukin monotherapy • Arm 4: Investigator’s choice chemotherapy. Options for protocol-specific Investigator’s choice chemotherapy include one of the following: pegylated liposomal doxorubicin (PLD), paclitaxel, topotecan, or gemcitabine. The Investigator will pre-select the Investigator’s choice treatment before the randomization of each patient Note: This is only a partial description of treatment. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Some of the eligibility criteria include: - Female at least 18 years old - Diagnosis of advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT05092360 STU00217646 |
(xIRB NCI CIRB) Alliance A091903: A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal MelanomaThis phase II trial tests whether nivolumab in combination with cabozantinib works in patients with mucosal melanoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop … This phase II trial tests whether nivolumab in combination with cabozantinib works in patients with mucosal melanoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. This helps stop the spread of tumor cells. Giving nivolumab in combination with cabozantinib could prevent cancer from returning.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial.
Some of the eligibility criteria include: · Participants must have a diagnosis of melanoma · Participants must be 18 or older Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT05111574 STU00218656 |
(xIRB NCI CIRB) Alliance A022001: Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine TumorsThis study is being done to answer the following question: Which standard therapy is better for controlling your cancer for a longer period of time? We are doing this study because we want to find out which approach is better or worse for your advanced pancreatic neuroendocrine cancer. The usual … This study is being done to answer the following question: Which standard therapy is better for controlling your cancer for a longer period of time? We are doing this study because we want to find out which approach is better or worse for your advanced pancreatic neuroendocrine cancer. The usual approach is defined as care most people get for advanced pancreatic neuroendocrine cancer. If you decide to take part in this study, you will either get lutetium Lu 177 dotatate, a radioactive drug given through your vein, for up to 8 months, or you will get the drugs temozolomide and capecitabine, as tablets you take by mouth, for up to 12 months. After you finish your treatment, your doctor will continue to follow your condition at clinic visits and watch you for side effects. If you finish or choose to stop your treatment before your cancer gets worse, they will check on you every 3 months at clinic visits until your cancer gets worse or you start a different treatment. If your cancer gets worse or you start a different cancer treatment, they will check on you every 6 months by phone or medical record for a maximum of 8 years starting from the day you enrolled on the study. Participants must have a diagnosis of advanced pancreatic neuroendocrine tumor. NCT05247905 STU00218667 |
DRUG CURLU177PSM0001: A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate CancerThe purpose of this study is to learn if the study drug called Lutetium-177 PSMA I&T is safe and effective in patients with castration-resistant metastatic prostate cancer.… The purpose of this study is to learn if the study drug called Lutetium-177 PSMA I&T is safe and effective in patients with castration-resistant metastatic prostate cancer. Some of the key eligibility criteria include: · patients with castration-resistant metastatic prostate cancer · cancer cells with prostate specific membrane antigen (PSMA) · Age ≥18 years
NCT05204927 STU00217942 |
(xIRB NCI CIRB) ETCTN 10496: Phase 2 Study of Ipatasertib in Combination with Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and NeckThis phase II trial compares the effect of adding ipatasertib to pembrolizumab (standard immunotherapy) vs. pembrolizumab alone in treating patients with squamous cell cancer of the head and neck that has come back (recurrent) or that has spread from where it first started (primary site) to other places in the … This phase II trial compares the effect of adding ipatasertib to pembrolizumab (standard immunotherapy) vs. pembrolizumab alone in treating patients with squamous cell cancer of the head and neck that has come back (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Ipatasertib is in a class of medications called protein kinase B (AKT) inhibitors. It may stop the growth of tumor cells and may kill them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving ipatasertib in combination with pembrolizumab may be more effective than pembrolizumab alone in improving some outcomes in patients with recurrent/metastatic squamous cell cancer of the head and neck. Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Some of the eligibility criteria include:
· Participants must have a diagnosis of head and neck squamous cell cancer (HNSCC) · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT05172258 STU00218821 |
(xIRB NCI CIRB) Alliance A092104: A Randomized Phase 2/3 Study of Olaparib Plus Temozolomide Versus Investigator's Choice for the Treatment of Patients with Advanced Uterine Leiomyosarcoma After Progression on Prior ChemotherapyA Randomized Phase 2/3 Study of Olaparib Plus Temozolomide Versus Investigator's Choice for the Treatment of Patients with Advanced Uterine Leiomyosarcoma After Progression on Prior Chemotherapy… A Randomized Phase 2/3 Study of Olaparib Plus Temozolomide Versus Investigator's Choice for the Treatment of Patients with Advanced Uterine Leiomyosarcoma After Progression on Prior Chemotherapy Some of the eligibility criteria include: • Participants must have a diagnosis of advanced uterine leiomyosarcoma. • Participants must be 18 or older Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT05633381 STU00218847 |
(xirb) DRUG IO-202-CL-002: A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study of IO-202 in Combination with Pembrolizumab in Subjects with Advanced, Relapsed, or Refractory Solid TumorsTo assess safety and tolerability of increasing doses of IO-202 either as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors, and select the recommended Phase 2 dose (RP2D). Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive … To assess safety and tolerability of increasing doses of IO-202 either as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors, and select the recommended Phase 2 dose (RP2D).
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Dose Escalation: · Participants must have a diagnosis of any histologically or cytologically confirmed advanced or metastatic solid tumor and has received, has been intolerant to, or has been ineligible for standard systemic therapy known to confer clinical benefit. Dose Expansion: Participant must have failed at least one available therapy for the disease under study.
· Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT05309187 STU00218885 |
Alliance A032101: A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): A-DREAMThis study is being done to answer the following question: In patients whose cancer is responding exceptionally well to hormonal medications, can stopping treatment allow for testosterone recovery while staying off treatment for 18 months or more? The usual approach for patients who are not in a study is to … This study is being done to answer the following question: In patients whose cancer is responding exceptionally well to hormonal medications, can stopping treatment allow for testosterone recovery while staying off treatment for 18 months or more? The usual approach for patients who are not in a study is to continue treatment with hormonal medications that decrease testosterone levels indefinitely. Patients who are not in a study usually continue potent oral hormonal medications that block growth signals from male hormones (like testosterone) until they stop working against their cancer, after which they would switch treatment to chemotherapy or other cancer-directed therapy. If you decide to take part in this study, you will stop both of your hormonal medications. You will resume them if you have any of signs of your cancer growing back. After you restart both hormonal medications, you will continue to be followed for symptoms and PSA/testosterone levels at least every 12 weeks beginning from restarting treatment and have scans at least every 24 weeks beginning from restarting treatment. You will stop the potent oral hormonal medication when your treating physician feels like it is no longer providing you benefit. After you stop this medication and start a new treatment, the study team will check on you at least every 24 weeks for up to 10 years to see what cancer treatments you have received and how you are doing. Participants must have advanced prostate cancer for which you have been receiving hormonal medications including 1) a medication to decrease testosterone levels in your body and 2) a potent oral hormonal medication to block growth signals from male hormones (like testosterone) in the cancer cells. Your cancer has been responding exceptionally well to this therapy and your doctor thinks that it is appropriate to take a break from these medications as part of this study. NCT05241860 STU00218961 |
(xIRB NCI CIRB) SWOG 2302: PRAGMATICA - LUNG: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) plus Pembrolizumab (MK-3475; NSC 776864) versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung CancerThis phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may … This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out if giving ramucirumab with pembrolizumab is more effective at treating patients with stage IV or recurrent non-small cell lung cancer than standard chemotherapy.
NCT05633602 STU00218964 |
DRUG 2215-CL-0203: A Phase 1/2, Multicenter, Open-label, Single Arm, Dose Escalation and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients with Newly Diagnosed FMS3 Mutated Acute Myeloid Leukemia (AML) not Eligible for Intensive Induction ChemotherapyThe study consists of 2 parts:• Phase 1: Randomized Dose Ranging Phase• Phase 2: Dose Expansion PhaseEach study participant in phase 1 or 2 will undergo the following stages during their participation in the study: Screening Period, Triplet Treatment Period, Long-term Treatment Period, EOT Visit, 30-day Follow-up … The study consists of 2 parts: • Phase 1: Randomized Dose Ranging Phase • Phase 2: Dose Expansion Phase Each study participant in phase 1 or 2 will undergo the following stages during their participation in the study: Screening Period, Triplet Treatment Period, Long-term Treatment Period, EOT Visit, 30-day Follow-up Visit, and Survival Follow-up. The primary objective of this study include: - To determine the optimized dose for the triple combination of gilteritinib, venetoclax and azacitidine in FLT3mut AML participants who are newly diagnosed and not eligible for intensive induction chemotherapy, and to determine the safety, tolerability, efficacy and pharmacological activity by PIA and PK of the triple combination of gilteritinib, venetoclax and azacitidine in the dose ranging cohort - To determine CR rate of the triple combination of gilteritinib, venetoclax and azacitidine in FLT3mut AML participants who are newly diagnosed and not eligible for intensive induction chemotherapy in the expansion cohort Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Some of the eligibility criteria include:
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. NCT05520567 STU00218499 |
(xIRB NCI CIRB) Alliance A032001: MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients with Metastatic Urothelial CancerThis study is being done to answer the following question: Can we prolong life for patients with metastatic urothelial cancer by adding a drug called cabozantinib to standard maintenance treatment avelumab? We are doing this study because we want to find out if this approach is better or worse than … This study is being done to answer the following question: Can we prolong life for patients with metastatic urothelial cancer by adding a drug called cabozantinib to standard maintenance treatment avelumab? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your diagnosis of metastatic urothelial cancer. The usual approach is defined as care most people get for metastatic urothelial cancer. If you decide to take part in this study, you will either get avelumab every 2 weeks for up to 2 years or avelumab every 2 weeks plus cabozantinib, which is a study drug targeting blood vessel formation, daily for up to 2 years. After you finish treatment your doctor will continue to follow your condition for every 3 months for up to 5 years after you are registered to assess how you are doing. More Info |
(xIRB NCI CIRB) Alliance A051902: A RANDOMIZED PHASE II STUDY OF CHO(E)P VS CC-486-CHO(E)P VS DUVELISIB-CHO(E)P IN PREVIOUSLY UNTREATED CD30 NEGATIVE PERIPHERAL T-CELL LYMPHOMASA randomized phase II study of CHO(E)P vs CC-486-CHO(E)P vs duvelisib-CHO(E)P in previously untreated CD30 negative peripheral T-cell lymphomas… A randomized phase II study of CHO(E)P vs CC-486-CHO(E)P vs duvelisib-CHO(E)P in previously untreated CD30 negative peripheral T-cell lymphomas Some of the eligibility criteria include:
· Participants must have a diagnosis of T-cell lymphoma cancer · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT04803201 STU00219084 |
(xIRB NCI CIRB) NRG BR008: A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO*)This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low-risk HER2+ breast cancer who undergo breast-conserving surgery and receive HER2-directed therapy and are randomized not to receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the … This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low-risk HER2+ breast cancer who undergo breast-conserving surgery and receive HER2-directed therapy and are randomized not to receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care. The participant will either have radiation therapy to the breast for 1-6 weeks and take a HER2-targeted drug for at least six months, or he/she will only take a HER2-targeted drug for at least six months. Study subjects will be followed for 10 years. Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Some of the eligibility criteria include: • Participants must have a diagnosis of low-risk HER2-positive breast cancer • Participants must be 18 or older Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT05705401 STU00219115 |
NU MSK22H05: Phase 2 study of Zanubrutinib, Obinutuzumab, and Venetoclax in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) and Mantle Cell Lymphoma (MCL)This is a single-stage, phase 2 study of the combination of zanubrutinib, obinutuzumab, and venetoclax in previously untreated patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or mantle cell lymphoma (MCL), the latter including patients with evidence of TP53 mutation as well as transplant ineligible patients.The … This is a single-stage, phase 2 study of the combination of zanubrutinib, obinutuzumab, and venetoclax in previously untreated patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or mantle cell lymphoma (MCL), the latter including patients with evidence of TP53 mutation as well as transplant ineligible patients. The primary aim of this study is to establish the rate of minimum residual disease (MRD) undetectable response in patients with CLL, to establish the 2-year progression free survival (PFS) in patients with TP53 mutated MCL, and to establish the 3-year PFS in transplant ineligible patients. Time to completion of study is estimated at 5 years. The secondary objectives are to establish the recommended phase 2/3 duration of therapy, to determine the proportion of patients who successfully discontinue therapy after achieving an MRD undetectable response. Also, to determine the durability of clinical benefit after treatment discontinuation as measured by duration of peripheral blood MRD response and treatment-free survival. In addition, to determine whether induction therapy with 2 cycles of zanubrutinib and obinutuzumab prior to venetoclax reduces TLS risk assignment, and to assess safety and tolerability of the of zanubrutinib, obinutuzumab, and venetoclax regimen in the first-line setting. Finally, to assess safety and tolerability of the of zanubrutinib, obinutuzumab, and venetoclax regimen in the first-line setting. The exploratory objectives are to cross validate MRD testing using multiparameter flow cytometry with DNA sequencing-based MRD assays in peripheral blood and bone marrow. To evaluate clonal evolution of CLL and MCL in serial patient samples on therapy with zanubrutinib, obinutuzumab, and venetoclax, during post-treatment surveillance, and at progression. To investigate the effects of zanubrutinib, obinutuzumab, and venetoclax on immune responses. Some of the eligibility criteria include:
· Participants must have a diagnosis of mantle cell lymphoma (MCL) · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT03824483 STU00218530 |
(xIRB NCI CIRB) SWOG 2010: A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence With Endocrine Therapy In Young Women With Stage I-III Breast Cancer (ASPEN)This study is being done to answer the following question: Will monitoring side effects in between clinic visits help women keep taking their hormone therapy medicine as prescribed for early-stage breast cancer? We are doing this study because we want to find out if this approach is better or … This study is being done to answer the following question: Will monitoring side effects in between clinic visits help women keep taking their hormone therapy medicine as prescribed for early-stage breast cancer? We are doing this study because we want to find out if this approach is better or worse than the usual approach for helping women take their hormone therapy medicine. The usual approach is the follow-up care most people get after they are diagnosed with breast cancer and start hormone therapy.
Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Some of the eligibility criteria include:
· Participants must have a diagnosis of Breast Cancer · Participants must be 18 or older
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
NCT05568472 STU00219241 |
Combining topical imiquimod with local radiotherapy for treatment of mycosis fungoidesThe primary aim of this study is to assess the safety and efficacy of a combination local radiotherapy and topical imiquimod approach for the treatment of conventional (CD4+) mycosis fungoides (MF). Subjects will be asked to use the imiquimod cream at designated lesions nightly for 5 consecutive days a week … The primary aim of this study is to assess the safety and efficacy of a combination local radiotherapy and topical imiquimod approach for the treatment of conventional (CD4+) mycosis fungoides (MF). Subjects will be asked to use the imiquimod cream at designated lesions nightly for 5 consecutive days a week over 6 weeks. One week into the imiquimod treatment course, radiation therapy will be administered at Northwestern Medicine by radiation oncologists familiar with radiation treatment in 2 fractions of 4 Gy (units of radiation absorbed by the patient) (total 8 Gy) over 2 days to the same designated lesions. In addition, subjects will have two skin biopsies during the screening period and again at the same locations at week 8. Patients must have confirmed stage IA-IIB mycosis fungoides, have failed at least one standard therapy for MF, have active, but stable disease for at least 6 months with 4 or more discrete lesions (with at least 2 lesions >50cm2 in area combined). Patients of child bearing potential must have a negative pregnancy test before enrolling on the study.
NCT05838599 STU00218514 |